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Opioid receptors are important therapeutic targets for mood disorders and pain. Kappa 
opioid receptor (KOR) antagonists have recently shown potential for treating drug addiction and 
depression. Arodyn (Ac[Phe1,2,3,Arg4,D-Ala8]Dyn A(1-11)-NH2), an acetylated dynorphin A (Dyn 
A) analog, has demonstrated potent and selective KOR antagonism, but can be rapidly metabolized 
by proteases. Cyclization of arodyn could enhance metabolic stability and potentially stabilize the 
bioactive conformation to give potent and selective analogs.  
Accordingly, novel cyclization strategies utilizing ring closing metathesis (RCM) were 
pursued. However, side reactions involving olefin isomerization of O-allyl groups limited the 
scope of the RCM reactions, and their use to explore structure-activity relationships of aromatic 
residues. Here we developed synthetic methodology in a model dipeptide study to facilitate RCM 
involving Tyr(All) residues. Optimized conditions that included microwave heating and the use of 
isomerization suppressants were applied to the synthesis of cyclic arodyn analogs. Initial 
pharmacological data indicates the constraints involving aromatic residues were generally well 
tolerated at KOR with most of the analogs exhibiting affinities within 3- to 4-fold that of arodyn. 
RCM was also used in the synthesis of head to side chain cyclized arodyn analogs. 
Attempted cyclizations involving Tyr(All) residues proceeded in low yields, in contrast to 
cyclizations involving AllGly residues. However, ring contraction products as a result of olefin 
isomerization were also observed during the latter cyclizations. The resulting head to side chain 
cyclized arodyn analogs exhibited a 5-fold decrease in KOR affinity compared to arodyn. 
We further explored synthesis of arodyn analogs cyclized in both the N-terminal and C-
terminal segments resulting in bicyclic arodyn analogs. Here, we present the synthesis of two 
initial bicyclic peptide KOR ligands with different topologies. The RCM-based bicyclic arodyn 
iv 
 
analog exhibited KOR affinity within 3-fold that of arodyn, whereas the lactam-based bicyclic 
analog displayed a substantial loss in affinity for KOR. There are currently no reports of bicyclic 
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1.1 Background and significance 
Over the last century, there has been increasing interest in opioid receptors to understand 
their physiological and pharmacological effects. The three classical opioid receptors mu (MOR), 
kappa (KOR), and delta (DOR), were cloned in the 1990’s in addition to a fourth structurally 
related but pharmacologically distinct receptor,  the nociceptin (NOPR) receptor.1  Opioid 
receptors regulate multiple physiological processes and are important in analgesia, addiction, 
depression, inflammation, immunity, and the cardiovascular system.2 MOR selective agonists such 
as morphine are clinically used analgesics, but have deleterious side effects such as addiction, 
tolerance, respiratory depression, and constipation.3 KOR selective agonists are analgesics devoid 
of MOR associated side effects, but also induce dysphoria and sedation. Recently, KOR selective 
antagonists have received increasing attention for their potential therapeutic utility in drug 
addiction, stress-related conditions, and mood disorders.4, 5 Prototypical small molecule selective 
KOR antagonists such as norBNI and JDTic, however, show prolonged duration of action in vivo 
which has slowed their development and limits their use as pharmacological tools.6-9 
The majority of peptidic ligands at KOR are derivatives of the endogenous KOR ligand 
dynorphin A (Dyn A, Figure 1.1). In contrast to small molecule antagonists, peptide antagonists 
offer a promising profile for potential further development due to their finite duration of action in 
vivo.10 Arodyn (Ac[Phe1,2,3,Arg4,D-Ala8]Dyn A(1-11)-NH2, Figure 1.1), an acetylated Dyn A 
analog, displays potent and selective KOR antagonism.11 Further, arodyn prevented stress-induced 
reinstatement of cocaine seeking behavior in a conditioned place preference assay in mice.12  
 




        Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys 
          Dyn A(1-11) 
           Ac-Phe-Phe-Phe-Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2 
                                                         Arodyn 
Figure 1.1 Dyn A(1-11) and arodyn. 
In recent years there has been increasing interest in the development of peptides for 
therapeutic applications;13 cyclic peptides are particularly promising as they can have enhanced 
receptor affinity, target selectivity, and metabolic stability.14-16 Our research has significance in 
two areas, the exploration of new approaches to peptide cyclization and the potential to identify 
new and novel potent KOR antagonists as leads for the potential development of treatments for 
drug addiction. Drug addiction predisposes individuals to various medical complications, violence, 
and risky behaviors.17 Effective treatments are needed to alleviate the impact of drug addiction on 
individuals and society.18 
This thesis focuses on novel cyclization strategies via ring closing metathesis (RCM) 
involving aromatic residues to synthesize cyclic derivatives of arodyn. Notably, there are limited 
reports of cyclizations involving aromatic residues in opioid peptides.19, 20 In contrast to cyclization 
approaches such as lactam or disulfide bridges that generally involve non-critical residues, RCM 
allows the cyclization via aromatic residues that contribute to KOR affinity in arodyn. Cyclization 
can potentially stabilize the bioactive conformation and enhance the proteolytic stability of arodyn. 
Cyclic arodyn analogs offer complementary tools to small molecule ligands to study KOR 
pharmacology.  
1.2 Research projects and hypotheses 
The primary goal of this dissertation is the synthesis of conformationally constrained 
analogs of the KOR antagonist arodyn to evaluate the effects on KOR affinity, selectivity, efficacy, 
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and potency. To this effect, the synthesis of arodyn analogs cyclized in the “message” and 
“address” domains was explored. According to the “message” and “address” concept proposed by 
Chavkin and Goldstein, the “message” sequence contained in all mammalian opioid peptides is 
responsible for activating the receptor, while the “address” sequence that is unique to Dyn A 
(Figure 1.2) imparts affinity for KOR.21 As in Dyn A, aromatic residues in the “message” sequence 
of arodyn (Figure 1.2) contribute to its affinity for KOR.22 
            
Figure 1.2 “Message” and “address” domains of dynorphin A (1-11) and arodyn. 
In chapter 4 we developed synthetic methodology using RCM to optimize the yield of 
arodyn analogs containing conformationally constrained aromatic residues for pharmacological 
evaluation. RCM is compatible with peptide synthesis and standard amino acid protecting groups, 
but side reactions such as olefin isomerization can compromise the product yield.23 While RCM 
involving allylglycine (AllGly) residues showed moderate to high yields,24 reactions involving O-
allyl groups in Tyr(All) resulted in desallyl products that compromised reaction yields.20, 25 A 
model dipeptide, Fmoc-Tyr(All)-Tyr(All), was used to probe strategies to minimize side reactions 
and enhance reaction yields. Different reaction parameters, including the examination of reagents 
reported to suppress side reactions,23, 26were examined.  
   In chapter 5 optimized reaction conditions from the model dipeptide study were applied to 
the synthesis of conformationally constrained arodyn analogs. Optimized model dipeptide 
conditions using conventional heating facilitated RCM of arodyn analogs containing Tyr(All) for 
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pharmacological evaluation, but sequence dependent effects decreased the yields of some analogs. 
Further optimization using microwave heating was explored to enhance RCM of arodyn analogs 
containing Tyr(All). 
 In chapters 6 and 7, additional arodyn analogs cyclized from head to side chain and from 
side chain to side chain were explored. In chapter 6 microwave assisted RCM using AllGly or 
Tyr(All) with N-terminal alkenyl amides was explored to synthesize monocyclic arodyn analogs 
for pharmacological evaluation. In chapter 7, RCM and lactam chemistries were explored to 
synthesize two different bicyclic arodyn analogs. Notably, there are currently no reported 
polycyclic opioid peptide ligands.27 The RCM synthetic methodology developed for cyclization of 
arodyn was explored to synthesize an initial bicyclic KOR ligand cyclized in both the “message” 
and “address” domains. A rigid aromatic linker, benzene-1,3,5-tricarboxylic acid (trimesic acid), 
was used to synthesize a lactam-based bicyclic KOR ligand. 
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2.1 History and background of opioids 
Opioid analgesics such as morphine (Figure 2.1a) act at opioid receptors and are 
particularly useful in the treatment of severe pain, despite their deleterious side effect profile 
including abuse liability and respiratory depression.1, 2 The therapeutic use of morphine is of 
particular historical importance. Not long before the isolation of morphine from opium by Sertuner 
in the 1800’s,3 opium had been the subject of great unrest in the opium war between the British 
and the Chinese.4, 5 Despite prevailing opium use, it was not until the 1800’s that the use of 
morphine entered the clinic, spurred by the invention of the hypodermic needle.5 The use of 
morphine for pain relief was, however, accompanied by considerable safety and addiction 
concerns. Ironically, towards the end of the 19th century, heroin (diacetyl morphine) was 
synthesized in the quest to find a safe and non-addicting opioid, but to no avail.4, 5  
The advent of opiates and opioids with different pharmacological effects came to the 
forefront in the late 1930’s and 1940’s. Methadone (Figure 2.1b), a synthetic opioid structurally 
distinct from morphine, was developed as a replacement for morphine.6 Similarly, nalorphine (N-
allylnormorphine, Figure 2.1b) was developed to counter respiratory depression and abuse, both 
deleterious side effects of morphine.5 Despite the analgesic activity of nalorphine, accompanying 
side effects such as dysphoria were a considerable concern leading to the development of 
compounds such as naloxone (Figure 2.1b), a related compound which was identified but exhibited 
opioid antagonist activity.5  
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Figure 2.1 Structures of opioid ligands; also shown is the prototypical ligand for the sigma receptors. 
2.2 Opioid receptors 
In 1954, Beckett and Casy proposed the involvement of opioid receptors in mediating 
opioid effects.7 As of the 1960’s it was becoming increasingly apparent that the aforementioned 
pharmacological profiles could only be rationalized by the effects of the ligands on multiple opioid 
receptors, as proposed by thought leaders such as Portoghese8 and Martin.9 Following the 
discovery of opioid binding sites in the mammalian brain,10 pharmacological studies pointed to 
multiple opioid receptors.11-13 However, it was not until the 1970’s that Martin and co-workers 
classified multiple opioid receptors.14 The receptors were named after the opioid ligands used in 
the study; µ (morphine), κ (ketocylazocine) and σ (SKF 10,047, N-allylnorcyclazocine, Figure 
2.1c).The σ receptor, proposed as an opioid receptor by Martin et al,14 was later shown to differ in 




The discovery of endogenous ligands for the opioid receptors in the 1970’s marked a major 
advancement in opioid research. First, the discovery of the enkephalins,17 endogenous ligands for 
a distinct receptor, concomitantly led to the proposal of the DOR.18 The pentapeptides Tyr-Gly-
Gly-Phe-Met (Met-enkephalin) and Tyr-Gly-Gly-Phe-Leu (Leu-enkephalin) were identified in 
brain extracts, and their effects on the guinea pig ileum could be reversed by naloxone.17, 19, 20 
Shortly thereafter, β-endorphin21 and dynorphin (κ),22 both bearing structural similarities to the 
enkephalins, were identified (see Table 2.1 for structures of endogenous opioid peptides). New 
endogenous ligands for MOR were later discovered in the 1990’s by Zadina and co-workers who 
isolated and synthesized these endogenous agonists, endomorphin- 1 and -2 (Table 2.1).23 
Table 2.1 Endogenous opioid receptor and related peptides. 




Met-enkephalin-Arg6-Phe7                 Tyr-Gly-Gly-Phe-Met-Arg-Phe 
Met-enkephalin-Arg6-Gly7-Leu8        Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu 
  
Prodynorphina  
Dynorphin A Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln 
Dynorphin B Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr 
-Neoendorphin                                  Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Arg-Pro-Lys 
-Neoendorphin                                   Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Arg-Pro 
  
Pro-opiomelanocortina  








Nociceptin and related peptide  
Nociceptin/orphanin FQ Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln 
Orphanin FQ2 Phe-Ser-Glu-Phe-Met-Arg-Gln-Tyr-Leu-Val-Leu-Ser-Met-Gln-Ser-Ser-Gln 
a Precursor protein of corresponding opioid peptides bPrecursor not known 
 
Ultimately, the definitive demonstration of the three opioid receptors, MOR, KOR, and 
DOR, came from molecular biology. Advances in molecular biology led to the cloning of the 
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MOR, DOR, and KOR in the early 1990’s, clearly establishing the existence of distinct MOR, 
KOR and DOR that share about 60% sequence homology.24-28 In 1994 a related receptor, 
nociceptin/orpahnin FQ (NOPR), also referred to as the opioid receptor like-1 (ORL-1) receptor, 
was identified. Following cloning of the NOPR receptor, a heptadecapeptide named nociceptin 
was identified as the endogenous ligand, as it caused hypersensitivity to pain in vivo.29, 30  
Nociceptin (Table 2.1) was also referred to as orphanin FQ where F and Q are the first and last 
residues in the heptadecapeptide.30 Notably, the opioid receptor did not show appreciable affinity 
to opioid ligands, despite sharing ~60% sequence homology with the classical opioid receptors.31 
2.2.1 Clinically used opioids 
Opioids invoke a variety of physiological responses that can be leveraged for therapeutic 
benefit. Opioids are used therapeutically primarily as analgesics (morphine and its analogs), but 
also as antidiarrheal agents (loperamide), and antitussive agents (codeine) (Figure 2.2). 
Additionally, opioid ligands such as methadone and buprenorphine (Figure 2.2) are used to treat 
opioid addiction. Agonists at the MOR are the most common therapy for chronic pain. Fentanyl 
(Figure 2.2) and fentanyl-related compounds, the 4-anilidopiperidines, which are potent agonists 
at MOR, are used as adjuvants to anesthesia.32 KOR agonists induce analgesia while lacking the 
MOR agonist-related reinforcing effects; however, sedation and dysphoria have limited their 
utility.33 Recently, the KOR-selective agonist nalfuramine hydrochloride (TRK-820, Figure 2.2) 
was approved in Japan as a treatment for severe itching related to liver disease and hemodialysis. 
34 
Opioid ligands with mixed pharmacological activity at the MOR and the KOR exhibit 
particular advantages with respect to addiction liability. Pentazocine, nalbuphine, and butorphanol 
(Figure 2.2) are mixed agonist/antagonists with limited abuse potential used as analgesics.1 While 
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pentazocine and nalbuphine exhibit agonism at KOR and antagonism at MOR, butorphanol 
exhibits partial agonism at MOR and KOR. Buprenorphine has mixed pharmacology at three 
opioid receptors: partial MOR agonism, KOR antagonism and NOPR agonism.35-37  
Buprenorphine is clinically approved to treat opioid dependence; the ceiling effect from 
partial agonism at the MOR mitigates respiratory depression associated with MOR agonism.38 
Abuse deterent formulations of buprenorphine with naloxone have been developed to prevent it 
potential misuse (Figure 2.2).39 The inclusion of naltrexone, another opioid antagonist, in 
buprenorphine formulations has been examined in humans to provide “functional KOR 
antagonism” which has shown efficacy in the treatment of opioid dependence.40-42  
Opioid antagonists are clinically used to counter the effects of opioids and alleviate 
reinforcing behaviors. Naloxone is critical in the reversal of opioid overdose and post-operative 
sedation, while naltrexone is used to treat opioid dependence.1, 43 Peripherally restricted 
antagonists methylnaltrexone bromide44  and the recently approved naloxegol45 are used as anti-
constipation medications, while alvimopan46 is used for post-operative recovery of gastrointestinal 
function (Figure 2.2). Opioid antagonists have shown promise in the treatment of compulsive 
disorders including gambling47 and alcohol addiction; naltrexone and nalmefene (Figure 2.2) are 
used to treat alcohol dependence.48 Nalmefene, a MOR and DOR antagonist and a partial agonist 




Figure 2.2. Opioid agonists and antagonists in clinical use discussed in text. 
2.2.2 Opioid receptor signaling 
The opioid receptors are G protein-coupled receptors (GPCR’s), which comprise the 
largest receptor class in the human genome.50, 51 As a result, GPCRs are important targets in 
medication development. Not surprisingly, a considerable percentage of clinically used 
medications, ~36%, target GPCR’s.52 Opioid receptors are coupled to G-proteins consisting of α, 
β, and γ subunits.53 Activation of opioid receptors follows canonical GPCR signaling; ligand 
binding induces a conformational change in the receptor resulting in dissociation of the 
heterotrimeric G-protein complex and guanine-nucleotide exchange to give GGTP-α, and the Gβγ 
subunits.54, 55 Opioid receptors are coupled to inhibitory G-proteins (Gαi); activation results in the 
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inhibition of adenylyl cyclase and calcium channels, and the activation of inwardly rectifying 
potassium channels.56, 57 The heterotrimeric G-protein complex is reformed following GTP-
hydrolysis which terminates the signal.58  
A multitude of downstream signaling pathways have been associated with dissociated 
GTP-α, β, and γ subunits following opioid receptor activation.59 Over the last decade, G protein–
coupled receptor kinases (GRKs) and β-arrestins, initially discovered and characterized for their 
mechanism of GPCR signal termination, have been shown to also transduce GPCR signals.60 
GPCRs show arrestin-dependent signaling following receptor phosphorylation, resulting in 
mitogen activated protein kinase (MAPK) signaling. MAP kinases phosphorylate a number of 
targets including cytosolic targets and transcription factors in the nucleus.60  
Among the three MAP kinase families, a number of kinases are well characterized: 
extracellular signal related kinases 1/2 (ERK1/2), c-Jun-N-terminal kinases (JNK1-3), and p38-
MAP kinases (α, β, γ, δ).61 With respect to opioid receptors the ERK 1/2 subfamily is the best 
characterized; both β-arrestin dependent and G-protein activation cause ERK 1/2 activation.62 Of 
note, aversion as a result of KOR activation, which limited the therapeutic utility of  KOR agonists, 
has been linked to p38-MAPK signaling.62, 63 Additionally, c-Jun-N-terminal kinase (JNK) 
signaling, extensively studied by Chavkin and co-workers, has been linked to the long lasting 
effects of KOR selective antagonists, norbinaltorphimine (norBNI) and JDTic (Figure 2.3).62, 64 
2.2.3 Ligands used for in vitro studies of opioid receptors 
Since cloning of the opioid receptors in the early 1990’s, cell-based assays with cloned 
receptors are extensively used for in vitro evaluation of opioid ligands.1 Cell lines, such as chinese 
hamster ovary (CHO) cells, expressing one opioid receptor are broadly used for in vitro evaluation 
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of opioid ligands. This involves both radioligand binding assays to determine receptor affinity and 
selectivity, and functional assays to determine efficacy and potency. 
              The radioligand: [3H]DAMGO ([D-Ala2,MePhe4,glyol]enkephalin), [3H]DPDPE(cyclo[D-
Pen2,D-Pen5]enkephalin), and [3H]U69593 (Figure 2.3)for , , and  receptors, respectively, are 
routinely used for the binding assays. Functional assays related to signaling and CAMP production, 
such as the [35S]GTPS  assay, measure efficacy and potency of opioid agonists in [35S]GTPS 
binding, an indication of opioid receptors activation.65 Given the coupling of opioid receptors to 
adenylyl cyclase via Gi, inhibition of adenylyl cyclase activity resulting in reduced cAMP 
production is used to measure agonist activity.66 
                       
Figure 2.3 Structure of opioid ligands discussed in text. 
    
2.2.4 Opioid receptor structures 
Opioid receptors, consisting of 7 transmembrane regions (7TM), an extracelluar N-
terminus, intracellular C-terminus, extracellular and intracellular loops, are members of the 
rhodopsin family of GPCRs. Prior to the elucidation of high resolution opioid receptor crystal 
structures, receptor chimera studies and site-directed mutagenesis were important in elucidating 
the molecular basis for observed differences in the affinity of ligand binding between the opioid 
receptors. Receptor chimera studies elucidated regions of the receptors that were responsible for 
selectivity and discriminating ligands, while site-directed mutagenesis studies highlighted the 
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relative importance of specific residues. For instance, receptor chimera studies showed the 
importance of the KOR EL2 for the affinity of the endogenous ligand dynorphin A.67, 68 More 
recently, Danielsson and co-workers inserted EL2 of KOR in a soluble β-barrel and used NMR 
paramagnetic relaxation data to demonstrate direct binding of dynorphin A to EL2.69 Site-directed 
mutagenesis studies on the other hand established important residues for ligand recognition such 
as Glu297, Ser 310, Tyr 312 and Tyr 313 in the KOR.70  
Opioid receptors share the highest sequence homology in the 2nd, 3rd, and 7th TM regions 
(Figure 2.4).1 The four receptors, MOR, KOR, DOR, and NOPR share ~60% sequence homology 
with a conserved Asp residue in TM3, common in all aminergic GPCRs.71 The crystal structures 
of all four opioid receptors were solved in 2012, thereby providing structural information to further 
explain opioid pharmacology. The mouse MOR and DOR crystal structures were resolved by 
Kobilka and co-workers,72, 73 while the human KOR and NOPR receptor structures were resolved 
by Stevens and co-workers.31, 74 A considerable amount of molecular engineering was required to 
crystallize the membrane-bound receptors including thermostabilizing mutations. Additional 
innovative approaches included truncation of the flexible N- and C-termini of the receptors, T4-
lysozyme fusion for the KOR, MOR and DOR, and incorporation of apocytochrome b562RIL for 
the NOPR to stabilize the receptor structures.75 Notably, the engineered receptors were functional 
and responded to selective agonists with only modest changes in affinity. MOR, DOR, and KOR 
receptors were crystallized as dimers, highlighting the ongoing discussions on the existence of 
receptor dimers in vivo;76 however, the receptors were purified as monomers, and dimerization 
could be an artifact of the crystallization conditions.75  
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Figure 2.4 Schematic of the protein structure of the MOR, DOR and KOR showing the percentage 
of identical residues within the respective segments. Transmembrane helices are indicated by 
rectangles (from ref1).  
 
           Notably, all four receptors were crystallized in the inactive state with the respective 
antagonists; β-funaltrexamine for MOR, naltrindole for DOR, JDTic for KOR, and a peptide 
mimetic for NOPR.31, 72-74 The crystal structures highlighted observations from previous 
pharmacological studies using chimeric receptors and site directed mutagenesis studies, 
particularly concerning ligand recognition. All receptor structures were characterized by a central 
ligand binding pocket encircled by transmembrane (TM) helices.75  Conserved residues include 
Pro residues resulting in bends in most of the TM helices (TM2, TM4, TM5, TM6, and TM7) and 
cysteine residues forming a disulfide bridge between extracellular loop 2 (EL2) and the end of 
TM3. In addition, a common β-hairpin loop in EL2 allows access to the ligand binding pocket. 
More diversity was observed in extracellular loops where EL2 of KOR and NOPR had more acidic 
residues, Asp and Glu, compared to MOR and DOR, which correlates with the higher proportion 
of basic residues in the endogenous ligands dynorphin (KOR) and nociceptin (NOPR). Sequence 
conservation among the EL of the receptors was lowest in EL3 located between TM6 and TM7 
(EL3 of KOR was however not resolved in the crystal structure).77 
Ligand binding interactions included the conserved Asp residue in TM3, [Asp 1473.32 
(MOR), Asp 1283.32 (DOR), Asp 1383.32 (KOR), and Asp 1303.32 (NOPR)], which is involved in 
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charge-charge interactions with an amine in the ligands (superscripts show position of the residue 
as per Ballesteros-Weinstein numbering).78 This conserved Asp occurs in all aminergic receptors,71 
and the ionic interaction had been proposed in the early 1950’s by Beckett and Casy in their three 
binding site model for opioid receptor binding.7 A conserved His in TM6, thought to be involved 
in a hydrogen bond with the phenol in opioids,79 was observed in all receptors except the NOPR 
where it is replaced with a Gln residue. Conserved residues within 4Å of the ligand binding site in 
all four receptors were Asp3.32, Tyr3.33, Met3.36 , Trp6.48 , and Tyr7.43 while divergent residues were 
observed around the binding pocket entrance surrounded by TM2, TM3 and TM7, suggesting a 
selectivity filter.77 
JDTic in the KOR crystal structure makes a number of important interactions at the 
orthosteric binding site important for affinity. JDTic was observed in the binding pocket, capped 
by the EL2 β-hairpin, fixed in a V-shape conformation.74 A salt bridge between the piperidine and 
isoquinoline protonated amines and Asp 1383.32 anchors JDTic in the binding pocket. Hydrophobic 
contacts with Val 1082.53, Val 118 2.63, Ile 2946.65, and a hydrophobic/polar interaction with Tyr 
3127.35 are unique to KOR contributing to selectivity at KOR, consistent with mutagenesis and 
SAR studies.80 Additional contacts of particular interest include a salt bridge with Glu 2976.58 and 
the hydrophobic contact of the isopropyl group in JDTic and Trp 2876.48 (Figure 2.5).81 
 




More recently, further studies in opioid pharmacology have leveraged the structural 
information from opioid receptor crystal structures, mutagenesis, and molecular modeling to 
rationally design chemogenetic tools that allow spatiotemporal control of neuronal activity.82 In 
one particularly interesting study, Vardy et al mutated the conserved Asp residue in TM3 to abolish 
binding of endogenous KOR agonists.83 The D138N mutant receptor was named kappa opioid 
receptor DREADD (Designer Receptor Exclusively Activated by Designer Drug) or KORD. 
KORD showed no response to endogenous opioids, but was activated by salvinorin B (Figure 2.6), 
an inactive metabolite of salvinorin A. Further studies with KORD indicated neuronal silencing in 
vivo.83, 84 Chemogenetic tools such as KORD compliment tools such as optogenetics in 
understanding opioid pharmacology. Chemogenetic manipulation is limited however by the 
properties of the ligand; for instance, pharmacokinetic properties and the limited solubility of 
salvinorin B are important considerations in experimental design.83 Overall, the mutant receptor 
provides a novel tool to study neuronal signaling.  
                                                  
Figure 2.6 Non-nitrogenous KOR agonist salvinorin A and the metabolite salvinorin B. 
Additional structures of the opioid receptors have been reported since 2012. These include 
a nanobody-stabilized human KOR in its active state crystallized with the epoxymorphinan opioid 
agonist MP1104,85 a nanobody-stabilized mouse MOR in its active state crystallized with the 
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morphinan agonist BU72,86 and the human DOR crystallized with naltrindole.87 Moreover, the 
first structures of a peptide in complex with opioid receptors were reported. These included an X-
ray structure of a bifunctional DOR antagonist and MOR agonist tetrapeptide, dimethyl 
tyrosine(Dmt)-Tic-Phe-Phe-NH2, with the human DOR
88 and an NMR-based structure of 
dynorphin bound to the human KOR.89 Comparison of the active85, 86 and the inactive73, 74 crystal 
opioid receptor structures revealed global conformational changes indicating a general activation 
mechanism that involves contraction of the helical bundle on the extracellular face to allow 
opening of the helical bundle on the intracellular  face.85 
The DOR crystal structure with naltrindole, at a 1.8 Å resolution represents the highest 
resolution opioid structure to date. This structure shows the allosteric sodium site offering insights 
into opioid receptor signaling.87 Notably, sodium ions are known for negative allosteric 
modulation of opioid receptors, decreasing the affinity of agonists at the orthosteric site.90  
Elucidation of the crystal structures of the opioid receptors opened up the opportunity for 
structure-guided drug design efforts.77, 91 For instance, virtual screening has led to a number of 
novel ligands at opioid receptors.92, 93 The crystal structures are also an avenue to probe ligand-
dependent signaling by looking at receptor function at the molecular level. This is particularly 
important in the context of ligand-induced conformations resulting in ligand-dependent cellular 
signaling.94 For instance, Vardy et al. examined the binding modes of different structural classes 
of KOR agonists, showing how the different chemotypes stabilized corresponding receptor 
conformations.81 Multiple chemotypes of KOR agonists have been developed to date; Roth and 
co-workers demonstrated ligand-dependent signaling based on chemotype, suggesting differing 
binding modes in the KOR.95 
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2.2.5 Ligand-directed signaling 
Tolerance and dependence are among the drawbacks of MOR agonists such as morphine.96-
98 Bohn et al. showed that mice lacking β-arrestin-2 showed enhanced antinociception following 
administration of morphine.99, 100 Bohn et al. reported that β-Arrestin-2 knock out mice did not 
show receptor desensitization following chronic morphine treatment, suggesting the involvement 
of β-arrestin-2 in developing tolerance. Dependence however, was not affected100 as the 
characteristic upregulation of adenylyl cyclase101 was not prevented following chronic morphine 
administration. 
β-Arrestin signaling is a non-canonical GPCR signaling pathway that has gained 
prominence in recent years because of its capacity to affect the side effect profile of drugs targeting 
GPCRs.102 For a long time, β-arrestins were only implicated in GPCR desensitization by binding 
to the phosphorylated receptor thereby terminating GPCR signaling and directing it to clathrin-
coated pits.103 However, an increasing body of research has shown that β-arrestin signaling is 
distinct from canonical GPCR signaling involving G proteins, spurring the development of a new 
type of potential therapeutic targeting GPCRs.104, 105 This non-canonical GPCR signaling kinase 
appears to involve ERK1/2 and JNK3 MAP kinases.103 GPCRs can adopt different conformations, 
resulting in distinct downstream signaling depending on the ligand.106 This ligand bias, also termed 
functional selectivity or ligand-directed signaling, has become an approach to design drugs with 
fewer side effects.107 Biased ligands can differentiate between canonical and non-canonical 




Figure 2.7 Schematic showing ligand-biased signaling at GPCRs.108  
Ligand bias has gained prominence because of the potential to avert side effects that limit 
the therapeutic utility of opioid agonists. Recent reports on biased ligands at opioid receptors 
document the progress toward separation of therapeutically relevant effects from unwanted side 
effects.109, 110 Recently, a G-protein-biased MOR agonist TRV-130 exhibited analgesia with 
reduced respiratory depression and constipation than morphine and in clinical trials for acute pain 
management.111, 112 The dynorphin/KOR system has been targeted for the treatment of pain and 
mood disorders because it does not potentiate MOR related side effects such as reward and 
respiratory depression. However, side effects such as dysphoria and sedation have limited clinical 
use of centrally acting KOR ligands.113, 114 Functional selectivity in downstream signaling has been 
reported for a number of KOR ligands. For example, the activation of ERK1/2 differed after 
treatment with KOR agonists U69,593 and MOM salvinorin B, whereas U69,593 activates 
astrocyte proliferation while 2-methoxymethyl(MOM) salvinorin B does not.115 Another KOR 
agonist, 6′-guanidinonaltrindole (6′-GNTI), preferentially activated G-protein signaling over β-
arrestin2 recruitment, but did not result in phosphorylation of ERK1/2.109  β-Arrestin-mediated 
signaling has been associated with dysphoria, and therefore G-protein biased KOR ligands are 
desirable as analgesics.116 Increasing reports describe KOR agonists with G-protein biased 
signaling as desirable analgesics; these agonists include recently KOR discovered chemotypes 
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such as the triazoles (Figure 2.8).117 In recent preclinical studies, Brust et al. reported a functionally 
selective triazole KOR agonist that induced analgesia and antipruritic effects without KOR-
associated liabilities such as dysphoria and sedation.117 
 
 
                                                      
Figure 2.8 Structure of G-protein biased a) TRV-130111 and b) the triazole chemotype of KOR agonist.116 
2.3 Significance of the KOR 
Wide expression of the KOR in brain areas associated with reward pathways, mood 
regulation, and cognitive function is well documented in both rat and human brains.118, 119  These 
brain areas include the ventral tegmental area, nucleus accumbens, prefrontal cortex, substantia 
nigra, striatum, hippocampus and hypothalamus. KOR ligands, both agonists and antagonists, have 
been pursued for their therapeutic effects in pain, drug addiction, and mood disorders. KOR ligands 
have also shown promise as anti-angiogenic agents120 and to inhibit HIV-1 expression in microglial 
cells.121  
Activation of KOR notably produces analgesic effects without the undesirable side effects 
of MOR activation,  including addiction liability and respiratory depression.122 However, KOR 
agonists produce dysphoria that has limited their clinical use.123 KOR and MOR were shown to 
have opposite effects, with KOR showing aversive effects whereas MOR showed positive 
reinforcing effects in a conditioned place preference (CPP) assay following treatment with the 
respective receptor agonists.124  
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KOR activation results in dysphoria, psychotomimetic effects and anxiety-like effects 
while MOR activation elevates the mood. The opposing effects were shown to emanate from 
modulation of dopamine release in the nucleus accumbens; Shippenberg and coworkers 
demonstrated modulation of dopamine release at dopaminergic neurons as a result of stimulating 
the KOR and MOR.125 MOR activation by agonists, such as DAMGO and β-endorphin, in the 
ventral tegmental area elevated the mood. On the other hand, KOR activation by KOR agonists, 
such as dynorphin and U-69593, in the nucleus accumbens resulted in aversion. Blockade of the 
MOR by antagonists reduced dopamine release, whereas blockade of the KOR by norBNI 
increased dopamine levels.125  
Further studies have demonstrated the involvement of the dopamine reward system in both 
drug addiction and mood disorders.126-128 Notably, drugs of abuse increase dopamine levels in the 
nucleus accumbens.129 Given the opposing effects of MOR and KOR in modulation of dopamine 
release, KOR agonists have been used to counter elevated dopamine levels in drug abuse treatment. 
Ironically, however, chronic administration of KOR agonists increases drug intake by the 
induction of stress.130  
KOR antagonists, on the other hand, are beneficial in preventing relapse to drug seeking 
behavior41, 130, 131 and have shown therapeutic promise in stress-induced dysphoria.132-134 
Additional reports have highlighted the utility of KOR antagonists in preventing reinstatement of 
drug seeking behavior induced by stress.135, 136 
KOR activation in acute and chronic stress plays an important role in the behavioral 
response to the stressor. In acute stress, KOR activation can provide the necessary motivation to 
overcome threats; in chronic stress, however, KOR activation can precipitate adverse behaviors 
such as drug-seeking. A number of studies have demonstrated that increased stress precipitates 
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relapse of drug use in humans.137 In animal models, depressive effects such as immobility and 
social defeat behavior have been observed following dynorphin release after chronic stress tests 
such as the forced-swim test (FST).138 McLaughlin et al. showed that repeated forced-swim stress 
significantly potentiated the preference of mice for cocaine in the conditioned place preference 
(CPP) assay; blockade of the KOR system blocked the potentiation of cocaine-CPP.139 
Additionally, KOR agonists potentiated cocaine-CPP in a similar fashion to forced-swim stress, 
mice lacking KOR did show potentiation of cocaine-CPP in response to stress.140 Of note, a 
growing body of evidence on depression and the KOR has demonstrated profound effects of KOR 
ligands on motivation and mood, thereby increasing the interest in KOR antagonists as potential 
therapeutics in mood disorders.141 
2.3.1 KOR selective agonists 
The KOR is activated by a structurally diverse group of peptidic and non-peptidic ligands. 
Early studies of the KOR utilized less selective KOR ligands such as the benzomorphan derivative 
ketocyclazocine (Figure 2.1c). Increasingly KOR selective ligands include the arylacetamides 
U50,488, U69,593 and enandoline (Figure 2.9); U50,488 and U69,593 are used extensively to 
characterize opioid receptors.142-144 Notably, modifications of U50,488 to include a spiroether 
resulted in the more selective U69,593;145 modifying the phenyl ring in U69,593 to a benzofuran 




Figure 2.9 Structures of non-peptidic KOR agonists discussed in text a) arylacetamides b) 
diphenylethylamines, and c) octahydroquinoline carboxamides. 
 
More recently, selective KOR agonists of different classes including neoclerodane 
diterpenes (Salvinorin A, Figure 2.6), diphenylethylamines (HS665, Figure 2.9b), and 
octahydroisoquinoline carboxamides (Figure 2.9c) derivatives have been developed. 146-148Of note, 
the undesirable side effect profile of KOR agonists limits their clinical utility (see section 2.3). 
However, preclinical studies of promising analogs with a reduced side effect profile such as 
analogs of Salvinorin A (Figure 2.6), the first non-nitrogenous opioid receptor agonist, have been 
pursued.149, 150 Simonson et al reported that the Sal A analog, Mesyl Sal B, had a longer duration 
of action that Sal A and thus holds potential for further development and clinical utility.151 Brain-
penetrant KOR ligands with bias towards G-protein signaling over β-arrestin signaling have also 
shown promise. Spetea et al reported reduced side effects due to G-protein biased signaling of the 
diphenethylamine HS666 (Figure 2.9b), a partial agonist at KOR.152    
KOR agonists that do not penetrate the BBB, and thus avoid centrally mediated side effects 
such as sedation and dysphoria, have been examined in both preclinical and clinical studies. These 
include ADL 10-1010 and asimadoline (Figure 2.10a), which has been investigated for a number 
of indications including irritable bowel syndrome153 and pruritus.154 More recently, a clinical trial 
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of asimadoline was conducted in pruritus associated with atopic dermatitis.155 Additional 
peripherally selective KOR agonists include the peptidic FE200665 (now known as CR665) and 
FE200666, both of which are all D-tetrapeptides. (Figure 2.10b) that are unrelated to Dyn A. 
CR665 has been in examined in clinical trials for postoperative pain 33 while a second generation 
analog, CR845 (Figure 2.10b), that is orally available has been examined in Phase 2 studies in 
acute postoperative pain, chronic pain and pruritus.156 Ongoing studies include a Phase 3 clinical 
trial to evaluate IV CR845 in hemodialysis patients with moderate to severe pruritus.157   
 
Figure 2.10 Structures of peripherally restricted a) non-peptidic and b) peptidic KOR agonists. 
Majority of peptidic KOR selective ligands are based on the endogenous KOR ligand Dyn 
A. Modifications to Dyn A resulting in KOR selective agonists include N-terminal alkylation, 
substitutions at position 3, and modifications to increase metabolic stability.33 N-terminal 
alkylation of [D-Pro10]Dyn A(1-11) with allyl, cyclopropylmethyl(CPM) or benzyl groups 
enhanced KOR selectivity.158 Of note, the N-allyl and N-CPM analogs displayed potent KOR 
agonist activity while the N-benzyl analog displayed partial KOR agonist activity.158, 159 KOR 
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selectivity was also enhanced considerably by Ala or D-Ala substitutions of position 3 in Dyn A(1-
11) amide.160 
In Dyn A(1-13), N-terminal  (e.g. N-MeTyr) and C-terminal modifications (e.g. C-terminal 
amide) resulted in increased metabolic stability.33 Further modifications to improve metabolic 
stability include D-amino acid substitutions such as D-Ala2, D-Ala8, and D-Pro10;161 the D-Ala2 
substitution however decreased KOR selectivity.162. Combinations of modifications to Dyn A(1-
8) resulted in E-2078 and SK-9709 (Figure 2.11) with increased metabolic stability which were 
studied in vivo.163, 164 Of note, SK-9709 has a reduced amide bond between Arg6-Arg7 and 
displayed a 3-fold lower affinity toward KOR, but was 15-fold more selective for KOR over MOR 
compared to E-2078.163 
                            
Figure 2.11 Structures of Dyn A-based KOR agonists with increased metabolic stability studied in 
vivo. 
2.3.2 KOR selective antagonists 
2.3.2.1 Non-peptidic KOR selective antagonists 
KOR antagonists are also of varied chemical classes and are being pursued for their 
potential therapeutic utility in neuropsychiatric disorders, stress-related conditions and 
addiction.151 Initial studies of KOR antagonists focused on morphinan related compounds. In the 
1980’s Portoghese and co-workers reported 1,8-bis(β-naltrexamino)-3,6-dioxaoctane (TENA),165 
a modestly selective KOR antagonist that was 4- and 2.5-fold selective for MOR and DOR, 
respectively. Portoghese and co-workers later reported norbinaltrophimine (norBNI) as the first 
potent and highly selective KOR antagonist (Figure 2.12); norBNI was 520- and 580-fold selective 
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over MOR and DOR, respectively.166 Subsequently, the same group reported the naltrindole-based 
5’-guanidinonaltrindole (GNTI) with increased selectivity and potency than norBNI. Interestingly 
however, 6’-guanidinonaltrindole (6’-GNTI, Figure 2.12) displayed KOR agonist activity.167 
Inspite of the utility of norBNI and 5’-GNTI as pharmacological tools, they exhibit long lasting 
KOR antagonism lasting weeks which complicates their use.168, 169  
 
Figure 2.12 Non-peptidic KOR antagonists. 
In 2001 Thomas et al. reported the highly potent and KOR selective antagonist trans-3,4-
dimethyl-4-(3-hydroxyphenyl)piperidine derivative JDTic (Figure 2.5).170 JDTic is more selective 
for KOR than norBNI and was recently used to elucidate the crystal stricture of the human KOR.74 
In vivo evaluation of JDTic in alcohol,171 cocaine,135 and opioid dependence172 indicated promising 
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results pointing to its potential as a therapeutic. In 2014 JDTic entered clinical trials, but was 
withdrawn due to precipitation of non-sustained ventricular tachychardia (NSVT).173 Carroll and 
co-workers at the Research Triangle Institute have reported a number of JDTic analogs to improve 
properties such as blood-brain barrier penetration, onset, and duration of action that characterize 
JDTic.134, 174 Extensive modification of JDTic has been pursued to improve the drug-like properties 
of JDTic, but with limited success in obtaining analogs that retain the affinity and selectivity of 
JDTic.  
In 2014 Bailey and co-workers reported a promising KOR antagonist, BU09059 (Figure 
2.12), with a metabolically labile ethyl ester that retained the affinity and selectivity of JDTic and 
displayed improved pharmacodynamic properties.175 Notably, BU09059 did not exhibit extended 
effects lasting weeks following single administration; reduced KOR antagonism was observed 
after 7 and 14 days. Further JDTic analogs to improve ADME properties have been reported by 
Perrio and co-workers who investigated O- and N-fluoroalkyl substitutions on the 
tetrahydroisoquinoline of JDTic.176 N-Alkylation of the isoquinoline nitrogen retained affinity at 
KOR and displayed increased selectivity for KOR compared to JDTic;176 however, functional and 
in vivo evaluation have yet to be reported. 
Other scaffolds that have shown promise to provide selective KOR antagonists include 
biarylsulfonamides and aminobenzyloxyamides. The biarylsulfonamide PF-04455242 (Figure 
2.11), developed by Pfizer, displayed a shorter duration of action than JDTic following in vivo 
evaluation in the warm water tail withdrawal assay and receptor occupancy studies.177-179 PF-
04455242 entered clinical trials180 but was unfortunately withdrawn due to toxicological concerns 
in animals following a three month exposure to the compound. 
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CERC-501 (formerly LY2456302) is a potent aminobenzyloxyarylamide KOR antagonist 
that was discovered by Eli Lily while developing a radiotracer for receptor occupancy studies.181 
Following oral dosing, CERC-501 lowered self-administration of alcohol in animal models of 
chronic alcoholism and reduced immobility in animal models of depression. CERC-501 advanced 
into clinical trials for mood and anxiety spectrum disorders182 as well as stress precipitated 
smoking lapse.183  
Another KOR selective aminobenzyloxyarylamide, AZ-MTAB (Figure 2.11), was 
developed by AstraZeneca following virtual screening and extensive SAR to improve KOR 
activity and selectivity.184, 185 AZ-MTAB dose-dependently inhibited diuresis induced by U50,488. 
Additionally, AZ-MTAB exhibited promising anxiolytic activity, similar to CERC-501, in the 
elevated plus-maze (EPM) model in rats.174 Poor oral availability and hERG activity among other 
factors prevented development of AZ-MTAB. 
 
2.3.2.2 Peptidic KOR selective antagonists 
Peptidic KOR antagonists include linear and cyclic peptide analogs, the majority of which 
are analogs of the KOR endogenous ligand Dyn A. Dyn A-based KOR antagonists have been 
obtained following modifications in the N-terminus “message” sequence as well as in the C-
terminal “address” sequence. These include dynantin, Pro3 derivatives of Dyn A(1-11)NH2, [N,N-
diallyl-Tyr1,D-Pro10]Dyn A(1-11), JVA-901 (venorphin), cyclodyn, arodyn, and zyklophin (Figure 
2.13).33 Cyclodyn, a cyclic analog based on JVA-901, is constrained in the “message” sequence, 
whereas zyklophin is constrained in the “address” sequence. Zyklophin and the acetylated dyn A 





Figure 2.13 Peptidic KOR antagonists. 
Arodyn (Figure 2.13) is a potent and selective KOR antagonist developed in the Aldrich 
laboratory that dose dependently antagonized U50,488 in vivo and attenuated stress-induced 
reinstatement, but not cocaine primed drug seeking behavior in the CPP assay.187, 188 The Aldrich 
34 
 
laboratory reported initial SAR study of arodyn including alanine scan analogs, and N-MePhe1 
derivatives.189 Alanine scan results suggested that while basic residues Arg6 and Arg7 were 
important for binding to KOR, basic residues in positions 4, 9 and 11 also made contributions to 
binding affinity.190 Among these initial arodyn analogs [NMePhe1]arodyn displayed the highest 
KOR affinity (Ki=4.56 nM) and higher selectivity (=1/1100/>2170) compared to arodyn 
(=1/174/583). Interestingly, [Tyr1]arodyn displayed inverse agonist activity. Cyclic 
derivatives of arodyn were prepared using ring closing metathesis between Tyr(All) residues in 
the “message” sequence.191 Despite their reduced selectivities towards MOR and DOR compared 
to arodyn, the cyclic analogs displayed potent KOR antagonism (KB=3.25 and 27.2 nM) 
comparable to arodyn (KB=17 nM).  
Zyklophin (Figure 2.13), also developed in the Aldrich laboratory, is a potent (Ki=30 nM) 
and selective (=1/194/>330) KOR antagonist cyclized between the 5th and 8th residues.192 In 
contrast to arodyn, which is rapidly metabolized, the metabolic stability of zyklophin facilitated 
systemic administration. 136 Importantly, systemically administered zyklophin antagonized 
centrally administered KOR agonist U50488 and displayed short-acting antagonism lasting 12-
18h, in contrast to long-lasting antagonism of prototypical KOR antagonist norBNI and JDTic. 
Similar to arodyn, zyklophin prevented stress-induced reinstatement of cocaine abuse. SAR 
analysis of zyklophin revealed that Arg7 is important for KOR antagonism, and residues Phe4 and 
Arg6 contribute to KOR binding affinity.193 Interestingly however, Tyr1 was not important for 
KOR binding, unlike in Dyn (1–11)NH2. Variations in the lactam ring size resulted in 2-4-fold 
variations in KOR affinity and larger ring sizes did not lead to considerable losses affinity. 
Additionally, N-terminally substituted analogs were evaluated and were well tolerated at KOR; N-
phenethyl and N-cyclopropylmethyl derivatives exhibited the highest KOR affinity and had higher 
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KOR vs. MOR selectivities compared to zyklophin. Following Dyn A(1-13) stimulation in 
the[35S]GTPγS assay, the N-benzyl-Phe1 and N-cyclopropylmethyl analogs displayed KOR 
antagonist potencies that were 11- and 28- fold respectively more potent than zyklophin. 
The natural product CJ-15,208, (cyclo[Phe-D-Pro-Phe-Trp], which is unrelated to Dyn A, 
has displayed KOR antagonism in vitro (Figure 2.13). The macrocyclic tetratpeptide CJ-15,208, 
isolated from the fungus Ctenomycetes serratus, displayed moderate selectivity for the KOR 
(κ/µ/ẟ=1/6/55) and displayed KOR antagonism in a smooth muscle assay.194 Interestingly, Aldrich 
and coworkers synthesized CJ-15,208 and its D-Trp isomer and demonstrated that CJ-15,208 
exhibits mixed agonist/antagonist activity in vivo.195 Further, CJ-15,208 inhibited cocaine and 
stress-induced reinstatement following oral administration in a dose and time dependent 
manner.196  
The D-Trp isomer of CJ-15,208 displayed short acting KOR selective antagonism lasting 
less than 18 h and minimal MOR agonism following intracerebrovascular administration.195 Short-
acting KOR antagonism was also observed following oral administration.196 The D-Trp isomer 
inhibited stress- but not cocaine-induced reinstatement of extinguished cocaine seeking behavior, 
consistent with its KOR antagonist activity.195, 196 The promising oral activity of CJ-15,208 and 
it’s D-Trp isomer highlights their therapeutic potential in drug abuse treatments, particularly in 
relapse. Furthermore, the finite duration of action adds to their promise as lead compounds for 
substance abuse treatments. 
SAR studies on CJ-15,208 and [D-Trp]CJ-15,208 have been pursued by Aldrich and co-
workers as well as Dolle and co-workers.197-199 In an in vivo antinociceptive assay, the alanine scan 
of CJ-15,208 analogs displayed KOR antagonist behavior but also displayed MOR agonist activity 
in contrast to the parent peptide.198 Similarly, alanine scan analogs of [D-Trp]CJ-15,208  displayed 
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activity that was different from the parent peptide, exhibiting potent agonist activity in vivo.199 
Notably, treatment with one analog that displayed KOR agonist and antagonist behavior in vivo 
prevented both stress- and cocaine induced reinstatement of cocaine seeking in a time-dependent 
manner in a CPP assay. KOR selective CJ-15,208 and [D-Trp]CJ-15,208 analogs have been 
elusive; nevertheless, the unusual behavior of these macrocyclic peptides and their analogs 
presents an intriguing area for further study in peptide-based analgesics or substance abuse 
therapy. 
2.4 Conclusions 
 Increasing studies since the discovery of opioid receptors have led to the discovery of 
selective ligands to further understand opioid pharmacology. KOR ligands have gathered 
increasing interest due to their potential therapeutic effects in pain, drug addiction, and mood 
disorders. Several KOR ligands with mixed activity involving KOR are used in the clinic, while 
others are in clinical development. Extensive studies on analogs of Dyn A, the endogenous peptidic 
ligand for KOR, have resulted in the identification of various ligands, both agonists and 
antagonists. Both non-peptidic and peptidic KOR antagonists are being developed for potential 
therapeutic application in substance abuse and mood disorders. While classical non-peptidic KOR 
antagonists have a long duration of action, peptidic ligands are promising due to their finite 
duration of action. Peptides can however be rapidly metabolized leading to challenges in their 
delivery. To this effect, a variety of modifications, including the incorporation of D-amino acid 
residues and cyclization, have been applied to peptides to enhance their potential therapeutic 
utility. 
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Chapter 3 - Literature review: challenges and opportunities for ring closing metathesis in 




Interest in peptides has surged in recent years1-3 alongside increasing interest in cyclic 
peptides4, 5 which can effectively modulate difficult targets such as protein-protein interactions.6, 7 
Peptides as a class are conformationally flexible and a large body of work has focused on 
restricting their flexibility. Accordingly, tools for conformational control have emerged as useful 
approaches to leverage the unique properties of peptides to modulate biological targets.8-10 Various 
strategies to confer conformational constraint have been broadly applied to overcome disorder in 
linear peptides and thus stabilize the bioactive structure or a particular secondary structure.9, 11 
These strategies include: cyclization, incorporating rigid building blocks and rigid peptide bond 
isosteres, which also reduce peptide degradation by proteases and improve physicochemical 
properties.12-14 
In addition to enhancing metabolic stability, cyclization can increase cell permeability and 
stabilize the bioactive conformation of peptides.15-21 Notably, the cyclization strategy can mimic 
naturally occurring cyclic motifs in highly potent ligands that are resistant to thermal and 
proteolytic degradation, such as cyclotides22, 23 and the fungal toxin α-amanitin.24, 25 Examples of 
naturally occurring and clinically relevant cyclic peptides include: ziconotide, vancomycin, and 





Figure 3.1 Therapeutically relevant cyclic peptides a) ziconotide b) vancomycin, and c) cyclosporine. 
Peptides can be cyclized from either termini or from the side chains to generate a variety 
of cyclization motifs such as: head to tail, end (head/tail) to side chain, and side chain to side chain 
(Figure 3.2).9 Notably, the cyclic constraint can consist of only peptide bonds (homodetic) or 
comprise of different functional groups (heterodetic).4 Early cyclization strategies predominantly 
focused on stabilizing secondary structures utilizing chemistries such as lactam and disulfide 
bridges in addition to lactones (Figure 3.3a-c).9 More recently, hydrocarbon linkages have become 
established approaches for peptide cyclization (Figure 3.3d).  
 
Figure 3.2 Cyclization motifs for peptide cyclization a) head to tail b) end (head/tail) to side chain, and c) 
side chain to side chain. 
 
An increasing variety of linkages continue to be explored including: triazole, amine, ureido 
and guanine linkages, which have been extensively reviewed (Figure 3.3).9, 26 Of note, 
hydrocarbon linkages using ring closing metathesis have made wide ranging impact in peptide 
59 
 
stapling to stabilize alpha helical structures leading to the development of effective cell permeable 
inhibitors of protein-protein interactions.27 Grubbs and coworkers pioneered the use of 
hydrocarbon peptides by replacing a disulfide with a hydrocarbon crosslink.28, 29  
 
Figure 3.3 Representative peptide cyclization chemistries showing a) lactam, b) lactone, c) disulfide, d) 
alkene, e) triazole, and f) ureido cyclizations.  
 
Hydrocarbon linkers confer resistance to metabolic degradation, a restrictive attribute of 
peptide therapeutics that limits in vivo administration, due to their non-native character.5 
Conversely, amide, disulfide or thioether linkages can be proteolytically or oxidatively 
metabolized. Walensky and coworkers demonstrated the enhanced proteolytic stability of singly 
and doubly stapled analogs of enfuvirtide and exanetide, both lengthy peptides used as drugs in 
HIV and diabetes, respectively.30 Hydrocarbon stapling was also applied in the synthesis of 
proteolytically stable HIV-1 immunogens for HIV vaccines.31 In addition to proteolytic stability, 
hydrocarbon stapling is reported to enhance cell penetration, which makes them particularly useful 
for drugging intracellular targets.32 33, 34 Notably, peptide stapling alone does not confer 
permeability as other factors such as sequence optimization are particularly important 
considerations.33, 34  
An additional characteristic of hydrocarbon linkers is the difference in dihedral angle 
geometry of the linkage relative to typical linkages such disulfides. Disulfide linkages with a 
dihedral angle of approximately ±90 differ from lactam linkages which can be 0 o (cis) or 180 o 
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(trans) amide bonds. Ring closing metathesis results in either cis or trans olefins which may be 
separated unlike lactam linkages where the amide bond bridge is generally in the trans 
configuration. 
Of note, interactions between the cyclic bridge and the protein target can potentially 
contribute to the affinity to the target; for instance, stabilizing hydrophobic contacts were observed 
between the hydrocarbon bridge and the MCL-1 binding interface.35 However, in the constraint of 
human tumor susceptibility gene 101 protein (Tsg101) binding peptides, cyclization resulted in 
mixed results where some cyclic analogs significantly lost affinity while some retained affinity for 
the target similar to the wild type peptide.36 Similar results have been reported where optimization 
of the ring size, ring linkage, and ring configuration all factor into affinity for the target.18  
3.1.1 Solution phase and solid phase cyclization of peptides 
Cyclization of peptides can be performed in solution or on-resin during solid-phase peptide 
synthesis (SPPS,37 Figure 3.4). Notably, each cyclization strategy has advantages and 
disadvantages relating to among other factors: compatibility with SPSS, efficiency of the ring 
closing reaction, sequence-dependent effects, and compatibility with amino acid functional 
groups. Unnatural amino acids are required for a number of cyclization strategies some of which 
utilize orthogonal protection and selective deprotection to facilitate cyclization of the peptide. The 
growing demand for peptides has spurred advances in SPPS, including increasingly modified 
building blocks, incorporation of mechanical strength and sufficient swelling in common solvents 




Figure 3.4 Solid phase peptide synthesis using the Fmoc strategy showing a) solution phase and b) on-resin 
cyclization.  
 
On-resin cyclization is a useful and expedient route to access cyclic peptides given the 
fewer purification steps required. In a comparative study of solution phase and on-resin cyclization 
of a 22-residue peptide, Andreu and coworkers observed that while solution phase cyclization 
consistently gave higher yields, global yields from on-resin cyclization were comparable factoring 
in the necessary purification steps.39 In a similar study by the same group, on-resin cyclization of 
a 15-residue peptide showed greater results compared to solution phase cyclization.40 Solution-
phase cyclization requires high-dilution strategies to avoid oligomerization41, but on-resin 
cyclization does not. An additional advantage to on-resin cyclization is the pseudodilution effect42-
44 due to attaching the peptide to an insoluble solid support thereby favoring the intramolecular 
reaction over the intermolecular reaction. Accordingly, on-resin cyclization of peptides has 
increased in the recent past including strategies such as ring closing metathesis, intramolecular 
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nucleophilic substitution reactions (SN2 or SNAr), thiol-ene cyclization, Cu (I) catalyzed azide-
alkyne cycloaddition, and transition metal catalyzed coupling reactions.45 
3.2 Ring closing metathesis (RCM) of peptides 
Olefin metathesis facilitates the construction of C-C bonds and is widely applied due to the 
mild condition requirement for the transformation, functional group tolerance, high catalytic 
activity, and stability of commercially available Ru-alkylidene catalysts46 (Figure 3.5a). 
Consequently, olefin metathesis has been applied in molecules with multiple functional groups, 
including peptides, to generate hydrocarbon crosslinks via ring closing metathesis (RCM) and ring 
closing alkyne metathesis. RCM proceeds through a catalytic cycle that involves 
metallacyclobutane intermediates (Figure 3.5b); release of ethylene gas drives the reaction 
forward.47, 48  
a) 
                 
b) 
                                   
Figure 3.5 a) Structures of ruthenium-based Grubbs catalyst developed by altering the ligands around the 
metal center to tune catalyst activity and the stability of 1st and 2nd generation catalysts and b) a 





RCM has been used to enhance various secondary structures such as alpha helices and ẞ-
turns as well as to replace disulfide bonds with dicarba mimics. Typically, selected residues on the 
peptide that are not critical to binding are substituted by alkene containing non-natural amino acids, 
such as allyl glycine, to facilitate RCM (Figure 3.6a). Grubbs and coworkers used allyl glycine in 
the seminal RCM on peptides to mimic a cystine stabilized ẞ-turn.28 Other RCM precursors 
residues include α,α disubstituted alkenyl amino acids, allyl serine and cysteine residues, and allyl 
tyrosine residues (Figure 3.6b). Notably, α-methyl, α-alkenyl amino acids which have been 
extensively used in stapled peptides to reinforce an alpha helical structure.49 RCM has also been 
applied to stabilize alpha helical conformation in hydrogen bond surrogates where the hydrocarbon 
cross link is formed between olefins at the N-terminus and an N-alkylated residue resulting in an 
end-capped alpha helix (Figure 3.6c).50, 51 Interestingly, Grossman and coworkers have more 
recently applied RCM to stabilize irregular secondary structures involved in protein-protein 
interactions, thereby expanding the utility of RCM in molecular recognition applications.52 
 
Figure 3.6. a) General scheme for ring closing metathesis of a resin-bound peptide following incorporation 
of allylglycine residues b) a representative example of alkene precursors on a peptidic substrate, and c) 




Hydrocarbon crosslinks have been used as cystine bridge replacements in a variety of 
peptides such as oxytocin analogs. Vederas and coworkers studied hydrocarbon crosslinks of 
oxytocin highlighting the effect of olefin geometry, ring size, and olefin saturation on biological 
activity.53 Initial studies indicated that a cis isomer was more potent than the trans isomer although 
less active than the parent peptide while saturated analogs were less potent than the parent peptide. 
Further studies on oxytocin analogs and antagonists indicated that a 20-membered ring was more 
active than peptides with larger rings; notably, the 22-membered ring peptide was inactive. 
Robinson and coworkers reported that unsaturated analogs are more active thereby emphasizing 
advantage of conformational restriction relative to the native S-S bond. 
Despite the widespread utility of RCM, challenges remain in cyclization using Grubbs 
catalysts. Evidently, it is difficult to find general conditions that guarantee successful RCM due to 
a multitude of parameters influencing the process.54, 55 Additionally, competing reactions including 
olefin isomerization limit RCM efficiency; 56, 57  olefin isomerization due to catalyst degradation 
products such as ruthenium hydrides can result in unwanted side products.58-60 Schroeder and co-
workers reported high degrees of olefin isomerization during olefin metathesis resulting in CH2 
insertions and deletions while61 Liskamp and coworkers have reported significant olefin 
isomerization of peptidic substrates during RCM.62, 63 Interestingly, ring contraction products 
could result from RCM of isomerized olefins (Figure 3.7). For instance, Larhed and coworkers 
observed olefin isomerization and ring contraction products during RCM of macrocyclic HIV-1 
protease inhibitors.64 Olefin isomerization and ring contraction products were also reported by 






Figure 3.7 Proposed mechanism of formation of ring contraction products following olefin isomerization 
during RCM.  
 
Furthermore, on-resin RCM is influenced by the choice of solid support, solvent, catalyst 
and alkene precursor. It is therefore not surprising that considerable challenges have been reported 
during on-resin peptide RCM. In another example, Bergman et al reported that a 4:1 mixture of 
trifluoroethanol (TFE) and dichloromethane (DCM) facilitated RCM between O-allyl serine 
residues in a ẞ3-peptide following extensive screening of commonly used solvents in 
RCM.66Additionally, the amount of catalyst required for sufficient conversion was dependent on 
the solid-support used for SPPS. Further examples and several strategies to improve peptide RCM, 
include using solvent mixtures, additives, and microwave, heating have been reported (Table 3.1). 
Robinson and coworkers have documented challenges in peptide RCM that limit efficient 
cyclization including sequence dependence of the linear precursor and peptide aggregation on the 
solid support.67 For difficult substrates, chemical modification is required; pseudoproline insertion 
facilitated RCM of a human growth hormone fragment after microwave heating and addition of 
chaotropic salts to disrupt peptide aggregation failed to promote cyclization.68 Pseudoproline 
insertion induces a cis amide bond that allows reacting termini to localize favorably thereby 
promoting RCM.  
Similarly, Kessler and coworkers used reversible backbone protection of a serine residue 
to promote RCM of a decapeptide that only cyclized with the turn-inducing insertion.69 
Characterization of the olefin tether, typically done using 1H-NMR, also presents non-trivial 
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challenges; Robinson and coworkers highlight difficulties in determination of geometrical isomers 
due to poor resolution of olefin peaks which led them to develop the use of 13C NMR for 
geometrical assignments.70 Similarly, Liskamp and coworkers reported difficulties in structural 
characterization of the olefins following RCM to mimic the bicyclic vancomycin structure.63 
Table 3.1 Selected RCM conditions for synthesis of cyclic peptides and corresponding reaction conditions 
illustrating various reaction optimization and synthetic challenges 
 




20 mol% G II DCM, LiCl in 
DMF, 100 oC, µW, 1h 
Peptide contained a turn inducing 
pseudoproline residue; chaotropic salt 




>Stoichiometric G I, DCM, 
40 oC, 12h 
Reversible backbone protection 
(Ser(ΨMe,Mepro) to induce a favorable 
conformation for RCM 
3 Cyclic peptoids71 
2 mol% Grubbs catalysts, 
DCM, 40 oC, 2 h or  
1,2-dichlorobenzene, 300  
W µW, 2 min 
RCM efficiency dependent on type of 





10 mol% G I, 1,1,2-
trichloroethane (TCE), 
additives, 16h 
Screening of additives to suppress 
olefin migration in amide backbone 
cyclized peptides, length of alkenyl 






Stoichiometric G II, 
TCE/DMF, hydride 
scavengers, 80 oC, 10 min 
Addition of hydride scavengers to 
minimize olefin isomerization during 
RCM between aryl-allyl and O-allyl 
substrates; complex characterization of 




10 mol% G II (10 mM) TCE, 
additives, various thermal 
and µW conditions 
Additives including Lewis acids were 
explored to improve RCM efficiency. 






20 mol% G II DCM, 130 oC, 
µW, 1h 
Olefin migration and ring contraction 
following RCM 
8 ẞ3-peptide66 
20-35 mol % HG II, 
trifluoroethanol (TFE)/DCM 
4:1, rt, 48h 
RCM efficiency was highly solvent 
dependent; catalyst loading dependent 





10 mol% various catalysts 
and conditions under thermal 
and µW heating 
RCM efficiency dependent on solvent, 
temperature, and catalyst used. 
Differences in G II and HG II catalyst 
activity under µW heating 
aGrubbs 1st generation catalyst (G I), Grubbs 2nd generation catalyst (G II), Hoveyda-Grubbs 2nd 




Control of olefin geometry has been a considerable challenge in ring closing metathesis, 
giving mixtures of E and Z isomers which can be difficult to separate. Separation of geometrical 
isomers is particularly important due to differences in biological activity which are commonly 
observed between cis and trans isomers.53, 74 A number of approaches have been devised to address 
the geometry of olefin metathesis such as selective enrichment via ethenolysis75 and development 
of stereoselective catalysts.76 Grubbs and coworkers explored the use of a Z-selective catalyst on 
peptidic substrates highlighting that the type of olefin and amino acid side chain significantly 
influenced the catalyst activity.77 Additionally, noteworthy differences in cyclization based upon 
the solid support used for on-resin RCM were observed. Strikingly, preorganization of the peptide 
hindered Z-selective RCM instead resulting in the E- isomer, thereby indicating the effect of 
substrate bias on peptide RCM.  
Given the challenges of on-resin RCM, alternative approaches such as using aqueous media 
have been explored to potentially address issues such as peptide aggregation on-resin. One such 
approach is RCM of peptides in aqueous media. Vederas and coworkers probed the use of 
detergents and tert-butanol to solubilize ruthenium based catalysts, but found mixed results 
depending on the alkene precursor following aqueous RCM.78 More recently, Donahue and 
coworkers demonstrated RCM of a DNA-bound peptide in aqueous media where they used MgCl2 
to limit Ru-induced decomposition of DNA.79 This seminal work highlights the challenges of 
peptide RCM, but also the opportunities to broaden the utility of olefin metathesis in constraining 
peptides.  
3.2.1 Polycyclic ligands and RCM 
Polycyclic peptides have garnered increasing interest given the success of 
conformationally constrained peptides such as vancomycin and cyclosporine, which have had 
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demonstrable clinical success. Given the advantages of monocyclic peptides, the additional 
conformational constraint and metabolic stability of polycyclic peptides can potentially enhance 
target binding affinities and selectivities to antibody-like levels.80 This is especially important in 
the context of undruggable targets such as protein-protein interactions. For instance, a remarkable 
improvement in potency and selectivity was observed upon conversion of the monocyclic 
undecapeptide growth factor receptor-bound protein 2 (Grb2) Src homology 2 (SH2) domain 
peptide inhibitor into a bicyclic peptide.81 In this example, bicyclization resulted in a 60-fold 
increase in potency and 200-fold increased selectivity for the Grb2 SH2 domain. Walensky and 
coworkers have also reported benefits of additional constraints; double stapling not only improved 
metabolic stability but also enhance biological activity of enfuvirtide, an HIV fusion inhibitor.30 
Similarly, improved proteolytic stability and cell penetration was observed in a doubly stapled 
“stitched peptide” with a contiguous alkene bridge (Figure 3.8a).82 
Rhodes and Pei have extensively reviewed progress in the synthesis of bicyclic peptides, 
and highlight multiple synthetic approaches as well as the increasing utility of these constrained 
motifs.80 Indeed, multiple cyclization strategies can be combined to generate polycyclic peptides 
as has been reported for HDAC inhibitors83 (Figure 3.8b) and is observed in the natural product 
HDAC inhibitor romidepsin (Figure 3.8c), which is clinically approved to treat cutaneous and 
peripheral T-cell lymphoma.84 The combination of multiple cyclization approaches increases the 
diversity of polycyclic peptides. Additionally, polycyclization facilitates attachment of multiple 
pharmacophores; Lian et al reported a bicyclic peptide that targets peptidyl–prolyl cis–trans 




Figure 3.8. Representative polycyclic peptides: a) schematic structure showing a stitched peptide with 
contiguous alkene bridging, b) bicyclic HDAC inhibitor, c) romidepsin, d) a Pin 1 inhibitor fused with a 
cell penetrating peptide, and e) a bicyclic oxytocin analog. Pip = pipecolic acid, Nal = naphthylalanine. 
 
Combinatorial library screens and rational design have resulted in the discovery of bicyclic 
ligands.80 Heinis et al screened a phage display library of bicyclic peptides resulting in a potent 
human plasma kallikrein inhibitor.86 Using rational design Hruby and coworkers generated 
bicyclic ligands from monocyclic lead peptides. Hruby and coworkers synthesized a bicyclic 
oxytocin receptor antagonist that demonstrated both in vitro (pA2=8.2) and in vivo (pA2=6.45) 
potency (Figure 3.8e).87 Notably, no bicyclic ligands for the opioid receptors have been reported 
though dynorphin analogs are reported, though dynorphin analogs offer the necessary size to allow 
modifications resulting in a polycyclic ligand.88 
Generally, synthesis of polycyclic peptides is challenging because of the multiple 
orthogonal protection strategies that are necessary to prevent unwanted isomers. For instance, 
cysteine scrambling is a prominent concern during the synthesis of peptides with multiple cysteine 
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bridges such as conotoxins.89 Accordingly, multiple strategies have been pursued to achieve 
regioselectivity in the synthesis of polycyclic peptides via RCM. Sequential ring closure was 
employed during synthesis of the lantibiotic analog, lanticin 3147 A2 (Figure 3.9a)90, while a 
preorganization-based strategy was used for the synthesis of a nisin analog mimic bearing an 
interlocked alkene bridge (Figure 3.9b).91 Notably, preorganization can allow facile bicyclization 
and separation of cis/trans isomers as was observed by Rijkers and coworkers.91 However, in the 
absence of preorganization, cyclization and separation of cis/trans isomers in polycyclic peptides 
with alkene bridges is challenging.63 67 
 
Figure 3.9 Structure of polycyclic peptides synthesized through RCM a) lanticin 3147 A2 synthesized by 
sequential RCM and b) the carbon-bridged nicin DE ring mimic synthesized in one-step. Dhb= 
didehydroaminobutyric acid. 
 
Other strategies to achieve regioselectivity during formation of polycyclic alkene bridged 
peptides include using alkene precursors with varying activity towards the catalysts and using 
orthogonal metathesis catalysts.67 Robinson and coworkers leveraged the reduced metathesis 
reactivity of prenyl glycine to selectively form alkene bridges between AllGly residues during the 
synthesis of the α-conotoxin Rg1A analog (Figure 3.10). Notably, cross metathesis and 
assymmetric hydrogenation were employed to facilitate ring closing metathesis of the metathesis 
inactive prenyl glycine.92 Besides regioselectivity, undesired side reactions also present a 
challenge in the synthesis of polycyclic peptides that limits the scaffolds accessible through 
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sequential RCM. For instance, Bird and Walensky observed that side reactions are dependent on 
ring size and distance and therefore optimized these parameters to limit side reactions.49 
  
Figure 3.10 A representative schematic of the regioselective synthesis of the α-conotoxin Rg1A analog 
where prenyl glycine residues were used to prevent unwanted cyclization during RCM.  
 
In contrast to the strategy above that leveraged sequential ring closure to achieve 
regioselectivity, RCM and ring closing alkyne metathesis (RCAM) can simultaneously facilitate a 
one-pot synthesis due to the orthogonal nature of the two transformations. This strategy was 
employed by Cromm et al. who demonstrated regioselective ring closure in a one-pot reaction to 
generate a bicyclic peptide targeting the GTPase (Figure 3.10).93 Cromm et al prepared the bicyclic 
GTPase Rab8 inhibitor in one step using Grubbs first generation catalyst (G I) for RCM and 
molybdenum based catalyst (Figure 3.11) for RCAM. Notably, the less reactive Ru-catalyst G I 
was used to promote RCM rather than later generations of Grubbs catalysts because the increased 




Figure 3.11 One-pot bicyclization of the GTPase Rab8 inhibitor using G I and the molybdenum based 
RCAM catalyst. 
 
3.2.2 RCM and opioid peptides 
Opioid peptides have been cyclized using a variety of cyclization approaches 
including disulfide, lactam, and ring closing metathesis approaches. These cyclic opioid peptides 
have been extensively reviewed by Remesic et al88 as well as by Janecka and coworkers.26 
Similarly, ring closing metathesis of opioid peptides has been briefly reviewed by Jacobsen and 
coworkers.94 Opioid peptide ligands generally consist of short peptides (enkephalins and 
dermorphins) preferentially active at µ and ẟ opioid receptors, and longer peptides (dynorphins) 
preferentially active at the κ opioid receptor. Endorphins and enkephalins are pentapeptides while 
dermorphin is a heptapeptide; undecapeptide peptide analogs of the heptadecapeptide dynorphin 
A consisting of the first 11 residues are typically used as κ opioid receptor ligands. This discussion 
will highlight cyclization of opioid peptides by ring closing metathesis with a focus on cyclic κ 
opioid receptor ligands.  
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The groups of Schiller95 and Hruby96 have reported RCM of short opioid peptides while 
the Aldrich group has reported RCM of dynorphin A (1-11)97 (Figure 3.12). Cyclization of short 
peptides by RCM introduced a conformational constraint in the “message” region that binds and 
activates the receptor while cyclization of dynorphin analogs examined cyclization at the 
“message” and C-terminal “address” segment that enhances potency for a particular receptor 
(Figure 3.13).98 The “message” region contains the opioid receptor pharmacophoric residues, Tyr 
and Phe, separated by Gly spacers. Both Schiller and Hruby and their coworkers prepared cyclic 
enkephalins where the disulfide bridge in H-Tyr-c[D-Cys-Gly-Phe-D-Cys] was replaced by a 
dicarba bridge. In contrast to cyclic C-terminal amide analogs prepared by Schiller and coworkers, 
Hruby and coworkers synthesized cyclic enkephalin analogs with a C-terminal acid (Figure 3.12a). 
The analogs were cyclized in a side chain to side chain motif using D/L-allylglycine (AllGly) and 
retained affinity at both µ and ẟ opioid receptors (Figure 3.12a). As expected, all cyclic analogs 
exhibited selectivity for the µ and ẟ opioid receptors over the κ opioid receptors. Additionally, 
considerable differences were observed between cis and trans isomers as well as saturated analogs.  
                            
Figure 3.12 Representative examples of opioid peptides cyclized by RCM. A) cyclic enkephalin analogs, 
and b) cyclic dynorphin A analogs.  
 
                          
Figure 3.13 “Message” and “address”99 regions of opioid peptides illustrated in dynorphin A (1-11). 
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Aldrich and coworkers explored RCM of dynorphin analogs as well the effect of 
stereochemistry at position 2 on opioid receptor binding .97 A mixed solvent system was used for 
the RCM reactions for compatibility with the resin and the reaction gave reasonable yields (56-
74%, Figure 3.14). Cyclization was preformed between AllGly residues at position 2 and 5, or 5 
and 8 whose modification is tolerated by the κ opioid receptor (KOR). Notably, RCM results in a 
hydrophobic tether that maintains the hydrophobic nature of the residues at these positions. 
Whereas cyclizations involving D-AllGly at residues 2 and 5 retained high affinity for all three 
opioid receptors, they exhibited minimal selectivity for KOR over µ (MOR) and ẟ opioid receptors 
(DOR) (Table 3.2).  Cyclizations involving L-AllGly at residues 2 and 5 showed lower affinity but 
exhibited higher selectivity for KOR compare with the parent peptide Dyn A (1-11)NH2. 
Cyclizations involving AllGly at residues 5 and 8 displayed intermediate affinities but higher 
selectivity for KOR than the parent peptide. The trans isomer in cyclizations involving L-AllGly 
at positions 2 and 5 or 5 and 8 displayed higher KOR binding affinity than the cis isomer, indicating 
the effect of olefin geometry on KOR binding affinity (Table 3.2).  
                                    
Figure 3.14 Schematic representation showing RCM of dynorphin A analogs. 
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Table 3.2 Binding affinities of Dyn A analogs cyclized by RCM. 
 Ki (nM ± SEM) Ki ratio 




Dyn A(1-11)NH2a 0.57 ± 0.01 1.85 ± 0.52 6.81 ± 1.01 1/3/11 
cyclo[Ala2(-CH=CH-)Ala5]Dyn A(1-11)NH2b 
 




trans 9.46 ± 1.80 180 ± 10 1130 ± 98 1/19/119 
cyclo[D-Ala2(-CH=CH-)Ala5]Dyn A(1-11)NH2b 
cis 0.84 ± 0.10 2.33 ± 0.20 9.30 ± 1.00 1/2.8/11 
trans 1.38 ± 0.31 2.33 ± 0.22 7.17 ± 0.55 1/1.7/5.2 
cyclo[Ala5(-CH=CH-)Ala8]Dyn A-(1-11)NH2b 
cis 10.9 ± 1.8 93.0 ± 6.0 1210 ± 90 1/8.5/111 
trans 2.46 ± 0.57 36.0 ± 2.1 460 ± 51 1/15/187 
a From ref100 ; b from ref74 
 
3.2.2.1 RCM of KOR antagonists 
Previous conformationally constrained antagonists at the KOR have included lactam 
cyclizations (Figure 3.15).101, 102 103 104 The kappa opioid antagonist arodyn (Figure 3.16) is a 
relatively potent (Ki = 10 nM) and selective (κ/µ/ẟ)=1/174/583) peptide ligand that was shown to 
block stress induced reinstatement of cocaine-seeking in vivo after intracerebrovascular 
adminstration.105 However, arodyn is rapidly metabolized which prevented evaluation following 
systemic administration. Cyclization of arodyn via lactam or alkene bridges has been explored to 
introduce conformation rigidity in this lead peptide KOR antagonist (Figure 3.16).106 Cyclization 
was explored between residues 2 and , or 5 and 8, residues that showed minimal contribution to 
KOR affinity in an alanine scan.107 Most of the cyclic analogs initially prepared exhibited low 




Figure 3.15 Structures of cyclic kappa opioid receptor antagonists. 
 
                              
Figure 3.16 Structure of arodyn.  
RCM was employed to synthesize alkene bridged arodyn analogs, both head to side chain 
and side chain to side chain cyclization motifs were explored, but synthetic challenges did not 
permit the synthesis of several analogs.106 Generally, side chain to side chain cyclizations 
involving AllGly at residues 2, 5, and 8 resulted in high yields (70-90%), but the head to side chain 
cyclizations were generally unsuccessful likely due to unfavorable conformations of the olefin 
precursors in the linear peptides. Cyclization was only successful for one head to side chain analog 
after N-methylation of the N-terminus; in this case an N-terminal Alloc group was used to prevent 
a side reaction related to N-methylation (Figure 3.17).108 
 
 





To introduce cyclizations in the N-terminal segment that maintain aromatic character, 
Tyr(All) residues were incorporated into arodyn to constrain relatively important residues. 
However, a side reaction leading to the loss of the allyl group compromised the yields of side chain 
to side chain cyclizations involving aromatic residues (Figure 3.18).106, 109 Reaction product 
mixtures contained mixtures of mono and bis-desallyl products, indicating that the side reaction 
competed with cyclization and suggesting that the reacting olefins did not orient favorably for 
cyclization. Varying receptor affinities were observed for cyclized arodyn analogs.109 Cyclization 
between Tyr(All)3 and AllGly5 displayed a 40-fold loss in affinity for KOR while cyclization 
between adjacent aromatic residues was better tolerated at KOR. (cyclo[Tyr2(CH2-CH=CH-
CH2)Tyr
3,Ile8]arodyn displayed a 5.5 fold loss in affinity (Ki = 55 nM) for KOR compared to 
arodyn (Figure 3.18) while (cyclo[Tyr1(CH2-CH=CH-CH2)Tyr
2,Ile8]arodyn displayed a 7-fold loss 
in affinity (Ki = 71.7 nM) for KOR.
109 It should be noted however that this analog contained Ile8 
in place of D-Ala8. Incorporation of D-Ala8 could enhance affinity to the KOR. Sequence 




5,Ile8] where cyclizations 
were unsuccessful resulting in des-allyl products. 
 









Cyclic peptides have a growing prominence, especially with respect to probing biological 
function. Ring closing metathesis, which involves the exchange of intramolecular olefins to 
generate carbon-carbon bonds catalyzed by Grubb’s catalysts46 (Figure 3.5a), is one approach that 
has had wide impact in peptide cyclization. The resulting ethylene bridge has become increasingly 
valuable in constraining peptides and peptidomimetics, as demonstrated by reports of increased 
metabolic stability and bioactivity of cyclic ligands.27, 110, 111 Despite challenges in peptide RCM 
(Table 3.1), new developments in peptide stapling technology through development of stable 
catalysts and modified reaction conditions for different substrates increase the utility of ring 
closing metathesis. 
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Cyclization of peptides is a useful approach to probe ligand binding at biological targets. 
A cyclic constraint can potentially improve metabolic stability,1 enhance affinity for a biological 
target by stabilizing the bioactive conformation2 and/or improve membrane permeability.3,4 Ring 
closing metathesis (RCM) is a widely used cyclization strategy in which intramolecular alkene 
precursors undergo olefin metathesis, resulting in a C-C double bond that reduces the 
conformational freedom of the product. Unlike standard peptide cyclization strategies such as 
disulfide and lactam linkages, RCM generates a non-native C-C bond with distinct geometry that 
is particularly stable.5 The synthesis of cyclic peptides by RCM, on-resin and in solution, has 
increased extensively6,7 due to the broad versatility of RCM. 8-10 In addition to the development of 
stable catalysts,11-14 the rising utility of RCM in peptide modification is due, in part, to the 
increasing availability of non-natural alkene amino acid precursors as a result of their improved 
syntheses.15-17 It is not surprising that a corresponding increase in the use of RCM in peptide and 
biological applications has been observed.18,19  
Notably, peptide RCM generally features all-hydrocarbon RCM bridges utilizing amino 
acid residues such as α-alkenyl and allylglycine residues.4,18,20,21  Additionally, several studies have 
used heteroatom substituted allylic or homoallylic residues to increase the diversity of RCM 
bridges; these include allylserine, allylcysteine, and allyl tyrosine (Tyr(All) residues.22-24 
Incorporation of these amino acids into the peptide sequence allows the formation of RCM bridges 
with distinct lengths and properties.  
While the selectivity of RCM for alkenes in the presence of multiple functional groups is 
a significant advantage, particularly in peptide RCM, there are accompanying shortcomings.  
Chelation of the catalyst to polar functionalities in the peptide has been reported to decrease the 
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amount of catalyst available for productive metathesis.25 Additionally, aggregation of the peptide 
on the solid support can be limiting.23 Approaches that have been reported to enhance on-resin 
RCM include additives such as chaotropic salts or Lewis acids, and the use of microwave 
heating.26,27 Sequence dependent effects also affect the efficiency of the cyclizations;28 Robinson 
and co-workers reported that incorporation of a turn-inducing residue and microwave irradiation 
were required to facilitate RCM of a human growth hormone fragment.23  
A number of reports describing additives, further development of catalysts, and 
optimization of reaction conditions to enhance olefin metathesis highlight its utility, but also its 
shortcomings.29-32 Whereas ruthenium catalyzed olefin isomerization has been conveniently 
employed to synthesize various heterocyclic compounds33,34 and complex natural products,35 it can 
be a limiting factor in RCM cyclizations, particularly in isomerization-prone substrates such aryl-
allyl groups36 and heteroatom substituted allylic groups.37 Despite the utility or RCM, side 
reactions, such as olefin isomerization,12,30 can limit the utility of RCM in synthesizing the desired 
cyclic peptide derivatives. 
This study stems from initial attempts to prepare constrained analogs of the novel 
acetylated dynorphin A (Dyn A) analog arodyn (Ac[Phe1,2,3,Arg4,D-Ala8]Dyn A(1-11)-NH2, 
Figure 4.1) with cyclizations involving aromatic residues.38 Arodyn is a potent and selective kappa 
opioid receptor  (KOR) antagonist which has high affinity (Ki = 10 nM) and selectivity for KOR 
(Ki ratio (κ/µ/δ) = 1/174/583).
39 KOR antagonists, used classically as pharmacological tools, have 
more recently shown potential for the treatment of depression and drug addiction.40 Unlike 
cyclization of Dyn A analogs via RCM utilizing allylglycine residues,41 attempts to cyclize the 
peptide via RCM of [Tyr(All)2,3,Ile8]arodyn resulted in a mixture including desallyl products38 
(Figure 4.2), thereby limiting the utility of RCM for cyclizations involving Tyr(All) residues. In 
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this study, we describe the optimization of methodology to enhance on-resin RCM between 




R = Arg(Pbf)-Leu-Arg(Pbf)-Arg(Pbf)-Ile-Arg(Pbf)-Pro-Lys(Boc)-NH-resin 
 
R1 = Arg-Leu-Arg-Arg-Ile-Arg-Pro-Lys-NH2   
 
 
Figure 4.2 Reaction mixture resulting from RCM of [Tyr(All)2,3,Ile8]arodyn.38 
Olefin isomerization during RCM can compromise yields of the target macrocycle in 
isomerization-prone substrates. Undesirable olefin isomerization during metathesis is common in 
aryl-allyl groups as well as heteroatom substituted allylic groups.36,37 Heteroatom substituted 
homoallylic groups are also susceptible to isomerization.37 Olefin isomerization can result in ring 





 Figure 4.1 Structure of arodyn and Dyn A(1-11), a fragment of the endogenous KOR ligand Dyn A. 
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contraction42 or deallylation,37,43 thereby resulting in a complex mixture and reducing the RCM 
product yield.44 
Olefin isomerization is reportedly caused by catalyst degradation products such as 
ruthenium hydrides.30,45 A number of additives, including phenol,46 1,4-benzoquinone,30,47 and 
copper (I) halides,43 have been reported to substantially suppress olefin isomerization. Phenol and 
copper iodide are also reported to increase the rate of olefin metathesis.46,48 However, while 1,4-
benzoquinone suppresses olefin isomerization, it also suppresses the catalytic activity of Grubbs 
catalysts.36 Although copper iodide retards ruthenium hydride formation,43 it can be difficult to 
remove from reaction mixtures.49  
On-resin RCM of peptides and peptidomimetics has particular advantages compared to 
solution phase RCM. Reactions on solid phase allow easy removal of reagent byproducts by 
filtration; on-resin RCM therefore allows cyclization of the resin-bound peptide and washing of 
impurities following SPPS without additional steps. Furthermore, pseudodilution on the solid 
phase favors the desired intramolecular cyclization and limits intermolecular cyclization.  
In order to enhance RCM yields of the cyclic peptides, we used a model dipeptide Fmoc-
Tyr(All)-Tyr(All) (Figure 4.3a) to explore conditions that minimize olefin isomerization and 
deallylation. The possible desallyl side products (Figure 4.3b) were synthesized so that the extent 
of deallylation during RCM could be easily monitored. Here, we present synthetic methodology 






b)                           
Figure 4.3 a) Model dipeptide RCM reaction and b) potential desallyl side products. 
4.2 Results and discussion 
While RCM between allylglycine residues in dynorphin analogs resulted in high RCM 
product yields,41 RCM between Tyr(All) residues in arodyn and the model dipeptide using the 
same conditions resulted in low RCM product yields (Table 4.1). Products potentially due to 
unproductive metathesis, desallyl products, and oligomers reduced the RCM product as has been 
observed for Grubbs catalysts.50Additionally, the fraction of desallyl products varied with reaction 
temperature. Given concerns with higher catalyst loadings, including increased catalyst 
degradation products and higher isomerization,50 we explored the use of a lower catalyst loading 
(15 mol%). In addition, we varied the catalyst concentration, temperature, and examined the 














1 [Tyr(All)2,3]arodync 60 32 31 -d 
2 [Tyr(All)2,3]arodync 40 18 44 - 
3 Fmoc-Tyr(All)-Tyr(All)c 60 20 25 - 
4 Fmoc-Tyr(All)-Tyr(All)c 40 - 18 16 
a3 mM, 40 mol% G II 2 d, DCM/DMF (4:1); bSM: starting material; cadditional side product 
peaks were observed in the product mixture (see Appendix 1); d- < 10%  
 
Reaction temperature had a significant effect on the RCM product yield (Table 4.2 and 
Figure 4.4). High yields of desallyl products were observed at 60 oC at all of the 2nd generation 
Grubbs catalyst (G II) concentrations examined, which is consistent with catalyst degradation at 
elevated temperatures. The desired RCM product was only observed in appreciable yields at 40 
oC, with the highest yields at 3 mM and 1 mM catalyst. Lowering the catalyst concentration further 
(0.3 mM) decreased the RCM product yield.  






RCM pdt. Total 
desallyl pdt. 
SMd 
1 60 3 - e 82 - 
 2 60 1 - 39 - 
3 60 0.3 - 78 - 
4 40 3 63 16 - 
 5 40 1 55 13 - 
6 40 0.3 24 10 60 
7 40 0.1 - 18 69 
aG II 15 mol%, in DCE (60 oC) or DCM (40 oC) for 2 d; bdetermined from analytical HPLC 
chromatogram: 30-70% aqueous MeCN with 0.1% TFA over 40 min; cadditional side 
product peaks were observed in the product mixture (see Appendix 1); dSM: starting 






Figure 4.4 Chromatograms of the RCM product mixture following RCM at a) 60 oC and b) 40 oC at a 3 mM 
catalyst concentration (Table 4.2). Structures of 1-4 are shown in Figure 4.3. 
We subsequently explored the use of phenol and 1,4-benzoquinone, additives that are 
reported to effectively suppress olefin isomerization during olefin metathesis reactions.30,46 
Catalyst degradation products such as ruthenium hydrides have been implicated in olefin 
isomerization during olefin metathesis.  
Even in the presence of the additive phenol, the temperature dependence of catalyst 
degradation was evident in the low RCM product yields, at 60 oC (Table 4.3). This is consistent 
with previous reports of increased catalyst degradation at similarly higher temperatures giving rise 
to isomerized products.51 As previously observed (Table 4.2), minimal amounts of the RCM 
product were observed at 60 oC. Even in the presence of phenol, substantial amounts of desallyl 
products were obtained, indicating that phenol did not effectively suppress desallyl side products 
formation at the higher temperature (Table 4.3). The RCM product yield was low (<15%) while 
appreciable desallyl products (25-55%) and starting material (23-39%) were observed. Reactions 
in toluene did not show improved yields of the RCM product. Negligible amounts of RCM product 
were observed in toluene. 
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Conversely, further experiments with phenol revealed higher RCM product yields (31- 
79%, Table 4.3) at the lower temperature (40 oC), suggesting a robust suppression of isomerization 
accompanied by substantial conversion to the desired RCM product. The highest yields were 
observed at a catalyst concentration of 0.3 mM at 40 oC with phenol. Improved yields of the RCM 
product at the lower temperature but not the higher temperature indicate the temperature dependent 
effect of the additive phenol with G II as the catalyst. 
With 1,4-benzoquinone as the additive, negligible quantities of desallyl products were 
observed but low RCM product yield was observed at both 60 oC and 40 oC. Starting material was 
predominant in the product profile at both 60 oC (67%) and 40 oC (76%), indicating poor 
conversion of starting material to the RCM product. Thus, 1,4-benzoquinone was effective at 
suppressing isomerization, but poor in supporting conversion of reactant to the desired RCM 
product. This is consistent with previous results where 1,4-benzoquinone suppressed both catalyst 
activity and olefin isomerization.36 The marked disparities (Figure 4.5) here suggest different 
operative mechanisms of action for the two additives.  
Table 4.3 Effect of phenol, temperature,a,b and catalyst concentration on model dipeptide RCM product 
yields.  




RCM pdt. Total 
desallyl pdt. 
SMe 
1 3 phenol 42 20 -f 
2 1 phenol  60 - - 
3 0.3 phenol  79 - - 
4 0.1 phenol  31 15 43 
aResults shown are in DCM at 40 oC for 2 d; bat 60 oC in DCE, phenol did not effectively suppress desallyl 
side products formation; c15 mol% G II for 2 d; dadditional side product peaks were observed in the 









Figure 4.5 Chromatograms of the RCM product mixture following RCM (G II 15 mol% in DCM at 40 oC 
for 2 d) in the presence or absence of the additives 1,4-benzoquinone and phenol (1 equiv each). SM:starting 
material. Structures of 1-4 are shown in Figure 4.3. 
Given the poor conversion to the RCM product at elevated temperatures we explored the 
use of Hoveyda-Grubbs II (HG II) that is reported to have higher thermal stability.11 Notably HG 
II has an isopropoxy ether chelated to the metal center while G II has a coordinating phosphine 
ligand (Figure 4.6). We explored the performance of HG II at 60 oC and 40 oC and the effect of 
adding phenol (Table 4.4).  
 
Figure 4.6 Structures of Grubbs 2nd generation (G II) and Hoveyda-Grubbs 2nd generation (HG II) catalysts  
Whereas temperature dependent catalyst activity was observed for G II (Table 4.2), HG II 
exhibited comparable catalytic activity at both temperatures examined, particularly in the absence 
of an additive (Table 4.4). At the higher temperature and in the absence of phenol, HG II exhibited 
drastic improvements in the RCM product yield (Table 4.4) compared to GII (Table 4.2); this is 
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consistent with the greater thermal stability of HG II. The presence of phenol at 60 oC, however, 
interfered with product formation, presumably due to competing chelating effects of phenol and 
the isopropyl ether ligand which in turn affects thermal stability and catalyst degradation. On the 
other hand, substantial RCM product yield was observed at 40 oC with phenol, as previously 
observed for G II (Table 4.3) under similar reaction conditions. In contrast to G II, however, higher 
yields of the RCM product were observed without phenol, consistent with the increased stability 
of HG II.  
Table 4.4 Model dipeptide RCM product yields with HG II at 40 and 60 °C.a 




RCM pdt.     Total 
desallyl pdt. 
S.Mb 
1 60 -  86 - -c 
2d 60 phenol 17 32 - 
3 40 -  80 - - 
4 40 phenol  72 15 - 
a 0.3 mM 15 mol% HG II in DCE (60 oC) or DCM (40 oC) for 2 d; b SM: starting material; c - 
< 10%; dadditional side product peaks were observed in the product mixture (see Appendix 1) 
 
We subsequently explored the utility of the optimized conditions on cyclization of a 
tripeptide with Tyr(All) residues (Figure 4.7). Reasonably high yields of the RCM product (65-
84%) were generally observed at 40 oC with both G II and HG II; interestingly, much lower yields 
were observed with HG II at 60 oC (Table 4.5). Consistent with the model dipeptide study, the 
highest yields were observed at the lower temperature examined. Overall, satisfactory RCM 





                               
Figure 4.7 Structure of model tripeptide Fmoc-Tyr(All)-Phe-Tyr(All). 
Table 4.5 Tripeptide RCM product yields under optimized conditions with G II and HG II.a  
Entry Catalyst Temp.(°C) 
Additive 
(1 equiv) 
  RCM 
Pdt. 
Total 
desallyl     
pdt. 
1b HG II 60 - 27 28 
2 HG II 40 - 84 - c 
3 HG II 40 phenol 67 - 
4 G II 40 phenol 65 - 
a0.3 mM 15 mol% G II or HG II in DCE (60 oC) or DCM (40 oC) for 2 d; badditional side 
product peaks were observed in the product mixture (see Appendix 1); c- < 10% 
 
4.3 Conclusions 
The model dipeptide study illustrated several important modifications to improve yields of 
the desired product. Particularly, we observed the superior efficiency of phenol compared to 1,4-
benzoquinone to suppress deallylation, the temperature dependent effectiveness of phenol with G 
II, as well as the influence of the thermal stability of the catalyst. As a result, we had optimized 
conditions at 40 oC with G II in the presence of phenol. Furthermore, we identified conditions that 
resulted in appreciable yields of the RCM product with HG II. Overall the optimized conditions 
from the model dipeptide using G II and HG II were effective and gave satisfactory yields of the 
RCM product. The best yields were obtained in DCM at 40 oC in both the model dipeptide and the 
tripeptide; notably, phenol was required with G II but not with HG II to suppress deallylation. 
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Further synthesis of arodyn analogs containing Tyr(All) using the optimized conditions for 
pharmacological evaluation was undertaken (see Chapter 5). The methodology presented here 
could be beneficial in RCM reactions where olefin isomerization complicates purification and 
could enhance the yields of the desired RCM product, particularly for peptidic substrates. 
4.4 Experimental 
Materials and methods 
The Rink amide ChemMatrix resin was purchased from Biotage (Charlotte, NC), the 
Fmoc-protected PAL-PEG-PS was purchased from APPTec LLC (Louisville, KY), and the 2-
chlorotrityl chloride resin was purchased from Chem-Impex International (Wood Dale, IL). All 
standard protected amino acids were purchased from Bachem (King of Prussia, PA), EMD 
Millipore Chemicals (San Diego, CA), Peptides International (Louisville, KY), or Chem-Impex 
International. Fmoc-L-Tyr(All)-OH was purchased from Chem-Impex International. The coupling 
agent benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) and the 
coupling additive 1-hydroxybenzotriazole hydrate (HOBt) were obtained from Peptides 
International. Dichloromethane (DCM), N,N-diisopropylethylamine (DIEA), dimethylformamide 
(DMF), diethyl ether, acetonitrile, methanol, and trifluoroacetic acid (TFA) were purchased from 
Fisher Scientific (Hampton, NH). All other chemicals were purchased from Aldrich Chemical Co. 
(Milwaukee, WI).  
Instruments  
Electrospray ionization mass spectrometry (ESI/MS) was performed on an LCT 
Premier (Waters Corp., Milford MA) instrument with a time of flight mass analyzer or the Advion 
expression L compact MS (Advion, Inc. Ithaca, NY).  A Voyager DE STR high performance 
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matrix-assisted laser desorption time-of-flight mass spectrometer (MALDI-TOFMS) was used for 
MALDI analysis. 
Analytical HPLC was performed on an Agilent 1200 system fitted with a Grace Vydac 
analytical column (C18, 300 Å, 5 μm, 4.6 mm x 50 mm) equipped with a Vydac C18 guard 
cartridge. HPLC chromatograms were monitored at 214 nM. 
Solid phase peptide synthesis (SPPS) on the 2-chlorotrityl chloride resin 
Peptides were prepared by the Fmoc (9-fluorenylmethoxycarbonyl) solid-phase synthesis 
strategy. The general method reported previously (Scheme 4.1) for the synthesis of linear peptides 
on 2-chlorotrityl resin52,53 on a custom-made manual peptide synthesizer (CHOIR) was followed 
in the synthesis of the following dipeptides and tripeptide: Fmoc-Tyr(All)-Tyr(All)-OH, Fmoc-
Tyr(All)-Tyr-OH, Fmoc-Tyr-Tyr(All)-OH, Fmoc-Tyr-Tyr-OH,  and Fmoc-Tyr(All)-Phe-
Tyr(All)-OH (Table 4.6). Briefly, after swelling of the resin in DCM (2×10 min), the Fmoc-
protected C-terminal amino acid (2 equiv in DCM/DMF(4/1)) and DIEA, 5 equiv) were added to 
the resin, the reaction mixture was agitated with nitrogen gas for 6 h with addition of DCM every 
30 min to maintain solvent volume. DIEA (5 equiv) was added every 2 h. MeOH (15 %) and DIEA 
(5 %) in DCM (2×10 min) were then used to cap unreacted sites on the resin, after which the resin 
was washed with DCM/DMF (1:1, 5x). After Fmoc deprotection (20% piperidine, 1 x 5 min, 2 x 
20 min), the resin was washed with DMF (5x), DCM/DMF (1:1, 5x) and DCM (5x). 
Cycles of Fmoc deprotection and amino acid couplings (2 equiv in DCM/DMF, 4/1) were 
performed to add amino acids to the growing peptide chain. Amino acid couplings were performed 
using PyBOP (2 equiv), HOBt (2 equiv), and DIEA (5 equiv) in DCM/DMF (1/1) for 2–4 h. 
Nitrogen gas was used to agitate the mixture during coupling. To cleave the peptide from the resin, 
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1% TFA in DCM was bubbled through the resin (5 mL x 10, 2 min each), then drained into a round 
bottom flask and evaporated.  
Table 4.6 Analytical data of synthesized linear and cyclic peptides. 




cyclo-Fmoc-Tyr(All)-Tyr(All)-OH 18.0 [M+Na]+ 641.22 [M+Na]+ 641.22 
Fmoc-Tyr(All)-Tyr-OH 14.6 [M+Na]+ 629.22 [M+Na]+ 629.90 
Fmoc-Tyr-Tyr(All)-OH 14.4 [M+Na]+ 629.22 [M+Na]+ 629.80 
Fmoc-Tyr-Tyr-OH 6.0 [M+Na]+ 589.19 [M+Na]+ 589.19 
Fmoc-Tyr(All)-Tyr(All)-OH 23.0 [M+Na]+ 669.25 [M+Na]+ 669.25 
Fmoc-Tyr(All)-Phe-Tyr(All)-OH 26.4 [M+Na]+ 816.32 [M+Na]+ 816.33 
cyclo-Fmoc-Tyr(All)-Phe-Tyr(All)-OH 21.6 [M+Na]+ 788.29 [M+Na]+ 788.29 
[Tyr(All)2,3]arodyn 32.2b [M+H]+ 1647.01 [M+H] + 1647.86 
cyclo[Tyr(All)2,3]arodyn 29.3b [M+3H]3+ 540.30 [M+3H]3+ 540.50 
a30-70% aqueous MeCN with 0.1% TFA over 40 min; b5-50% aqueous MeCN with 0.1% TFA over 
45 min 
 
 Synthesis of Fmoc-Tyr(All)-Tyr(All)-OH 
SPPS was performed as described above on the 2-chlorotrityl resin (1 g, 0.84 mmol, 0.84 
mmol/g).  Fmoc-Tyr(All)-OH (2 equiv 745 mg, 1.68 mmol) was loaded following the general 
method for the first amino acid loading on 2-chlorotrityl resin SPPS as described above. After 
Fmoc-deprotection, Fmoc-Tyr(All)-OH (2 equiv 745 mg, 1.68 mmol) was coupled to the resin to 
extend the peptide chain followed by Fmoc deprotection as described in the general procedure for 
SPPS to give Fmoc-Tyr(All)-Tyr(All)-OH ESI/MS m/z 669.25 observed, 669.25 calculated 
(M+Na)+, HPLC tR = 23.0 min (30-70% aqueous MeCN with 0.1% TFA over 40 min at a flow 
rate of 1 mL/min). 
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Scheme 4.1 Synthesis of Fmoc-Tyr(All)-Tyr(All)-OH. 
 
a) Fmoc-Tyr(All)-OH, DIEA, DCM, rt, 6-8 h; b) Piperidine/DMF (1:4), (1 x 5 min, 2 x 20 min ) 
rt; c) Fmoc-Tyr(All)-OH, PyBop, HOBt, DIEA, DCM/DMF, rt, 2-6 h. 
SPPS of [Tyr(All)2,3]arodyn 
 [Tyr(All)2,3]arodyn was prepared by the Fmoc SPPS strategy using the automated Biotage 
microwave peptide synthesizer (Initiator+ Alstra; Biotage, Sweden) on a 0.14 mmol scale. 
Rinkamide ChemMatrix (0.45-0.52 mmol/g) or Fmoc-PAL-PEG-PS resin (0.18-0.20 mmol/g) 
resin was swollen for 20 min at 70o C in DMF prior to cycles of amino acid coupling and 
deprotection (prior to the coupling reaction, the Fmoc group was removed from the Fmoc-PAL-
PEG-PS resin). Coupling reactions were performed using Fmoc amino acids (4 equiv, 0.5 M), 
activated with PyBOP (4 equiv, 0.5 M) and HOBt (4 equiv, 0.5 M) in the presence of DIPEA (8 
equiv in NMP, 0.5 M), for 5 min at 75 oC. Fmoc deprotection was performed at room temperature 
with 20% 4-methylpiperidine in DMF (4.5 mL, 1 x 3 min; 4.5 mL, 2 x 10 min). The side chains of 
Lys and Arg were protected with tert-butoxycarbonyl (Boc) and 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), respectively. N-Acetylation was performed 
using acetic anhydride (5 M in DMF) and DIEA (2 M in NMP) for 20 min at room temperature. 
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The resulting peptide-resin was washed with DMF (5 mL, 3 x 45 sec) and DCM (5 mL, 3 x 45 
sec). Generally, crude peptides were cleaved from the resin using acidic cleavage cocktails for at 
least 2h and then precipitated in cold ether following filtration. For the Rinkamide ChemMatrix 
resin, crude peptides were cleaved from the resin using TFA/triisopropylsilane(TIPS)/H2O 
(95/2.5/2.5). For Fmoc-PAL-PEG-PS resin, crude peptides were cleaved from the resin using 
TFA/phenol/H2O/TIPS (88/5/5/2); for cleavage of aliquots, the solution was diluted with 10% 
aqueous acetic acid (3–5 mL) and then extracted with diethyl ether (3 × 5 mL) following filtration.   
General procedure for RCM  
Generally, second-generation Grubbs’ catalyst (15 mol%) or second-generation Hoveyda 
Grubbs’ catalyst (15 mol%) was dissolved in DCM and added to Fmoc-Tyr(All)-Tyr(All)-2-
chlorotrityl resin (0.56 mmol/g) or Fmoc-Tyr(All)-Phe-Tyr(All)-2-chlorotrityl resin (0.51 
mmol/g). Catalyst loading was calculated relative to the resin-bound peptide loading. Additives 
(phenol or 1,4-benzoquinone) were added to the reaction mixture along with the catalyst, and the 
reaction mixture was heated as indicated for the respective reaction conditions for 2 days under 
nitrogen gas with gentle stirring. The solvent volume was varied according to the quantity of resin 
used in order to give the desired catalyst concentration for the reaction. After the specified reaction 
time, the resin was transferred to a 15 mL polypropylene syringe fitted with a 
polytetrafluoroethylene (PTFE) frit on a manual peptide synthesizer and washed with MeOH (3 x 
5 mL) and DCM (10 x 5 mL), with N2 agitation, to remove the catalyst. Following aliquot cleavage 
of the dried resin, analytical HPLC was performed using a linear gradient of 30-70% aqueous 
MeCN with 0.1% TFA over 40 min for the model dipeptide and tripeptide or 5-50% aqueous 
MeCN with 0.1% TFA over 45 min for [Tyr(All)2,3]arodyn. Yields for the respective reactions 
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were determined from analytical HPLC chromatograms (Appendix 1); in some cases, baseline 
resolution was not achieved so yields shown are an estimate. 
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Chapter 5 - Conformational constraint of aromatic residues in the “message” sequence of 





The last chapter described the use of a model dipeptide to explore reaction conditions that 
suppress deallylation during RCM and therefore enhance cyclization yields. Notably, cyclic 
constraints are generally incorporated at non-critical residues, typically with AllGly when using 
RCM. This chapter focuses on the constraint of aromatic residues in arodyn analogs with the goal 
of examining the pharmacological effect of these constrained analogs. Such a constraint could 
potentially stabilize the bioactive conformation in addition to improving metabolic stability of the 
kappa opioid receptor (KOR) antagonist arodyn. 
Aromatic residues in arodyn contribute to KOR affinity, as observed in the alanine scan 
where a 3- to 4-fold loss in KOR affinity resulted upon substitution of Phe1 and Phe3; Phe2 
substitution, however, had minimal effect.1 Aromatic residues are critical components of the opioid 
pharmacophore according to the “message-address” concept applied to opioid peptides by Chavkin 
and Goldstein.2 The “message”, which consists of two aromatic residues and a spacer, is common 
to all mammalian opioid peptides. The “message” binds to and activates the receptor, in contrast 
to the “address” which enhances affinity for a particular receptor. Of note, there are limited reports 
of cyclization of aromatic residues in opioid peptides.3,4 
Chimeric peptides with increased selectivity for the KOR have been developed based on 
the “message-address” concept. The chimeric peptide JVA 901 (now called venorphin), a KOR 
antagonist, was developed by combining the “message” sequence of a tetrapeptide with weak KOR 
antagonism, derived from cobra venom, with the address sequence of [D-Ala8]Dyn A 1-11.5 
Venorphin reversed agonism of Dyn A (1-13)NH2 in a concentration dependent manner and 
showed KOR selectivity comparable to [D-Ala8]Dyn A 1-11 despite having 100-fold lower KOR 




Similarly, extacet was developed by replacing the N-terminal “message” sequence of [D-
Ala8]-Dyn A 1-11 with Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 ([Arg
6]acetalin), which shows potent 
mu opioid receptor (MOR) antagonism.6 A 65-fold increase in affinity for KOR (Ki = 6.6 nM) was 
observed for extacet, but it also retained high MOR affinity (Ki = 1.12 nM). Further modifications 
and SAR on the “message” sequence in a combinatorial library led to the discovery of arodyn, 
Ac[Phe1,2,3, Arg4,D-Ala8]Dyn A-(1-11)NH2, a relatively potent (Ki = 10 nM) and selective KOR 
antagonist (Ki ratio (κ/μ/δ) = 1/174/583).
7 In vivo studies following intracerebroventricular 
injection demonstrated that arodyn prevents stress-induced reinstatement of cocaine-seeking 
behavior.8  
Previous cyclization of [Ile8]arodyn using RCM in the “message” sequence indicated that 
cyclization between adjacent aromatic residues was tolerated by the KOR, whereas cyclization 
between Tyr(All)3 and AllGly5 resulted in a substantial decrease (>39-fold) in KOR affinity.4 Like 
arodyn, potent KOR antagonism in the [35S]GTPγS assay was observed for arodyn analogs 
cyclized between aromatic residues 2 and 3 (KB = 3.2 nM), as well as between residues 1 and 2 
(KB = 27.5 nM).  Whereas these analogs retained affinity at KOR, they exhibited some loss in 
affinity compared to arodyn, possibly due to the Ile8 substitution. This chapter describes arodyn 
analogs with D-Ala in place of Ile8, which is expected to increase affinity to KOR (Bennet MA, 
Murray TF, Aldrich JV, unpublished results). 
To constrain aromatic residues using RCM, we employed Tyr(All) residues to give an 
alkene bridge. The alkene bridge could be introduced between any of the three aromatic residues 
(Figure 5.1). Initial cyclization of [Tyr(All)2,3]arodyn using Grubbs 2nd generation catalyst (G II) 
resulted in desallyl products, which complicated purification and compromised the product yield.  
This chapter describes the synthesis of arodyn analogs using conditions that suppress deallylation 
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during RCM. Based on docking studies, cyclization was explored between adjacent aromatic 
residues where the rings were modified by using meta- or para-substituted allyl tyrosine precursors 
(Figure 5.2). 
 
Figure 5.1 Structures of arodyn analogs and possible constraint of aromatic residues. 
 
Figure 5.2 Arodyn analogs cyclized at adjacent tyrosine residues. 
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5.2 Results and discussion 
5.2.1 Pharmacophore generation and docking study 
To generate a pharmacophore with key structural features, we used the KOR X-ray crystal 
structure that was solved in its inactive state with the antagonist JDTic bound at the orthosteric 
site.9 We made several important assumptions and developed criteria to inform and guide the 
docking study (see Appendix 2 for details of modeling methods). First, rather than dock the full 
peptides, which is computationally expensive, we docked the corresponding tetrapeptide fragment 
for arodyn (Ac-Phe-Phe-Phe-Arg-NHCH3) and each of its cyclic analogs to assess how the 
“message” sequence may interact with KOR. Importantly, Arg4 is included as part of the modeled 
fragments, as it is the first amino acid residue to likely interact with nonconserved acidic residues 
that directly flank the orthosteric site (Glu209 in extracellular loop 2 and/or Glu297
 
6.58).10 Many 
KOR ligands possess basic sites – including arodyn – that are hypothesized to interact with 
nonconserved acidic residues (Glu203, Asp206, Asp216, Asp217, and/or Asp218) that line 
extracellular loop 2 (ECL2). While these potential interactions are not considered in the current 
modeling approach, docking poses that direct the C terminus of the fragment peptide away from 
ECL2 were eliminated from further evaluation. 
The binding mode of arodyn and its analogs to KOR is somewhat unique, as these peptides 
do not possess the prototypical phenol or N-terminal basic amine that is present in most opioid 
ligands. Surprisingly, arodyn analogs containing these groups demonstrated diminished affinity 
for the KOR.1 We created a pharmacophore consisting of two basic sites (adjacent to Glu209 and 
Glu297) and two aromatic sites (see Appendix 2 for details on pharmacophore generation) to 
position the basic guanidinium and two of the three aromatic groups into regions of the pocket 
known to bind these moieties.9-12 
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Arodyn analogs with modifications in the “message” sequence exhibit binding affinities 
within 1- to 7-fold that of arodyn.1 An alanine scan of arodyn indicated that while the “address” 
sequence contributed substantially to binding at the KOR, aromatic residues Phe1 and Phe3 also 
contribute to KOR affinity.1 Accordingly, it is possible that the “message” sequence for the 
different analogs binds in similar conformations. The backbone and the side chains of Phe1 and 
Phe3 are oriented such that cyclizations may not appreciably change the positions of these groups 
in the receptor binding pocket among arodyn and its cyclic analogs. 
While many different conformations and docking poses of cyclic arodyn analogs were 
observed in the study (including some with slightly better docking scores), only one common 
molecular architecture (Figures 5.3 and 5.4a-d) emerged that satisfied all the pharmacophore 
criteria. In this arrangement, no moieties of the docked molecules formed contacts with the 
conserved Asp1383.32 residue, as expected from the SAR. While this ligand-receptor contact is 
present in all opioid receptor crystal structures which all contain basic opioid ligands, it does not 
appear to be important for the binding of noncationic ligands.13  
In this arrangement, the side chains of the first residue in arodyn (Phe) and its analogs (Phe, 
Tyr or m-Tyr) adopt similar anti conformations (similar χ1 angles, see Table A2.1a in Appendix 
2, Figure 5.5). These groups overlap with the tetrahydroisoquinoline of JDTic and, by extension, 
the phenols of the other opioid ligands in other crystal structures. The side chains of the second 
residue (Phe2, Tyr2, or m-Tyr2) do not appear to have a common conformation (different χ1 and χ2 
angles, see Table A2.1b in Appendix 2) among the docked species; in this case, the cyclizations 





Figure 5.3 Docked structure of arodyn (thick green sticks) docked in the KOR model. In this pose, Phe1 and 
Phe3 of arodyn occupy the two aromatic pharmacophoric sites (orange spheres); the guanidinium of Arg4 
lies in one of the basic sites of the pharmacophore (cyan sphere), forming an ionic contact (yellow lines) 
with Glu297. JDTic (thick gray sticks) and the important nonconserved acidic residues Glu209 and Glu297 
– as well as the conserved residues within 5.0 Å of Phe1, Phe2, and Phe3 of arodyn – of the minimized 




Figure 5.4 Structure of the a) p1p2 (magenta sticks), b) m1m2 (purple sticks), c) p2p3 (orange sticks), and d) 
m2m3 (brown sticks) cyclic arodyn analogs when docked inside the KOR model (not shown). In these poses, 
Phe1 and Phe3 of the analogs occupy the two pharmacophoric aromatic sites (orange spheres) while the 
guanidinium of Arg4 lies in one of the basic sites of pharmacophore (cyan sphere); Glu209 and Glu297 of 
the minimized receptor are also shown. The guanidinium of Arg4 forms an ionic contact (yellow lines) with 
the nearby Glu297 in all analogs except a) the p1p2 analog. In b) and d) the guanidinium of Arg4 also forms 
an intramolecular ion-dipole interaction with the carbonyl of m-Tyr2 (yellow lines). 
a)                                                        b)   
 







Figure 5.5 Overlay of arodyn and its analogs following docking in the KOR model (not shown). Arodyn 
(green) and its p1p2 (magenta), m1m2 (purple), p2p3 (orange), and m2m3 (brown) analogs have similar 
conformations. The acetyl group and backbone of residues 1-3 generally have a similar backbone across 
the analogs. The side chains of residues 1 and 3 (χ1, χ2) are generally similar, while the conformation of 
the side chain of residue 2 varies substantially. The conformation of Arg4 also varies among the different 
species; only the p1p2 analog does not appear to form an ionic contact with the side chain of Glu297. 
 
The side chains of the third residue (Phe, Tyr, or m-Tyr), in contrast to Phe1, were found to 
adopt a common gauche (-) conformation (observed χ1 angles, see Table A2.1c in Appendix 2). 
When superimposed on the corresponding crystal structures, the side chains overlay closely with 
the pendant phenyl ring of BU72 and the Phe3 side chain of DIPP-NH2, crystallized bound to the 
MOR and DOR, respectively. 11,12 These two phenyl groups do not appear to impart selectivity to 
BU72 and DIPP-NH2, as they lie in a conserved region of the pocket (Gln115
2.60, W1242.69, 
Val1343.28, Leu1353.29, Asp1383.32, Cys2104.77). In fact, BU72 is actually a mixed MOR and KOR 
agonist; 14 DIPP-NH2 is a mixed DOR antagonist and MOR agonist, achieving its modest 
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selectivity for DOR via the phenyl moiety of its Tic2 residue. 15 Overall, the phenyl groups of 
arodyn occupy a region in the receptor lined with conserved residues (Gln1152.60, Asp1383.32, 
Trp2876.48, Ile2906.51, Ile3167.39, Tyr3207.43) that flank the amide of JDTic in the KOR crystal 
structure.9 
Given that arodyn lacks the prototypical phenol or N-terminal basic amine common in 
opioid ligands, the docked arodyn analogs provided further insight into the possible binding mode 
of arodyn at the KOR. The proposed docking poses (Figures 5.4a-d) suggested that cyclization 
between aromatic residues would be compatible binding to the KOR. We therefore used RCM to 
introduce conformational constraint in arodyn between aromatic residues. 
5.2.2 Chemistry 
While RCM is a powerful technique to install C-C bonds, there is a lack of general 
conditions that guarantee successful metathesis.16,17 Of particular interest, ruthenium catalysts can 
also promote non-metathesis transformations,18 including olefin isomerization.19 that is 
problematic, especially in akenes with allylic heteroatoms or aromatic groups.20 Jacobsen and 
Rongved have extensively reviewed RCM in peptidic systems, particularly the impact of 
intramolecular RCM bridges on structure and pharmacological activity.21 A vast majority of RCM 
reactions are performed in solution phase, and a low concentration of substrate (2 mM) is typically 
used. Initial solid phase RCM of dynorphin A22 and arodyn analogs23 used a DCM/DMF solvent 
mixture which allows for higher reaction temperatures, compatibility with hydrophyllic peptides 
and on-resin cyclization. In later studies, low catalyst concentration and phenol as an isomerization 
suppressant24 were found to enhance RCM product formation and suppress side products, as 
demonstrated in the model dipeptide study (Chapter 4). In the model dipeptide study the highest 
yields of RCM product were obtained using DCM and a 0.3 mM catalyst concentration in the 
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presence of phenol. A series of cyclic arodyn analogs (Table 5.1, Scheme 5.1) were synthesized 
by conventional heating using these conditions developed for a model dipeptide.   
Table 5.1 Structures of the arodyn analogs cyclized by RCM under conventional heating and their linear 
precursors. In some cases a mixture of cis/trans analogs were obtained (indicated by a wavy bond). 
Peptide Arodyn analog Structure 





















Linear arodyn analogs 
10 [Tyr(All)2,3] Ac-Phe-Tyr(All)-Tyr(All)-R 
11 [Tyr(All)2,m-Tyr(All)3] Ac-Phe-Tyr(All)-m-Tyr(All)-R 
12 [m-Tyr(All)2, Tyr(All)3] Ac-Phe-m-Tyr(All)-Tyr(All)-R 
13 [m-Tyr(All)2,3] Ac-Phe-m-Tyr(All)-m-Tyr(All)-R 





Scheme 5.1 Synthesis of the p2p3 analog 2 by RCM with conventional heating using optimized conditions 
from the model dipeptide study. 
 
5.2.2.1 RCM by conventional heating 
 The optimized conditions found for the dipeptide were explored for RCM of arodyn 
analogs using conventional heating. As observed in the model dipeptide, lowering the temperature, 
reducing the catalyst loading, and using phenol as an isomerization suppressant with the 2nd 
generation Grubbs catalyst (G II) contributed to an increase in the RCM product 2 (Table 5.2). As 
observed in the model dipeptide reasonable yields were observed using both G II and the 2nd 
generation Hoveyda-Grubbs catalyst (HG II) (Table 5.2). The optimized conditions from the 
model dipeptide resulted in a 2-fold increase in the RCM product compared to the original 
121 
 
conditions (Table 5.2). The optimized conditions with G II in the presence of phenol (Table 5.2) 
were subsequently used in the synthesis of 2-6 for pharmacological evaluation (Figure 5.6 and 
Table 5.3). 
 Conformational effects influenced the cyclization efficiency of arodyn analogs. Varying 
yields of the respective cyclizations were observed indicating sequence dependent effects; notably, 
cyclization of 7 resulted in low yields under conventional heating. Sequence dependent effects 
were most prominent in the p1p3 analog 15 where no cyclization was observed even after 5 days 
of heating under the optimized conditions using G II. The bis-desallyl product was observed as the 
major product following RCM for 5 days.  
Table 5.2 Results for RCM of 10 using various reaction conditions.  
Entry Solvent Temp. (oC) [Cat.] (mM) Cat.a  mol % Additive RCM Pdt. 
1 DCM/DMF 60 3 40 - 34 
2 DCM 40 0.3 15 phenol 71 
3 DCM 40 0.3 15b - 64 
aG II catalyst; bHG II catalyst 
 
 
Figure 5.6 Arodyn analogs cyclized via conventional heating, showing the corresponding yields. 
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Table 5.3 Analytical data of purified cyclic peptides 2-6 and their linear analogs. 






2 8.38 (97.8) 9.47 (99.8) [M+3H]3+ 540.3 [M+3H]3+ 540.5 
3 8.95 (97.5) 9.24/9.48 (98.7)c [M+H]1+ 1619.0 [M+H]1+ 1619.5  
4 8.88 (96.8) 9.22 (98.5) [M+H]1+ 1619.0 [M+H]1+ 1619.4 
5 8.88 (96.6) 9.04/9.14 (99.7)c [M+H]1+ 1619.0 [M+H]1+ 1619.5 
6 8.60 (97.7) 9.15 (99.8) [M+H]1+ 1619.0 [M+H]1+ 1619.6 
10 8.99 (99.4) 10.09 (99.6) [M+H]1+ 1647.0 [M+H]1+ 1647.9 
11 9.15 (99.7) 10.35 (99.3) [M+H]1+ 1647.0 [M+H]1+ 1647.5 
12 9.12 (99.2) 10.48 (97.0) [M+H]1+ 1647.0 [M+H]1+ 1647.3 
13 9.47 (99.7) 10.13 (99.9) [M+H]1+ 1647.0 [M+H]1+ 1647.5 
14 9.29 (99.9) 10.46 (96.3) [M+H]1+ 1647.0 [M+H]1+ 1647.4 
a5-55% aqueous MeCN with 0.1% TFA over 10 min, 1 mL/min; b25-75% aqueous MeOH with 
0.1% TFA over 10 min, 1 mL/min;ctrans/cis   
 
Given the low yield observed for analog 7 (Figure 5.6) under conventional heating, reaction 
conditions using microwave heating were also explored. Microwave heating has been shown to 
improve RCM reactions of resin-bound peptides with low catalyst loadings and short reaction 
times.25 Two modes of microwave irradiation, open vessel and closed vessel microwave heating, 
were explored. 
5.2.2.2 Microwave Assisted RCM 
Generally, HG II performed better than G II in the model dipeptide under microwave 
heating (Table 5.3) and was thus adopted for microwave assisted RCM using the optimized 
conditions established in the model dipeptide study. Cyclization of the model dipeptide, 16, using 
HG II under open vessel heating at 60 oC resulted in 68% of the cyclic product after 2 h and 82% 
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after 3 h (Table 5.4), which was comparable to heating for 2 d under conventional heating.  HG II, 
which is more stable than G II,26 was therefore used in subsequent microwave assisted RCM.  
Whereas the dipeptide was rapidly cyclized, the tripeptide, 17, required a longer reaction time (5 
h) to achieve a similar cyclization yield; a 50% yield was observed after 3 h and increased to 79% 
after 5 h heating (Table 5.4).  
Cyclization of 10 also required a longer reaction time than the dipeptide, but only 30% of 
the cyclic product was observed after 5 h (Table 5.4). Additionally, a 2-fold increase in the catalyst 
loading (30 mol%) was required to obtain a reasonable yield of 2 (53%), suggesting catalyst 
decomposition under open vessel conditions. Closed vessel microwave heating was therefore 
explored to enhance cyclization yields. Of note, due to instrument design, closed vessel microwave 
heating allowed higher reaction temperatures in contrast to open vessel microwave heating.  
Table 5.4 Comparison of RCM product yields following cyclization of model dipeptide, tripeptide, and 
arodyn analogs under conventional heating using G II and with microwave irradiation using HG II.a 
Peptide Substrate 
RCM Pdt (%) 
conventional 
heatingb 
microwave heating c 
open vessel closed vessel 
16 Fmoc-Tyr(All)-Tyr(All) d 80 82e - 
17 Fmoc-Tyr(All)-Phe-Tyr(All) d 65 50e, 79 - 
10 [Tyr(All)2,3]arodynf 71 29, 53g 72, 72h 
18 [Tyr(All)1,m-Tyr(All)2]arodynf 22 - 44, 67h 
19 [m-Tyr(All)1,Tyr(All)2]arodynf - - 56h 
20 [m-Tyr(All)1,2]arodynf - - 66h 
a Initial RCM experiments using G II catalyst under open vessel heating resulted in negligible 
conversion of the model dipeptide; b G II (15 mol%, 0.3 mM) in DCM, phenol 40 oC, 2 d 
(optimized conditions from Chapter 4); c HG II (15 mol%, 0.3 mM) in dichloroethane, 60 oC, 5 
h unless otherwise specified; d peptide on 2-chlorotritryl resin; e 3 h; f  peptide on Rink amide 




Closed vessel microwave heating under the optimized conditions resulted in a similar yield 
(72%) in 5 h to that obtained by conventional heating compared to only 30% under open vessel 
microwave heating (Table 5.4). Furthermore, a 2-fold increase in the cyclization yield of 18 
compared to conventional heating was observed under the optimized conditions (Chapter 4). An 
additional improvement in the yield of 18 was observed following microwave irradiation at 75 oC 
for 2 h (Table 5.4).  Similarly, high cyclization yields were observed after 19 and 20 were cyclized 
for 2 h at 75 oC (Table 5.4). Presumably, closed vessel microwave heating limited the catalyst 
decomposition that could occur under open vessel heating and facilitated enhanced yields in the 
cyclization of 18. Microwave irradiation therefore facilitated the synthesis of arodyn analogs 
involving m-Tyr(All) in the cyclic constraint for pharmacological evaluation (Tables 5.5 and 5.6). 
Notably, however, the cyclization of [Tyr(All)1,3]arodyn was negligible under both open vessel 
and closed vessel microwave irradiation. This suggests that [Tyr(All)1,3]arodyn adopts a 
conformation that does not bring the alkene precursors in close proximity to facilitate cyclization 










Table 5.5 Structures of arodyn analogs containing m-Tyr(All) in positions 1 and 2 cyclized by RCM under 
microwave irradiation and their linear precursors. 







Linear arodyn analogs 
18 [Tyr(All)1,m-Tyr(All)2] Ac-Tyr(All)-m-Tyr(All)-Phe-R 
19 [m-Tyr(All)1,Tyr(All)2] Ac-m-Tyr(All)-Tyr(All)-Phe-R 






Table 5.6 HPLC and MS data of purified arodyn analogs 7-9 and their linear analogs 18-20. 






7 28.9;29.9c (98.1) 22.63 (95.0) [M+3H]3+ 540.3 
[M+2H]2+ 405.5 
[M+3H]3+ 540.7  
[M+2H]2+ 405.8  
8 29.1 (98.6) 23.3 (98.2) [M+3H]3+ 540.3 
[M+2H]2+ 405.5 
[M+3H]3+ 540.7 
[M+2H]2+ 405.8  
9 29.5 (98.7) 23.8 (95.1) [M+3H]3+ 540.3 
[M+2H]2+ 405.5 
[M+3H]3+ 540.7  
[M+2H]2+ 405.8  
18 33.7 (95.2) 29.3 (95.2) [M+3H]3+ 549.7 
[M+2H]2+ 412.5 
[M+3H]3+ 550.3  
[M+2H]2+ 413.0  
19 32.8 (98.0) 28.2 (98.9) [M+3H]3+ 549.7 
[M+2H]2+ 412.5 
[M+3H]3+ 550.3  
[M+2H]2+ 412.7  
20 33.3 (99.9) 29.0 (98.2) [M+3H]3+ 549.7 
[M+2H]2+ 412.5 
[M+3H]3+ 550.1  
[M+2H]2+ 412.9 
a 5-50% aqueous MeCN with 0.1% TFA over 45 min, 1 mL/min; b 25-70% aqueous 
MeOH with 0.1% TFA over 45 min, 1 mL/min; c cis/trans mixture 
 
5.2.2.3 NMR analysis 
NMR J-couplings and chemical shifts were employed to determine the cis/trans 
configuration of the olefins (Appendix 3).  For some spectra, multiplets were not well separated 
likely because the difference in chemical shifts was not significantly larger than the scalar coupling 
constants, thereby giving non-first order effects. In these instances, we performed homonuclear 
decoupling experiments, as illustrated for 2 (Figure 5.7a and b); as a result, we assigned the 
coupling constant, 16 Hz (3Jolefin), indicating a trans olefin. The same logic was applied to other 
cyclic analogs. Generally, the chemical shifts of vinyl protons were between 5.5 and 6.05 ppm for 
the cyclic analogs (Table 5.7). The olefins were predominantly in the trans configuration except 
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in RCM between adjacent m-Tyr(All) residues where appreciable quantities of the cis isomer 





Figure 5.7 a) 1H NMR of 2 showing olefin protons and the spectrum following homonunclear decoupling; 












Table 5.7 1H NMR data for cyclic arodyn analogs 2-9.   
                                                                     
Compound 
 
Chemical shifts (δ) of 
olefininc protons 
J (Hz) cis/trans 
ratio  
2 2-trans 
H1 = 5.82 J12 = 16.0 
- 
H2 = 5.90 J21 = 15.9 
3 
3-cis H1 = 5.74 J12 = 11.2 
1 
H2 = 5.87 J21 = 11.3 
3-trans 
 
H1 = 5.52 J12 = 15.8 
3 
H2 = 5.95 J21 = 16.1 
4 4-trans 
H1 = 5.71 J12 = 16.1 
- 




H1 = 5.71 J12 = 11.0 
1 
H2 = 5.91 J21 = 11.4 
5-trans 





H1 = 5.80 J12 = 16.2 
- 
H2 = 5.87 J21 = 15.8 
7 7-cisa H1 = 5.74 - 1 
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 H2 = 6.05 - 
7-trans 
 
H1 = 5.62 J12 = 16.1 
4 
H2 = 5.89 J21 = 16.1 
8 
8-cis 
H1 = 5.61 J12 = 11.6 
1 
H2 = 5.63 J21 = 10.8 
8-trans 
H1 = 5.76 J12 = 16.2 
67 
H2 = 5.82 J21 = 16.0 
9 
9-cis 
H1 = 5.77 J12 = 11.2 
1 
H2 = 5.96 J21 = 11.2 
9-trans 
H1 = 5.83 J12 = 15.8 
2 
H2 = 6.04 J21 = 15.7 
a Coupling constants could not be obtained due to poor resolution of the fine structure 
 
5.2.3 Affinity 
In vitro pharmacological evaluation  
The opioid receptor affinities of the cyclic arodyn analogs and their linear precursors were 
evaluated using Chinese hamster ovary (CHO) cells stably expressing cloned opioid receptors. 
Initial results indicate that cyclizations involving the aromatic residues were generally well 
tolerated at the KOR; cyclized analogs displayed affinities within 4-fold that of arodyn with the 
exception of 7 and 9 with meta-substituted Tyr(All) at positions 2 and positions 1 and 2, 
respectively (Table 5.8). Some analogs gained affinity for MOR, thus exhibiting reduced 
selectivity for KOR (Table 5.8). Reduced selectivity for KOR was observed for meta-substituted 
Tyr(All) derivatives 3 and 5 compared to their linear counterparts. The cyclic para substituted 
analogs 2 and 6 displayed the highest selectivity for the KOR relative to the MOR among the cyclic 
analogs evaluated to date.  
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The docking studies of arodyn and its cyclic analogs to the KOR crystal structure9 (Figure 
5.4) suggested that the binding mode does not change appreciably upon cyclization. The similar 
KOR affinities of the cyclic arodyn analogs are consistent with the results of the docking study.  








Kia Ki ratio 
(MOR/KOR) KOR MOR KOR MOR 
    1b 10.0 ± 3.0 1740 ± 130 174 
2 (p2p3) 14.7 ± 5.6 1372 ± 329 93 10 18.9 ± 3.6 1224 ± 239 65 
3 (p2m3) 19.8 ± 6.8 607 ± 28 31 11 11.7 ± 3.3
 1384 ± 145 118 
4 (m2p3) 39.2 ± 12.9 1958 ± 207 50 12 41.2 ± 14.3
 1326 ± 106 32 
5 (m2m3) 15.4 ± 3.4 828± 125 54 13 3.3 ± 0.3
 838 ± 77 255 
6 (p1p2) 11.7 ± 2.7 1434 ± 402 123 14 12.1 ± 4.3
 221 ± 17 18 
7 (p1m2) 56.7 ± 15.3 NDc - 18 62.2 ± 5.1
 ND - 
8 (m1p2) 29.2 ± 3.5
 
ND - 19 43.2 ± 5.5
 ND - 
9 (m1m2) 68.2 ± 10.4 ND - 20 65.8 ± 18.1
 ND - 
a Mean Ki values ± SEM from at least 3 independent experiments; b from ref.7; c not determined 
 
Negligible efficacies were observed in GTPγS screening at KOR at 10 µM for analogs 2-
6 and 10-14, indicating that both linear and cyclic analogs have minimal agonist activity at KOR. 
Further determination of binding affinities and further testing of all cyclized analogs is in progress. 
Of note, the originally prepared cyclic arodyn analogs 21 and 22 exhibited 5- and 7-fold losses, 
respectively, in affinity relative to arodyn (Table 5.9).23 D-Ala8 substitution was expected to 
improve affinity to KOR from earlier studies (Bennet, Murray, Aldrich, unpublished results). 
Compounds 2 and 6 exhibited similar affinity to arodyn, indicating increased affinity following D-
Ala8 substitution (Table 5.8). D-Ala substitution also affected KOR selectivity and a marked 
difference in selectivity for the KOR was observed; 93-fold for 2 (Table 5.8) and 16-fold for 21 
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(Table 5.9), indicating increased selectivity with D-Ala8 in the cyclized arodyn analogs. A similar 
substantial difference in selectivity was observed between 6 (Table 5.8) and 22 (Table 5.9) cyclized 
between residues 1 and 2.  





Ki ± SEM (nM)a Ki ratio 
(MOR/KOR) KOR MOR 
1b arodyn 10.0 ± 3.0 1740 ± 130 174 
21 (p2p3) cyclo[Tyr(All)2,3 ,Ile8]arodyn 55.4 ± 4.1 903 ± 34 16 
22 (p1p2) cyclo[Tyr(All)1,2,Ile8] 71.7 ± 5.2 1920 ± 150 27 
a Mean Ki values ± SEM from at least three independent experiments; from ref.7 
5.3 Conclusions 
The studies discussed in this chapter were aimed at examining the effect of constraining 
aromatic residues that contribute to the KOR affinity of arodyn. We successfully introduced a local 
constraint in the N-terminus of arodyn using conditions developed in a model dipeptide system to 
suppress olefin isomerization during RCM. The resulting non-native C-C bond is metabolically 
stable and is different from standard peptide cyclization approaches such as lactam or disulfide 
bridges. Additionally, while RCM is typically done at non-critical residues using AllGly, we used 
Tyr(All) residues to restrict the conformation of residues contributing to KOR affinity to 
potentially stabilize the bioactive conformation. Of note, docking studies suggested constrained 
aromatic residues would be compatible with binding to KOR. 
Optimized conditions from the model dipeptide study and microwave heating facilitated 
the synthesis of arodyn analogs with constrained aromatic residues using RCM. Accordingly, 
varying cyclization yields were observed due to sequence and conformationally dependent effects 
that lowered cyclization efficiency in some analogs. Microwave irradiation was vital in improving 
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the yields of peptide RCM while reducing the reaction times, particularly for cyclizations between 
the first two residues involving m-Tyr(All).  
The resulting cyclic arodyn analogs generally retained affinity at the KOR with binding 
affinities within 7-fold of arodyn. Cyclizations involving Tyr(All) between adjacent residues 
displayed the highest affinity and selectivity for KOR. In contrast, among the analogs evaluated to 
date, cyclizations involving m-Tyr(All) exhibited reduced selectivity for KOR. The general 
retention of KOR affinity in the cyclic arodyn analogs is consistent with modeling studies which 
suggested similar positioning of the aromatic groups of the different analogs in the KOR binding 
site.  
Incorporation of D-Ala8 improved KOR binding affinities compared to the corresponding 
analogs containing Ile8, indicating the contribution of this modification in the “address” sequence. 
A 5.5-fold improvement in affinity was observed for 2 relative to 21 while about a 6-fold 
improvement was observed for 6 relative to 22. Additionally, 2 was at least 7-fold more selective 
for KOR relative to MOR than 21 while 6 was about 4-fold more selective for the KOR than 22 as 
a result of increased KOR affinity. Overall, proposed binding modes from the docking study 
provide a plausible explanation as to why the cyclizations between aromatic residues in the 
“message” sequence was generally well tolerated at the KOR. 
5.4 Experimental 
Materials and methods. 
The Rink amide ChemMatrix resin was purchased from Biotage (Charlotte, NC), the 
Fmoc-protected PAL-PEG-PS was purchased from APPTec LLC (Louisville, KY), and the 2-
chlorotrityl chloride resin was purchased from Chem-Impex International (Wood Dale, IL). All 
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standard protected amino acids were purchased from Bachem (King of Prussia, PA), EMD 
Millipore Chemicals (San Diego, CA), Peptides International (Louisville, KY), or Chem-Impex 
International. Fmoc-L-Tyr(All)-OH was purchased from Chem-Impex International, and Fmoc-
m-Tyr(All) was purchased from PepTech Corporation (Bedford, MA, USA). The coupling agent 
benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) and the 
coupling additive 1-hydroxybenzotriazole hydrate (HOBt) were obtained from Peptides 
International. Dichloromethane (DCM), N,N-diisopropylethylamine (DIEA), N,N-
dimethylformamide (DMF), diethyl ether, acetonitrile, methanol, and trifluoroacetic acid (TFA) 
were purchased from Fisher Scientific (Hampton, NH). All other chemicals were purchased from 
Aldrich Chemical Co. (Milwaukee, WI).  
Instruments.  
Open vessel microwave assisted RCM was performed on a Biotage microwave peptide 
synthesizer (Initiator+ Alstra; Biotage, Sweden). Closed vessel microwave assisted RCM was 
performed on a Biotage Initiator+ SP Wave microwave synthesizer . 
Electrospray ionization mass spectrometry (ESI/MS) was performed on an LCT 
Premier (Waters Corp., Milford, MA) instrument with a time of flight mass analyzer or on the 
Advion expression L compact MS (Advion, Inc., Ithaca, NY).  A Voyager DE STR high 
performance matrix-assisted laser desorption time-of-flight mass spectrometer (MALDI-TOFMS) 
was used for MALDI MS analysis. 
1H NMR spectra of these compounds (0.5−2 mg) were obtained at 27 °C in DMSO-d6 on 
a Bruker Avance III 600 MHz equipped with a 5 mm cryoprobe in the McKnight Brain Institute 
at the National High Magnetic Field Laboratory’s AMRIS facility at the University of Florida or 
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a Bruker AVANCE DRX-500 spectrometer (500.13 MHz proton frequency) equipped with a 5 
mm z-gradient cryoprobe. 1H chemical shifts were referenced to the residual DMSO signal at 2.49 
ppm, and coupling constants were extracted from the 1D spectra. 
Analytical HPLC was performed on two instruments: an Acquity UPLC system (Waters 
Corp., Milford MA) fitted with an Acquity UPLC Ethylene Bridged Hybrid (BEH) column (C18, 
130 Å, 1.7 μm, 2.1 mm x 50 mm) or an Agilent 1200 system fitted with a Grace Vydac analytical 
column (C18, 300 Å, 5 μm, 4.6 mm x 50 mm) equipped with a Vydac C18 guard cartridge. 
Preparative HPLC was performed on a Vydac C18 column (10 µm, 300 Å, 22 x 250 mm) equipped 
with a Vydac C18 guard cartridge using a Waters HPLC system (Waters Corp., Milford MA) or 
an LC-AD Shimadzu liquid chromatography system at a flow rate of 20 mL/min. HPLC 
chromatograms were monitored at 214 nM. 
Solid phase peptide synthesis (SPPS) on the 2-chlorotrityl chloride resin 
The general method reported previously for synthesis of linear peptides on the 2-
chlorotrityl resin (0.84-1.0 mmol/g loading),27,28  using the Fmoc (9-fluorenylmethoxycarbonyl) 
strategy was followed in the synthesis of the dipeptide Fmoc-Tyr(All)-Tyr(All) and the tripeptide  
Fmoc-Tyr(All)-Phe-Tyr(All) (Table 5.10). Briefly, after swelling of the resin in DCM (2×10 min), 
the Fmoc-protected C-terminal amino acid (2 equiv in DCM/DMF(4/1)) and DIEA, 5 equiv) were 
added to the resin, and the reaction mixture was agitated with nitrogen gas for 6 h with addition of 
DCM every 30 min to maintain solvent volume. DIEA (5 equiv) was added every 2 h. Unreacted 
sites on the resin were capped with 15% MeOH and 5% DIEA in DCM (2×10 min) after which 
the resin was washed with DCM/DMF (1:1, 5x). After Fmoc deprotection (20% piperidine, 1 x 5 
min, 2 x 20 min), the resin was washed with DMF (5x), DCM/DMF (1:1, 5x) and DCM (5x). 
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Cycles of Fmoc deprotection and amino acid couplings (2 eq. in DCM/DMF(4/1)) were 
performed to add to the growing peptide chain. Amino acid couplings were performed using 
PyBOP (2 equiv), HOBt (2 equiv), and DIEA (5 equiv) in DCM/DMF (1:1) for 2–4 h. Nitrogen 
gas was used to agitate the mixture during couplings. To cleave the peptide from the resin, 1% 
TFA in DCM was bubbled through the resin (5 mL x 10, 2 min each) then drained into a round 
bottom flask and evaporated.  
Ring Closing Metathesis (RCM) of the resin-bound model dipeptide and tripeptide 
Generally, second-generation Grubbs’ catalyst (G II) (3.6 mg, 0.004 mmol, 849.0 g/mol, 
0.15 equiv) or second-generation Hoveyda-Grubbs’ catalyst (HG II) (2.6 mg, 0.004 mmol, 626.6 
g/mol, 0.15 equiv) was dissolved in degassed DCM or 1,2-dichloroethane (DCE) (14 mL, 0.3 mM) 
and added to Fmoc-Tyr(All)-Tyr(All)-2-chlorotrityl resin (50 mg, 0.028 mmol, 0.56 mmol/g) or 
Fmoc-Tyr(All)-Phe-Tyr(All)-2-chlorotrityl resin (50 mg, 0.026 mmol, 0.51 mmol/g). Catalyst 
loading was calculated relative to the resin-bound peptide loading. The additive phenol (1 equiv) 
was added to the reaction mixture when using G II and the reaction mixture was heated for 2 days 
under nitrogen gas with gentle stirring. Open vessel microwave assisted RCM was performed on 
a Biotage microwave peptide synthesizer (Initiator+ Alstra; Biotage, Sweden) in PTFE reaction 
vials. Following RCM, the resin was washed with MeOH (3 x 5 mL) and DCM (10 x 5 mL) before 
drying and cleavage from the solid support. Analytical HPLC was performed using a linear 
gradient of 30-70% solvent B (solvent A, water (0.1% TFA) and solvent B, MeCN (0.1% TFA) at 




Table 5.10. Analytical data for linear peptides synthesized on the 2-chlorotrityl resin and their cyclic 
analogs. 




1 Fmoc-Tyr(All)-Tyr(All)-OH 23.0 [M+Na]+ 669.26 [M+Na]+ 669.26 
2 cyclo-Fmoc-Tyr(All)-Tyr(All)-OH 18.0 [M+Na]+ 641.22 [M+Na]+ 641.22 
3 Fmoc-Tyr(All)-Phe-Tyr(All)-OH 26.4 [M+Na]+ 816.32 [M+Na]+ 816.33 
4 cyclo-Fmoc-Tyr(All)-Phe-Tyr(All)-OH 21.6 [M+Na]+ 788.29 [M+Na]+ 788.30 
 a30-70% aqueous MeCN with 0.1% TFA over 40 min at 1 mL/min on an Agilent 1200 system 
 
 Solid phase peptide synthesis (SPPS) of arodyn analogs 
The Rinkamide ChemMatrix (0.45-0.52 mmol/g) or Fmoc-PAL-PEG-PS resin (0.18-0.20 
mmol/g) was swollen for 20 min at 70 oC in DMF prior to cycles of amino acid coupling and 
deprotection (prior to the coupling reaction, the Fmoc group was removed from the Fmoc-PAL-
PEG-PS resin) on a Biotage microwave peptide synthesizer (Initiator+ Alstra; Biotage, Sweden). 
Coupling reactions were performed using Fmoc amino acids (4 equiv, 0.5 M), activated with 
PyBOP (4 equiv, 0.5 M) and HOBt (4 equiv, 0.5 M.) in the presence of DIEA (8 equiv in NMP, 
0.5 M), for 5 min at 75 oC. Fmoc deprotection was performed at room temperature with 20% 4-
methylpiperidine in DMF (4.5 mL, 1 x 3 min; 4.5 mL, 2 x 10 min). The side chains of Lys and 
Arg were protected with tert-butoxycarbonyl (Boc) and 2,2,4,6,7-pentamethyldihydrobenzofuran-
5-sulfonyl (Pbf), respectively. N-Acetylation was performed using acetic anhydride (5 M in DMF) 
and DIEA (2 M in NMP) for 20 min at room temperature. The resulting peptide resin was washed 
with DMF (5 mL, 3 x 45 sec) and DCM (5 mL, 3 x 45 sec). Generally, crude peptides were cleaved 
from the resin using acidic cleavage cocktails for at least 2 h and then precipitated in cold ether 
following filtration. For the Rinkamide ChemMatrix resin, crude peptides were cleaved from the 
resin using 4 mL TFA/triisopropylsilane(TIPS)/H2O (95/2.5/2.5). For Fmoc-PAL-PEG-PS resin, 
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crude peptides were cleaved from the resin using 4 mL TFA/phenol/H2O/TIPS (88/5/5/2); for 
cleavage of aliquots, the solution was diluted with 10% aqueous acetic acid (3–5 mL) and then 
extracted with diethyl ether (3 × 5 mL) following filtration.   
Ring Closing Metathesis (RCM) of arodyn analogs 
Generally, a solution of degassed DCM or 1,2-dichloroethane (DCE) containing Hoveyda-
Grubbs-II catalyst (3.0 mg, 0.3 mM, 0.15 equiv) or Grubbs-II catalyst (4.0 mg, 0.3 mM, 
0.15 equiv) was added to the resin-bound peptide (150 mg, 0.21 mmol/g) before heating. 
Conventional heating under N2 was performed for 2 days. Open vessel microwave assisted RCM 
was performed on a Biotage microwave peptide synthesizer (Initiator+ Alstra; Biotage, Sweden) 
in PTFE reaction vials while closed vessel microwave assisted RCM was performed on a Biotage 
Initiator+ SP Wave microwave synthesizer in capped microwave reaction vials. Following the 
reaction, the resin was washed with MeOH (3 x 5 mL) and DCM (10 x 5 mL) before drying and 
cleavage from the solid support. Analytical HPLC was performed using a linear gradient of 5-50% 
solvent B (solvent A, water (0.1% TFA) and solvent B, MeCN (0.1% TFA) at a flow rate of 1 
mL/min. 
Synthesis of cyclic peptides 2-6 
Following assembly of the protected peptide on the resin by SPPS as described above, the 
peptide was subjected to RCM as follows. A solution of degassed DCM containing Grubbs-II 
catalyst (4.0 mg, 0.3 mM, 0.15 equiv) and phenol (3.0 mg,  0.03 mmol, 1 equiv) was added to the 
resin-bound peptide (150 mg, 0.21 mmol/g) before heating, and conventional heating at 40 oC was 
performed under N2 for 2 days. The crude peptide was cleaved from the resin and isolated as 
described above under the procedures for SPPS and RCM of arodyn analogs. 
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Synthesis of cyclic peptides 7-9 
Following assembly of the protected peptide on the resin by SPPS as described above, the 
peptide was subjected to RCM as follows. A solution of degassed 1,2-dichloroethane (DCE) 
containing Hoveyda-Grubbs-II catalyst (3.0 mg, 0.3 mM, 0.15 equiv) was added to the resin-bound 
peptide (150 mg, 0.21 mmol/g) before heating at 75 oC for 2 h under closed vessel microwave 
heating. Closed vessel microwave assisted RCM was performed on a Biotage Initiator+ SP Wave 
microwave synthesizer in capped microwave reaction vials. The crude peptide was cleaved from 
the resin and isolated as described above under the procedures for SPPS and RCM of arodyn 
analogs. 
Purification and analysis of purified peptides 
The crude peptides were purified by preparative reversed-phase HPLC using a Waters 
HPLC system (Waters Corp., Milford MA) or an LC-AD Shimadzu liquid chromatography 
systemon a Vydac C18 column (10 μ, 300 Å, 22 x 250 mm). A linear gradient of 25–45% aqueous 
MeCN (containing 0.1% TFA) over 40 min (0.5% MeCN/min) for crude linear peptides and 20-
35% over 60 min (0.25%/min) for crude cyclic peptides was used for purification (cyclic peptides 
were isolated as cis/trans mixtures). The purifications were monitored at 214 nm.  
Analytical HPLC to verify the purity of the final peptides was performed on an Agilent 
1200 series liquid chromatograph system using a Vydac 218-TP column (5 μ, 300 Å, 4.6 mm x 50 
mm) equipped with a Vydac guard cartridge or an Acquity UPLC Ethylene Bridged Hybrid 
(BEH) column (C18, 130 Å, 1.7 μm, 2.1 mm x 50 mm). The two systems used for analysis on the 
Agilent 1200 series liquid chromatograph system were: a linear gradient of 5-50% solvent B 
(solvent A = aqueous 0.1% TFA and solvent B = MeCN containing 0.1% TFA) over 45 min at a 
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flow rate of 1 mL/min (system 1), and a linear gradient of 25-70% solvent B (solvent A = aqueous 
0.1% TFA and solvent B = MeOH containing 0.1% TFA) over 45 min at a flow rate of 1.0 mL/min 
(system 2). On the Acquity UPLC system system the two systems used for analysis were: a linear 
gradient of 5-55% solvent B (solvent A = aqueous 0.1% TFA and solvent B = MeCN containing 
0.1% TFA) over 10 min at a flow rate of 0.2 mL/min (system 1), and a linear gradient of 25-75% 
solvent B (solvent A = aqueous 0.1% TFA and solvent B = MeOH containing 0.1% TFA) over 10 
min at a flow rate of 0.2 mL/min (system 2). The final purity of the peptides by both methods was 
greater than 95%. Molecular weights of the peptides were determined by ESI-MS (Advion CMS) 
or MALDI (Voyager DE STR). 
Pharmacological evaluation 
Radioligand binding assay 
Competitive inhibition of [3H]diprenorphine and [3H]DAMGO ([D-
Ala2,MePhe4,glyol]enkephalin) was employed to determine binding affinities at KOR and MOR 
receptors, respectively. The receptors were expressed on Chinese hamster ovary (CHO) cells. 
Radioligand binding assays were performed for arodyn analogs cyclized by RCM and their 
corresponding linear precursors. Incubations were carried out in triplicate with varying 
concentrations of peptides (0.1-10,000 nM) for 90 min at RT in the presence of peptidase inhibitors 
(10 μM bestatin, 30 μM captopril, and 50 μM L-leucyl-L-leucine) and 3 mM Mg2+. Nonspecific 
binding was determined in the presence of 10 μM unlabeled Dyn A-(1-13)NH2 and DAMGO for 
KOR and MOR, respectively. IC50 values were determined by nonlinear regression analysis fit to 
a logistic equation for the competition data using Prism software (GraphPad Software Inc., San 
Diego, CA). Ki values were calculated from the IC50 values by the Cheng and Prusoff equation
29 
using KD values of 0.45 and 0.49 for [
3H]diprenorphine and [3H]DAMGO respectively. Arodyn 
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has low affinity for the ẟ opioid receptor (DOR) (Ki > 5 µM);
5 therefore binding affinities of the 
analogs were not evaluated for this receptor. 
GTPγS assay  
The binding of the GTP analog [35S]GTPγS to membranes containing KOR was assayed 
as described previously.30 The assay mixture contained 50 mM HEPES, pH 7.4, 1 mM EDTA, 5 
mM magnesium acetate, 1 µM GDP, 1 mM dithiothreitol, 100 mM NaCl, 10 µM bestatin, 30 µM 
captopril, 50 µM Leu-Leu, 1 mg/mL bovine serum albumin, and approximately 100,000 
disintegrations per min (dpm) [35S]GTPγS (0.08 - 0.15 nM). Approximately 10 µg of KOR 
expressing CHO cell membrane protein was used per tube. Following 90 min incubation at 22 °C, 
the assay was terminated by filtration under vacuum on a Brandel (Gaithersburg, MD) model M-
48R cell harvester using Schleicher and Schuell Inc. (Keene, NH) number 32 glass fiber filters. 
The filters were rinsed five times (4 mL for each wash) with ice-cold (5 oC) 50 mM Tris HCl, pH 
7.4, containing 5 mM MgCl to remove unbound [35S]GTPγS. Filter disks were then placed into 
counting vials to which 8 mL of Biocount scintillation fluid (Research Products International 
Corp., Mount Prospect, IL) was added. Filter-bound radioactivity was determined by liquid 
scintillation counting (Beckman Instruments, Fullerton, CA) following overnight extraction at 
room temperature. The amount of radioligand bound was less than 10% of the total added in all 
experiments. Specific binding was defined as total binding minus that occurring in the presence of 
3 µM unlabeled GTPγS. Nonspecific binding was approximately 1% of the total binding at 0.1 nM 
[35S]GTPγS. 
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Arodyn is a potent and highly selective kappa opioid receptor (KOR) antagonist and has 
been used as a lead peptide to generate conformationally constrained KOR ligands.1, 2 Lactam-
based cyclization of arodyn has been limited to side chain to side chain motifs, while RCM-based 
cyclizations have covered both side chain to side chain and head to side chain motifs involving 
non-critical residues 2, 5, and 8.3 Unlike the lactam strategy, RCM cyclizations involving residues 
2, 5, and 8 have met with varying degrees of success due to sequence dependent effects. Of note, 
cyclizations using RCM between Tyr(All) residues at positions 2 and 3 as well as between AllGly 
residues at positions 5 and 8 were KOR selective and reasonably well-tolerated at KOR (≤ 5-fold 
loss in affinity compared to arodyn).2, 3  
Previous work on head to side chain cyclization by RCM in arodyn suggested considerable 
sequence dependence in these cyclizations. RCM between an N-terminal vinylacetyl/Alloc group 
and an allylglycine residue at position 2, 5, or 8 were largely unsuccessful using Grubbs 2nd 
generation catalyst (G II) in DCM/DMF (4:1) under conventional heating for 2 days (Table 6.1).3 
The only analog obtained in this series was cycloN,2[COOCH2(CH=CH-) 
Ala2,NMePhe1,Ile8]arodyn, 4 (Table 6.1). Evidently, this N-methylated arodyn derivative could 
adopt a conformation that facilitates cyclization. Interestingly, NMePhe1 arodyn analogs are prone 
to deletion of AcNMePhe under acidic conditions, but the introduction of a heteroatom-containing 
group such as CH3OCO conferred acid stability.
4 cycloN,2[COOCH2(CH=CH-
)Ala2,NMePhe1,Ile8]arodyn displayed a 20-fold loss in affinity for the KOR (Ki= 208 ± 14) 





Table 6.1 Attempted cyclizations of head to side chain arodyn analogs. Only 4 was obtained.3 
 
 

















The difficulty of accessing the head to side chain cyclic analogs of arodyn (Table 6.1) is 
another illustration of the conformational and sequence dependent effects on RCM cyclization 
efficiency. In this section we describe the synthesis of head to side chain cyclized arodyn analogs 
using Tyr(All) and AllGly residues to further probe effects of cyclization on KOR affinity, 
selectivity, and efficacy. We employed microwave assisted heating (Chapter 5) to explore 
improving yields of difficult cyclizations in arodyn analogs. 
6.2 Results and discussion  
6.2.1 Head to side chain analogs using RCM involving Tyr(All) 
Head to side chain cyclizations involving an aromatic residue and N-terminal 4-penteneoic 
or 5-hexenoic acid were explored to constrain the N-terminal segment of arodyn via RCM using 
Hoveyda-Grubbs 2nd generation catalyst (HG II). Microwave conditions previously developed for 
arodyn analogs containing Tyr(All) (15 mol% HG II in DCE, 0.3 mM, 75 oC, 2 h) were employed. 
The low yields observed in this series suggest that the reactive termini could not adopt a 
conformation favorable for cyclization except for 10 (Table 6.2). The generally low yields in this 
series also illustrate the sequence dependence of cyclization efficiency, as was observed for the 
previous cyclizations in the N-terminal segment of arodyn described above (Table 6.1). Notably, 
cyclization at higher temperature did not improve the reaction yields, but increased degradation 
products. Similarly, cyclization for 5 h at 60 oC did not improve the product yield. The apparent 
poor conversion to the RCM product suggests that conformational limitations preclude efficient 




Table 6.2 Attempted cyclizations of head to side chain analogs of arodyn involving Tyr(All).a  













R= Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2; a yields of the RCM product of various ring sizes, 
ranging from 14 to 21 atoms, were less than 25% with the exception of 10 (45%); b 4pent:4-pentenoic 
acid; c5hex: 5-hexenoic acid 
 
6.2.2 Head to sidechain cyclization involving AllGly 
Head to side chain cyclizations of arodyn analogs containing the all-hydrocarbon RCM 
bridge were synthesized by incorporating allylglycine as the 5th residue, while 4-pentenoic acid or 
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5-pentenoic acid were incorporated at the N-terminus (Table 6.3). Various cyclization conditions 
were explored under microwave heating to maximize the RCM product yields. In the synthesis of 
13, minimal conversion to product was observed after long heating times (2 and 5 h) at 75 oC, but 
shorter reaction times at elevated temperatures considerably increased cyclization yields (Figure 
6.1), consistent with the temperature dependence of the 2nd generation Hoveyda-Grubbs catalyst 
(HG II).5, 6 However, elevated temperatures also increased side reaction products. 
Table 6.3 Attempted cyclizations of head to side chain analogs of arodyn involving AllGly and their linear 
precursors. 
  





15 [4pent,AllGly5] 4pent-Phe-Phe-Phe-Arg-R1 
16 [5hex,AllGly5] 5hex-Phe-Phe-Phe-Arg-R1 
R= Arg-Arg-D-Ala-Arg-Pro-Lys-NH2 R1= AllGly-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2. 
 
Cyclization involving AllGly required at least 100 0C for 2 h before any substantial product 
was formed (Figure 6.1, Table 6.4). In the RCM of 15, further heating at 150 oC shortened the 
reaction time while giving similar yields to microwave heating at 100 oC for 2 h, but with more 
side products (Figure 6.1, Table 6.4). LC-MS analysis revealed that the side products were ring 
contraction (17) and ring expansion products (14) consistent with CH2 deletion and insertion, 
respectively (Figures 6.1 and 6.2, Table 6.5). Schroeder and co-workers reported similar CH2 
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deletions and insertions resulting in chain shortened and homologated side products, presumably 
due to ruthenium hydride formation during olefin metathesis.7 Additionally, Schroeder and co-
workers found higher degrees of isomerization and homologation in longer-chain substrates. In 
another example, Hanson et al. reported olefin isomerization and ring contraction products 
following RCM in the synthesis of dolabelide C.8 
 
 
Figure 6.1 Representative chromatograms showing the RCM of 15 at various temperatures under 
microwave heating.  
 
 














Yields of major pdts.b,c 
13 17 
1 60 5h -d - 
2 75 2h - - 
3 100 2h 29 - 
4 120 2h 31 16 
5 150 15 min 34 19 
6 150
e 15 min 29 11 
a15 mol% HG II, 0.3 mM DCE; b analytical HPLC conditions: 5-50% aqueous MeCN (0.1% 
TFA) over 45 min; c < 10% of 14 (Figure 6.1) was observed;  d < 10%; e 15 mol% HG II, 1 mM 
 
Table 6.5 Analytical data of the major products following microwave assisted RCM of 15 at 150 oC. LC-








[M+2H]2+ 765.9  
[M+3H]3+ 511.0 






[M+2H]2+ 758.9  






a ESI-MS from the LC-MS of the crude reaction mixture; b analytical HPLC 
conditions: 5-50% aqueous MeCN (0.1% TFA) over 45 min. 
 
CH2 deletions and insertions were also observed in the RCM of 16 (Figures 6.3 and 6.4, 
Table 6.6) in addition to a similar temperature dependence to that observed in the RCM of 15 
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(Figure 6.1). Minimal cyclization (<10%) was observed after microwave heating at 75 oC for 2 h, 
while a considerable increase in yield was observed following heating at 150 oC for 15 min (Figure 
6.3). Of note, negligible quantities (<10%) of the linear precursor 16 (Figure 6.3) were observed, 
in contrast to a considerable amount (20%) of 15 (Figure 6.1) observed following its RCM at 150 
oC. The observed differences in depletion of the linear precursor during RCM suggest increased 
cyclization efficiency of the homologated analog 16 compared to 15.  
 
Figure 6.3 Representative chromatograms showing the RCM of 16 at various temperatures under 
microwave heating.  
 
 















Calc.  Obsvd. 
13 27.2 
[M+3H]3+ 511.2 
















a HPLC on an Agilent 1200 series liquid chromatography system; b ESI-MS from the LC-MS 
of the crude reaction mixture; b analytical HPLC conditions: 5-50% aqueous MeCN (0.1% 
TFA) over 45 min  
 
Olefin isomerization is widely reported as a side reaction of degradation products of 
Grubbs catalysts9-11 and can result in complex mixtures necessitating elaborate purification steps. 
Despite an increase in the desired RCM product, elevated temperatures were accompanied by 
multiple RCM products. This is presumably due to catalyst degradation which occurs at higher 
temperatures. Olefin isomerization products resulted in ring contraction which was the major side 
product in the cyclizations of both 15 and 16 (Figures 6.2 and 6.4).  
Following RCM of 16, the cis/trans isomers of 14 (Table 6.7, Appendix 4) were purified 
using a linear gradient of 20-40% aqueous MeCN (0.1% TFA) over 80 min using at a flow rate of 
20 mL/min (Table 6.8). The slow gradient was used to separate the cis isomer (14 cis) from the 
ring contraction product 13 (Figure 6.3); however, 13 could not be sufficiently purified.  
Initial evaluation of KOR binding affinity indicates that the cis/trans isomers of 14 retain 
similar affinities at the KOR (Table 6.9) which were 5-fold lower than arodyn. The linear peptide 
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16 displayed roughly 3-fold lower affinity than arodyn. Further pharmacological evaluation of the 
geometrical isomers of 14 and the linear precursor is in progress. 
Table 6.7 1H NMR data of cyclic arodyn analogs 14 cis and 14 trans.   
                                                                     
Compound Chemical shift of olefinic 
protons (ẟ) 
Jolefin (Hz) cis/trans 
ratioa 
14 cis 
H1 = 5.21 J12 = 10.4 1 
H2 = 5.38 J21 = 10.0 
   14 trans 
H1 = 5.30 J12 = 15.2 1.5 
H2 = 5.39 J21 = 15.3 
a Determined through peak integration from HPLC analysis of the crude reaction 
mixture  
 
Table 6.8 Analytical data of purified 14 and its linear precursor 16.  
Compound HPLC tR (min)







14 cis 24.8 (99.9) 17.3 (99.9) 
[M+2H]2+ 772.9 
[M+3H]3+ 515.6 
[M+2H]2+ 773.2  
[M+3H]3+ 515.9  




[M+3H]3+ 515.8  




[M+3H]3+ 525.2  
a HPLC on an Agilent 1290 series liquid chromatography system; b5-50% aqueous MeCN (0.1% 





Table 6.9 Preliminary KOR binding affinities of cycloN,5[5hex,AllGly5]arodyn and the linear precursor.  
Compound 
number Arodyn analog 
Ki ± SEM (nM)a 
KOR 
 arodynb 10.0 ± 3.0 
14 cis cycloN,5[5hex,AllGly5] 47.7 ± 3.6 
   14 trans cycloN,5[5hex,AllGly5] 46.4 ± 7.2 
16 [5hex,AllGly5] 26.9 ± 7.6 
a Mean Ki values ± SEM from at least 3 independent experiments; b from ref12 
 
6.3 Conclusions 
Cyclization of arodyn in the N-terminal “message” sequence was explored using RCM in 
a head to side chain motif with varying yields under microwave heating. Cyclizations involving a 
Tyr(All) residue in position 1, 2 or 3 were negatively impacted by sequence dependent effects, 
thereby limiting the analogs that could be obtained in appreciable yield. Longer range cyclizations 
involving AllGly at position 5 resulted in considerable product yields, but required elevated 
temperatures. Higher temperatures were, however, accompanied by side products, mainly ring 
contraction products presumably due to olefin isomerization. The resulting cyclic arodyn analogs 
exhibit interesting novel topologies. Initial KOR binding data indicated a 5-fold decrease in 
affinity for both geometrical isomers of cycloN,5[5hex,AllGly5]arodyn (14) compared to arodyn. 
Pharmacological analysis to determine the effects on MOR affinity, selectivity, and efficacy at 
KOR are in progress. 
6.4 Experimental 
Materials  
Fmoc-L-Tyr(All)-OH and Fmoc-AllGly-OH were purchased from Chem-Impex 
International (Wood Dale, IL). The coupling agent benzotriazol-1-yl-oxy-tris-pyrrolidino-
phosphonium hexafluorophosphate (PyBOP) was obtained from P3 BioSystems (Louisville, KY) 
while the coupling agent 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
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hexauorophosphate (HBTU) was obtained from Peptides International. The coupling additive 1-
hydroxybenzotriazole hydrate (HOBt) was obtained from Chem-Impex International. The sources 
of other materials are listed in Chapter 5. 
Instruments  
Microwave assisted RCM was performed on a Biotage Initiator+ SP Wave microwave 
synthesizer and solid phase peptide synthesis (SPPS) was performed on a Biotage microwave 
peptide synthesizer (Initiator+ Alstra; Biotage, Sweden). 
Electrospray ionization mass spectrometry (ESI/MS) was performed on an Advion 
expression L compact MS (Advion, Inc. Ithaca NY).   
1H NMR spectra of these compounds (0.5−2 mg) were obtained at 27 °C in DMSO-d6 on 
a Bruker Avance III 600 MHz equipped with a 5 mm cryoprobe in the McKnight Brain Institute 
at the National High Magnetic Field Laboratory’s AMRIS facility at the University of Florida. 1H 
chemical shifts were referenced to the residual DMSO signal at 2.50 ppm, and coupling constants 
were extracted from the 1D spectra. 
Analytical HPLC was performed on an Agilent 1200 system or an Agilent 1290 system 
fitted with a Grace Vydac analytical column (C18, 300 Å, 5 μm, 4.6 mm x 50 mm) equipped with 
a Vydac C18 guard cartridge. Yields for the respective reactions were determined from analytical 
HPLC chromatograms monitored at 214 nM; in some cases, baseline resolution was not achieved 
so yields shown are an estimate. 
Solid Phase Peptide Synthesis (SPPS)  
Arodyn analogs were prepared by the Fmoc (9-fluorenylmethoxycarbonyl) SPPS strategy 
using the automated Biotage microwave peptide synthesizer (Initiator+ Alstra; Biotage, Sweden) 
on a 0.14 mmol scale. Rink amide ChemMatrix resin (0.45-0.54 mmol/g) was swelled for 20 min 
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at 70o C in DMF prior to cycles of amino acid coupling and deprotection. Coupling reactions were 
performed using Fmoc amino acids (4 equiv, 0.5 M), activated with PyBOP (4 equiv, 0.5 M) and 
HOBt (4 equiv, 0.5 M) in DMF in the presence of DIEA (8 equiv in NMP) for 5 min at 75 oC. 
Fewer equivalents were used in the coupling of Fmoc-AllGly (2 equiv). Fmoc deprotection was 
performed at room temperature with 20% 4-methylpiperidine in DMF (4.5 mL, 1 x 3 min; 4.5 mL, 
2 x 10 min). The side chains of Lys and Arg were protected with tert-butoxycarbonyl (Boc) and 
2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf), respectively. Acylation was performed 
using 4-pentenoic anhydride or 5-hexenoic acid as described below. Synthesis of  
[5hex,AllGly5]arodyn (16) is shown in scheme 6.1 as an example. 
Acylation with 4-pentenoic anhydride 
Following synthesis of [AllGly5]arodyn using SPPS as described above, DIEA (1.4 mmol, 
10 equiv) was added to a 4-pentenoic anhydride solution in (0.35 M) in DMF (3 mL) and the 
resulting solution was added to the resin-bound peptide (150 mg, 0.14 mmol, 0.54 mmol/g). 
Acylation was performed for 20 min at room temperature, and the resin-bound peptide was then 
washed with DMF (5 mL, 3 x 45 sec) and DCM (5 mL, 3 x 45 sec) to give [4pent,AllGly5]arodyn 
(15); ESI/MS m/z 520.8 observed, 520.3 calculated [M+3H]3+, HPLC tR = 30.2 min (5-50% 









Scheme 6.1 Synthesis of [5hex,AllGly5]arodyn (16) and cycloN,5[5hex,AllGly5]arodyn (14). 
 
Acylation with 5-hexenoic acid 
Following synthesis of [AllGly5]arodyn using SPPS as described above, DIEA (1.12 mmol, 
8 equiv) was added to a solution of 5-hexenoic acid (0.70 mmol, 5 equiv) and HBTU (0.69, 4.9 
equiv) in DMF (3.5 mL). The mixture was added to the resin-bound peptide (0.14 mmol) and 
subjected to microwave irradiation (Biotage Initiator+ Alstra) for 5 min at 75 oC, and the resin-
bound peptide was washed with DMF (5 mL, 3 x 45 sec) and DCM (5 mL, 3 x 45 sec) to give 
[5hex,AllGly5]arodyn (16); ESI/MS m/z 525.2 observed, 525.0 calculated [M+3H]3+, HPLC tR = 
31.6 min (5-50% aqueous MeCN with 0.1% TFA over 45 min at a flow rate of 1 mL/min). 
Ring Closing Metathesis (RCM) 
A solution of degassed 1,2-dichloroethane (DCE) containing 15 mol % (0.15 equiv) of 
Hoveyda-Grubbs II catalyst (0.3 mM) was added to the resin-bound peptide (150 mg, 0.21 
mmol/g) before heating. Closed vessel microwave assisted RCM was performed on a Biotage 
Initiator+ SP Wave microwave synthesizer in capped microwave reaction vials for the indicated 
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amount of time at the indicated temperatures. Synthesis of cycloN,5[5hex,AllGly5]arodyn (14) is 
shown in scheme 6.1 as an example. The resin was washed with MeOH (3 x 5 mL) and DCM (10 
x 5 mL) before drying and cleavage. Yields were determined from analytical HPLC 
chromatograms using a linear gradient of 5-50% solvent B (solvent A = aqueous 0.1% TFA and 
solvent B = MeCN containing 0.1% TFA) over 45 min at a flow rate of 1 mL/min (Figures 6.1 and 
6.3). 
Synthesis of cyclo N,5[5hex,AllGly5]arodyn (14) 
[AllGly5]arodyn was synthesized using SPPS and acylated to give [5hex,AllGly5]arodyn 
(16) as described above. The resin-bound [5hex,AllGly5]arodyn (16, 150 mg, 0.03 mmol, 0.21 
mmol/g) was subjected to RCM as described in the RCM procedure for 15 min at 150 oC (Scheme 
6.1) to give cycloN,5[5hex,AllGly5]arodyn (14) (see Table 6.6 for analytical data). 
Cleavage, purification and analysis of purified peptides  
 Crude peptides (Scheme 6.1) were cleaved from the resin in TFA/triisopropylsilane 
(TIPS)/water (95/2.5/2.5) for at least 2 h and then precipitated in cold ether following filtration. 
The crude peptides were purified by preparative reversed-phase HPLC on a Shimadzu liquid 
chromatograph system, equipped with a CBM-20A system controller, LC-20AR solvent delivery 
module and SPD-20A UV-Vis detector, on a Vydac C18 column (10 μ, 300 Å, 22 x 250 mm). A 
linear gradient of 20–40 % aqueous MeCN (containing 0.1% TFA) over 80 min at a flow rate of 
20 mL/min was used with purifications, which were monitored at 214 nm. Analytical HPLC on an 
Agilent 1290 series liquid chromatograph system was performed to verify the purity of the final 
peptides using a Vydac 218-TP column (5 μ, 300 Å, 4.6 mm x 50 mm) equipped with a Vydac 
guard cartridge. Two systems, a linear gradient of 5-50% solvent B (solvent A = aqueous 0.1% 
TFA and solvent B = MeCN containing 0.1% TFA) over 45 min at a flow rate of 1 mL/min (system 
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1), and a linear gradient of 25-70% solvent B (solvent A = aqueous 0.1% TFA and solvent B = 
MeOH containing 0.1% TFA) over 45 min at a flow rate of 1.0 mL/min (system 2), were used for 
the analyses.  The final purity of all peptides by both methods was greater than 99% (Table 6.8). 
Molecular weights of the peptides were determined by ESI-MS (Advion CMS). 
Pharmacological assays 
Radioligand binding assays were performed using cloned rat κ opioid receptors stably 
expressed in CHO cells as described in Chapter 5. 
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Cyclization restricts conformational mobility and can potentially stabilize a bioactive 
conformation in addition to imparting proteolytic resistance. Accordingly, cyclic peptides are 
gathering increasing interest due to their selectivity and increased binding affinity in addition to 
enhanced permeability.1-3 More importantly, linear peptides can be rapidly metabolized and 
cyclization can impart metabolic stability which improves bioavailability.4  
Bicyclization imparts additional conformational constraint which can further enhance 
metabolic stability. This can be particularly important to limit proteolytic degradation observed in 
monocyclic peptides with larger ring sizes.5 For example, a bicyclic derivative of the HIV fusion 
inhibitor enfuvirtide displayed an 82-fold enhancement in proteolytic stability relative to the linear 
peptide and several-fold higher stability compared to a monocyclic derivative.6 Additionally, 
bicyclization can allow incorporation of an additional pharmacophore as demonstrated by fusion 
of a peptidyl–prolyl cis–trans isomerase (Pin1) inhibitor and a cell penetrating peptide.7 This 
potential and interest in bicyclic peptides has led to the development of numerous bicyclization 
methods to improve structural diversity.5 Furthermore, structural diversity can be increased by 
using various linkers and varying the location of reactive groups in the linear precursor of a 
polycyclic peptide. 
Of particular note, there are currently no known polycyclic opioid receptor ligands possibly 
due to the shorter peptide chain of the best studied opioid peptides;8 however, analogs of dynorphin 
A (Dyn A) are a promising starting point due to their longer peptide chain. Accordingly, analogs 
of dynorphin A such as arodyn lend themselves to the synthesis of polycyclic analogs due to the 
multitude of residues available for cyclization. In this initial synthesis of polycyclic derivatives of 
arodyn, we limited our design to involve positions where previous cyclizations were tolerated by 
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the kappa opioid receptor (KOR). To this effect, we explored using RCM and lactam chemistries 
in the synthesis of bicyclic KOR ligands. 
Structure-activity relationships (SAR) of arodyn,9, 10 particularly with respect to the effects 
of cyclization on KOR affinity, selectivity, and efficacy, was informative in the design of a bicyclic 
opioid receptor ligand based on Dyn A (Tables 7.1 and 7.2). Generally, the cyclizations involving 
AllGly at position 2 of arodyn displayed substantial losses in KOR affinity (Table 7.1).  Notably, 
however, the cis isomer of 4 (Table 7.1) was tolerated at the KOR unlike the trans analog, which 
highlights the effect of ligand conformation on KOR affinity. The binding assay results further 
indicate that both isomers of 4 lost selectivity for KOR over MOR relative to arodyn. Interestingly, 
preliminary results suggest that cyclization had mixed effects on KOR activation in the GTPγS 
assay, further exemplifying the effects of ligand conformation on biological activity (Table 7.2). 
Whereas arodyn displayed negligible KOR activation, cyclizations between AllGly at positions 2 
and either 5 or 8 activated the KOR (Table 7.2). For example, both isomers of 4 displayed 
appreciable KOR activation in the GTPγS assay. The SAR of cyclic arodyn analogs was therefore 
particularly informative in the design of a bicyclic arodyn analog. Importantly, cyclizations that 
individually had not resulted in considerable loss of KOR binding affinity are promising starting 









Table 7.1 Binding affinities of monocyclic RCM arodyn analogs. 
Compound Arodyn analog 




1 arodynb 10.0 ± 3.0 1750 ± 130 174 
 Cyclic arodyn analogsc    
2 cyclo2,5[Ala2(-CH=CH-)Ala5,Ile8] cis 131 ± 22 2310 ± 
440(4) 
18 
trans 410 ± 54 >10,000 >24 
3 cyclo2,5[D-Ala2(-CH=CH-)Ala5,Ile8] cis 202 ± 12 >10,000 >50 
trans 130 ± 20 >10,000 >77 
4 cyclo2,8[Ala2(-CH=CH-)Ala8] cis 59.9 ± 12.9 13.9 ± 3.0 (5) 0.2 
trans 453 +22 425 ± 74  0.9 
5 cyclo2,8[D-Ala2(-CH=CH-)Ala8] trans 4960 ± 170 ND  
6 cyclo5,8[Ala5(-CH=CH-)Ala8] cis 54.0 ± 3.9 >10,000 185 
trans 63.0 ± 6.3 9370 ± 590 149 
7 cycloN,5[COOCH2(CH=CH-)Ala5,NMePhe1,Ile8]
 208 ± 14 2850 ± 360 14 
8 cyclo3,5[Tyr3(-CH=CH-)Ala5,Ile8]d,e 398 ± 40 3460 ± 300 9 
9 cyclo1,2[Tyr1(-CH=CH-)Tyr2,Ile8]d,e 71.7 ± 5.2 1920 ± 150 27 
10 cyclo1,2[Tyr1(-CH=CH-)Tyr2]d,f 11.7 ± 2.7 1434 ± 402 123 
11 cyclo2,3[Tyr2(-CH=CH-)Tyr3,Ile8]d,e 55.4 ± 4.1 903 ± 34 16 
12 cyclo2,3[Tyr2(-CH=CH-)Tyr3]d,f 14.7 ± 5.6 1372 ± 328 93 
aThe results are expressed as the mean ± SEM of 3 independent experiments except where noted; 


























7.2 Synthesis of a bicyclic arodyn analog using RCM 
Various strategies have been employed in the synthesis of polycyclic peptides to achieve 
regioselectivity including sequential RCM12 and orthogonal metathesis.13 Based upon the KOR 
binding affinity and selectivity data for the monocyclic derivatives of arodyn (Table 7.1), 
constraints between positions 2 and 3 as well as positions 5 and 8 were chosen for the synthesis of 
a bicyclic analog cyclized using RCM (Figure 7.1). Binding affinities at the KOR indicate that 
these cyclizations were tolerated by the KOR and the resulting monocyclic analogs displayed 
negligible KOR activation, similar to arodyn. RCM using Hoveyda-Grubbs 2nd generation catalyst 
Compound number GTPγS binding @ 10 µMa  
1, arodynb 11 ±6% 
2 cis 84 ±6% 
2 trans 24 ±24% 
3 cis <10% 
3 trans ND 
4 cis 68 ± 8% 
4 trans 84 ±14% 
5 trans ND 
6 cis -18 ±18% 







a Compared to Dyn A (1-13)NH2 (100%); bFrom ref11 
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(HG II) was used sequentially to install the cyclic constraints (Scheme 7.1) to limit unwanted 
cyclizations. 
                           
Figure 7.1 Structure of bicyclic arodyn analog cyclo[Tyr(All)2,3,AllGly5,8]arodyn (13).    
Scheme 7.1 Synthesis of cyclo[Tyr(All)2,3,AllGly5,8]arodyn (13) using sequential RCM. PyBOP = 
benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate, HOBt = 1-




7.2.1 Results and discussion  
The C-terminal and N-terminal cyclic constraints were installed sequentially to limit 
unwanted regioisomers. Accordingly, the synthesis of the C-terminal segment 15 under various 
conditions (Figure 7.2) was explored to optimize reaction yields before synthesis of the 
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heteroatom-containing RCM bridge (Scheme 7.1). Notably, optimized conditions for the synthesis 
of the cyclic N-terminal segment had been previously developed (Chapter 5). 
A temperature dependent increase in yield similar to that observed in the head to sidechain 
arodyn analogs containing AllGly (Chapter 6) was observed in the synthesis of 15. The RCM 
product yields increased with increasing temperature (Figure 7.3, Tables 7.3 and 7.4). Doubling 
the temperature drastically increased conversion to the RCM product, consistent with the 
temperature dependent activity of Grubbs catalysts.14, 15 At 150 oC reaction times from 5 min to 30 
min resulted in appreciable RCM product yields (63-73%). Further increasing the temperature did 
not improve the RCM product yield, suggesting that catalyst activity peaks at 150 oC. Arora and 
coworkers observed a similar temperature dependence in the synthesis of hydrogen-bond surrogate 
helices using RCM; yields in cyclized peptide peaked at 200 oC for HG II.15 
 
    
Figure 7.2 Synthesis of cyclo[Fmoc-AllGly5,8]arodyn4-11 (15).  
 




Table 7.3 Analytical data for 14 and 15. 
Compound HPLC tR (min)a 
ESI-MS 
Calcd. Obsvd. 
14 25.3  [M+3H]3+ 428.6   [M+3H]3+ 428.7 
15 23.3  [M+3H]3+ 419.2  [M+3H]3+ 419.5 
a5-50% aqueous MeCN (0.1% TFA) over 45 min 
 
Table 7.4 Synthesis of 15 under various microwave heating conditions. 
Entry Temp (oC)a Time RCM Pdt yield (%) 
1 75 2h -b 
2 100 2h 46 
3 150 5 min 63 
4 150 15 min 73 
5 150 30 min 73 
6 175 15 min 67 
a15 mol% HG II 0.3 mM in DCE; b <10% 
   
Following synthesis of 15 in appreciable yields (Table 7.4), the resin-bound peptide 
containing 15 plus residual 14 was subjected to further solid phase peptide synthesis (SPPS) to 
incorporate the N-terminal residues containing Tyr(All) resulting in 16 and 17 (Scheme 7.2). The 
mixture containing resin-bound protected forms of 16 and 17 was then subjected to RCM using 
conditions previously established to install the heteroatom-containing RCM bridge involving 
Tyr(All) (Chapter 5, Scheme 7.2). Encouragingly, the bicyclic RCM product 13 was obtained in 
reasonable yields (52%, Figure 7.4). LC-MS analysis indicated that the product mixture also 
contained 16, 17, and 18 (Figure 7.4, Table 7.5). Peptide 18 is the cyclization product of 17 and 
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was observed as the major side product; this is consistent with previously observed minimal RCM 
of AllGly residues at 75 oC for 2 h (Table 7.4). Purification was performed using a linear gradient 
of aqueous MeCN (0.1% TFA) over 80 min (20-40%) at a flowrate of 20 mL/min. Of note, 13 was 
purified as a mixture of cis/trans isomers as these isomers could not be separated. Future 
experiments will include NMR analysis to establish the ratio for each linkage.  
Scheme 7.2 Synthesis of 13 using sequential RCM showing structures of major products in the reaction 
mixture.  





Figure 7.4 Chromatograms of the synthesis of the 13 showing major components of the reaction mixtures 
a) before and b) after RCM involving Tyr(All) residues.   
 
Table 7.5 Analytical data of major components of the RCM product mixture following the synthesis of 13.  




[M+2H]2+ 801.5  














[M+2H]2+ 815.5  
[M+3H]3+ 544.0 
[M+2H]2+ 815.4  
[M+3H]3+ 543.9 
a5-50% aqueous MeCN (0.1% TFA) over 45 min 
 
Encouragingly, the bicyclic analog cyclo[Tyr(All)2,3,AllGly5,8]arodyn (13) retained affinity 
at the KOR, displaying higher affinity for the KOR than the corresponding monocyclic derivatives 
6 and 11. (Table 7.6). Additional pharmacological evaluation of the synthesized bicyclic arodyn 




Table 7.6 Initial evaluation of receptor affinity of bicyclic arodyn analog 13 and related arodyn analogs. 
Compound 
number Arodyn analog 
Ki ± SEM (nM) 
κ μ 
1 arodyna 10.0 ± 3.0 1750 ± 130 
6 cyclo[AllGly5,8]b cis 54.0 ± 3.9 >10,000 
trans 63.0 ± 6.3 9370 ± 590 
11 cyclo[Tyr(All)2,3, Ile8]c,d 55.4 ± 4.1 903 ± 34 
13 cyclo[Tyr(All)2,3,AllGly5,8]e 26.4± 5.9 NDf 
a from ref11; bfrom ref9; ctrans; d from ref10; e mean Ki values ± SEM from at least 3 independent 
experiments; fnot determined 
 
7.3 Synthesis of a bicyclic arodyn analog using lactam chemistry  
Various cyclizations can impart different conformations to the peptide and influence 
binding topology at the target. Trivalent rigid linkers including tris(bromomethyl)benzene 
(TBMB) and benzene-1,3,5-tricarboxylic acid (trimesic acid) have been utilized in the synthesis 
of bicyclic peptides, particularly in bicyclic peptide libraries.16, 17 TBMB has been used in 
crosslinking three cysteine residues,16 whereas trimesic acid has been used to crosslink the N-
terminal amine to lysine and 1,3-diaminopropionic (Dap) residues.17 Furthermore, increasing 
varieties of chemical linkers have been developed for the synthesis of bicyclic peptides and peptide 
libraries.18 In the initial design and synthesis of a lactam-based bicyclic KOR ligand based on 
arodyn, we used a trimesic acid scaffold. Additionally, we used pharmacological data from 
previous monocyclic derivatives as an important guide to choose the location of the cyclic 
constraints.  
Binding affinity data were available for multiple monocyclic lactam derivatives of arodyn, 
therefore making arodyn an excellent lead peptide to explore bicyclization motifs and their effects 
on KOR affinity, efficacy, and selectivity. Notably, cyclizations incorporating a lactam bridge 
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displayed substantial losses in KOR affinity with the exception of cyclo[Asp5,Dap8]arodyn (Ki = 
61.0 ± 23.7 nM) and cyclo[D-Asp5,Dap8]arodyn (Ki =55.3 ± 15.1 nM, Table 7.7). In particular, 
side chain to side chain lactams involving position 2 of arodyn were not tolerated by the KOR 
similar to analogs cyclized using RCM (Table 7.1).  Similar substantial losses in affinity have been 
observed in head to side chain cyclizations of Dyn A analogs involving the third or fifth residues; 
this suggests unfavorable interactions with functionalities in the constraint or an unfavorable 
conformation.19 In contrast, it should be noted that cyclodyn, a head to side chain (Glu5) cyclized 
KOR antagonist based on Dyn A, retains affinity at the KOR (Ki = 26.8 ± 2.8 nM) but is less 








Ki ± SEM (nM)a Ki ratio 
(μ/κ) κ μ 
19 Arodynb 10.0 ± 3.0 1750 ± 130 175 
 Cyclic arodyn analogsc    
20 cyclo[D-Asp2,Dap5,Ile8] 2460 ± 300 (5) >10,000 >4 
21 cyclo[Asp2,Dap5,Ile8] 580 ± 150 >10,000 >17 
22 cyclo[Asp2,Lys5,Ile8] 862 ± 284 (4) ND ND 
23 cyclo[D-Asp2,Dap8] 677 ± 38 375 ± 83 0.6 
24 cyclo[Asp2,Dap8] 373 ± 43 1540 ± 160 4 
25 cyclo[D-Asp5,Dap8] 55.3 ± 15.1 >10,000 >182 
26 cyclo[Asp5,Dap8] 61.0 ± 23.7 >10,000 (5) >163 
aThe results are expressed as the mean ± SEM of 3 independent experiments except 
where noted; bFrom ref11; cFrom ref9 
7.3.1 Results and discussion 
Trimesic acid (TMA) was employed as a rigid linker for the synthesis of a lactam-based 
bicyclic arodyn analog. 2-Methyltrityl (Mtt) protected diaminopropionic (L-Dap) residues were 
incorporated at positions 5 and 8 of arodyn to facilitate formation of the bicycle. TMA was coupled 
to the N-terminus of protected [Dap5,8]arodyn, followed by selective deprotection of the Dap 
residues (Scheme 7.3). Cyclization with PyBOP and HOBt afforded the bicyclic peptide in one 
step under microwave heating (Table 7.8, Figure 7.5) with >90% conversion. Purification was 
performed using a linear gradient of aqueous MeCN (0.1% TFA) over 80 min (20-40%) at a flow 
rate of 20 mL/min (see experimental).  
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Scheme 7.3 Synthesis of cycloN,5,8[TMA,Dap5,8]arodyn (29).  
 
 
Table 7.8 Analytical data of 27, 28, and 29. 
















29 cycloN,5,8[TMA,Dap5,8]arodyn 30.4 
[M+2H]2+ 819.4  
[M+3H]3+ 546.6  
[M+2H]2+ 819.7  
[M+3H]3+ 547.0  





Figure 7.5 Chromatograms and structures of the lactam-based bicyclic arodyn analog and the 
corresponding linear precursors.  
In preliminary receptor affinity evaluation, however, cycloN,5,8[TMA,Dap5,8]arodyn (29, 
Ki=514± 149 nM) displayed a 51-fold loss in affinity compared to arodyn. Of note, RCM 
cyclizations involving the N-terminus and residue 5 of arodyn retained affinity at KOR (Chapter 
6) and cyclodyn, a head to side chain (Glu5) cyclized Dyn A derivative, also retained affinity at 
KOR.20 The substantial loss in affinity exhibited by cycloN,5,8[TMA,Dap5,8]arodyn was similar to 
those found for arodyn analogs with lactam constraints involving residue 2 in the “message” 
sequence (Table 7.7). Only cyclizations between residues 5 and 8 were tolerated at the KOR 
displaying much less drastic decreases in KOR affinity (Table 7.7). Monocyclic lactam derivatives 
with the rigid linker isophthalic acid (benzene-1,3-dicarboxylic acid) between the N-terminus and 
residue 5, the N-terminus and residue 8, as well as between residues 5 and 8 could give further 
insight on the effects of the different cyclization positions on KOR affinity.  
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7.4 Conclusions  
Polycyclic peptides are an emerging class of macrocycles whose unique attributes can be 
leveraged to modulate biological targets. Of particular interest, polycyclic peptides are promising 
therapeutics and chemical probes with enhanced proteolytic stability which can improve 
pharmacokinetic properties.5, 21  
In this initial study, we designed and synthesized two bicyclic opioid KOR ligands derived 
from the Dyn A-based antagonist arodyn and report the first bicyclic opioid receptor ligands 
(Schemes 7.1 and 7.3). Based on previous SAR of arodyn analogs, we limited the positions 
involved in the cyclizations to those where the constraint was both tolerated at the KOR and 
maintained KOR selectivity. Microwave heating facilitated cyclization of two bicyclic arodyn 
analogs, resulting in appreciable yields. Sequential RCM was utilized for regioselective cyclization 
of one bicyclic analog, while a rigid aromatic linker, trimesic acid, was employed in the synthesis 
of a lactam-based arodyn bicycle. Initial receptor affinity evaluation indicate that these two 
bicyclic arodyn analogs displayed vastly different affinities for the KOR that are likely due to 
differences in peptide topology. Whereas the RCM-based bicyclic analog 13 retained KOR 
affinity, the TMA bicyclic analog 29 displayed a considerable loss in KOR affinity. Future bicycles 
could expand the structural diversity of these KOR ligands by combining lactam and RCM 
cyclizations. In addition, proteolytic stability studies will be important, given that linear Dyn A 





Fmoc-Dap(Mtt) was purchased from Anaspec (Fremont, CA). The sources of other 
materials are listed in chapter 5. 
Instruments  
Microwave assisted RCM was performed on a Biotage Initiator+ SP Wave microwave 
synthesizer and solid phase peptide synthesis (SPPS) was performed on a Biotage microwave 
peptide synthesizer (Initiator+ Alstra; Biotage, Sweden). 
Electrospray ionization mass spectrometry (ESI/MS) was performed on an Advion 
expression L compact MS (Advion, Inc. Ithaca NY).   
Analytical HPLC was performed on an Agilent 1200 system fitted with a Grace Vydac 
analytical column (C18, 300 Å, 5 μm, 4.6 mm x 50 mm) equipped with a Vydac C18 guard 
cartridge. Yields for respective reactions were determined from analytical HPLC chromatograms 
monitored at 214 nM; in some cases, baseline resolution was not achieved so yields shown are an 
estimate. 
Solid Phase Peptide Synthesis (SPPS)  
Arodyn analogs were prepared by the Fmoc (9-fluorenylmethoxycarbonyl) SPPS strategy 
using the automated Biotage microwave peptide synthesizer (Initiator+ Alstra; Biotage, Sweden) 
on a 0.14 mmol scale. The Rink amide ChemMatrix resin (0.14 mmol, 0.52 mmol/g) was swelled 
for 20 min at 70o C in DMF prior to cycles of amino acid coupling and deprotection. Coupling 
reactions were performed using Fmoc amino acids (4 equiv, 0.5 M), activated with PyBOP (4 
equiv, 0.5 M) and HOBt (4 equiv, 0.5 M) in DMF in the presence of DIPEA (8 equiv in NMP) for 
5 min at 75 oC. Fewer equivalents were used in the coupling of Fmoc-Dap(Mtt) (2 equiv). Fmoc 
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deprotection was performed at room temperature with 20% 4-methylpiperidine in DMF (4.5 mL, 
1 x 3 min; 4.5 mL, 2 x 10 min). The side chains of Dap, Lys and Arg were protected with 
methyltrityl (Mtt), tert-butoxycarbonyl (Boc) and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-
sulfonyl (Pbf), respectively. N-Terminal acetylation was performed using acetic anhydride (5 M 
in DMF) and DIEA (2 M in NMP) for 10 minutes at room temperature. The resulting peptides 
were washed with DMF (5 mL, 3 x 45 sec) and DCM (5 mL, 3 x 45 sec). Crude peptides were 
cleaved from the resin using TFA/ triisopropylsilane (TIPS)/water (95/2.5/2.5) for at least 2 h and 
then precipitated with cold ether following filtration.  
Ring Closing Metathesis (RCM) 
A solution of degassed 1,2-dichloroethane (DCE) containing 15 mol % (0.15 equiv) of 
Hoveyda-Grubbs II catalyst (0.3 mM) was added to the resin-bound peptide (150 mg, 0.21 
mmol/g) before heating. Closed vessel microwave assisted RCM was performed on a Biotage 
Initiator+ SP Wave microwave synthesizer in capped microwave reaction vials for the indicated 
amount of time at the indicated temperatures, sequential RCM was performed as indicated in 
scheme 7.1. The resin was washed with MeOH (3 x 5 mL) and DCM (10 x 5 mL) before drying 
and cleavage.  
Synthesis of cyclo[Tyr(All)2,3,AllGly5,8] (13) 
 [Fmoc-AllGly5,8]arodyn4-11 (14) was synthesized using SPPS as described above and the 
protected resin-bound peptide (150 mg, 0.03 mmol, 0.23 mmol/g) was subjected to RCM for 15 
min at 150 oC as described in the RCM procedure (Scheme 7.2, see Figure 7.3 and Table 7.3 for 
analytical data). SPPS of the resin-bound peptide was performed to extend the peptide chain, and 
the resulting full length resin-bound peptide mixture (150 mg, 0.03 mmol, 0.21 mmol/g) was 
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subjected to RCM for 2 h at 75 oC as described in the RCM procedure (Scheme 7.2, see Table 7.5 
for analytical data). The final peptide was cleaved from the resin as described above and purified 
as described below.  
Synthesis of cycloN,5,8[TMA,Dap5,8]arodyn (29) 
Following synthesis of [Dap5,8]arodyn (27, Scheme 7.3), DIEA (388 µL, 2.24 mmol, 16 
equiv) was added to a solution of trimesic acid (117.6 mg, 0.56 mmol, 4 equiv), PyBOP (873 mg, 
1.68 mmol, 12 equiv), and HOBt (257 mg, 1.68 mmol, 12 equiv) in DMF (3.5 mL). The mixture 
was added to the N-terminal free amine of protected [Dap5,8]arodyn (0.14 mmol, 1 equiv) and 
subjected to microwave irradiation (Biotage Initiator+ Alstra ) for 5 min at 75 oC as indicated in 
scheme 7.3. See Table 7.8 for analytical data of [TMA,Dap5,8]arodyn (28) following aliquot 
cleavage. 
The protected resin-bound peptide, [TMA,Dap(Mtt)5,8]arodyn, was washed with 3% 
TFA/5% TIS in DCM (3 mL, 10 x 2min) to selectively remove the Mtt protecting group after 
which the resin was washed with DCM (3mL, 5 x 2 min). Following Mtt deprotection, DIEA (291 
µL, 1.68 mmol, 12 equiv) was added to a solution of PyBOP (582 mg, 1.12 mmol, 8 equiv), and 
HOBt (171 mg 1.12 mmol, 8 equiv) in DMF (3.5 mL). The mixture was added to the resin-bound 
peptide [TMA, Dap5,8]arodyn (0.14 mmol, 1 equiv) and subjected to microwave irradiation 
(Biotage Initiator+ Alstra ) for 10 min at 75 0C. The resin-bound peptide was washed with DMF 
(5 mL, 3 x 45 sec) and DCM (5 mL, 3 x 45 sec). See Table 7.8 for analytical data. 
Purification and analysis of purified peptides 
The crude peptides 13 and 29 were purified by preparative reversed-phase HPLC on a 
Shimadzu liquid chromatograph system equipped with a CBM-20A system controller, LC-20AR 
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solvent delivery module and SPD-20A UV-Vis detector on a Vydac C18 column (10 μ, 300 Å, 22 
x 250 mm) fitted with a C18 guard cartridge. A linear gradient of 20–40 % aqueous MeCN 
(containing 0.1% TFA) over 80 min at a flow rate of 20 mL/min was used for purification of both 
bicyclic peptides 13 and 29 (Table 7.9). The purifications were monitored at 214 nm. Analytical 
HPLC was used to verify the purity of the final peptides using a Vydac 218-TP column (5 μ, 300 
Å, 4.6 mm x 50 mm) equipped with a Vydac guard cartridge. Two systems, a linear gradient of 5-
50% solvent B (solvent A = aqueous 0.1% TFA and solvent B = MeCN containing 0.1% TFA) 
over 45 min at a flow rate of 1 mL/min (system 1), and a linear gradient of 25-70% solvent B 
(solvent A = aqueous 0.1% TFA and solvent B = MeOH containing 0.1% TFA) over 45 min at a 
flow rate of 1.0 mL/min (system 2), were used for the analyses.  The final purity of all peptides by 
both methods was greater than 99% (Table 7.7). Molecular weights of the peptides were 
determined by ESI-MS (Advion CMS). 
Table 7.9 Analytical data of bicyclic arodyn analogs. 







13 27.0 (99.9) 13.4 (99.9) 
[M+2H]2+ 801.5  
[M+3H]3+ 534.6  
[M+2H]2+ 801.7  
[M+3H]3+ 534.9  
29 30.4 (99.9) 26.9 (99.9) 
[M+2H]2+ 819.4  
[M+3H]3+ 546.6  
[M+2H]2+ 819.7  
[M+3H]3+ 547.0  
a 5-50% aqueous MeCN (0.1% TFA) over 45 min; b 25-70% aqueous MeOH (0.1% 
TFA) over 45 min 
Pharmacological assays 
Radioligand binding assays were performed using cloned rat κ opioid receptors stably 
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The objective of this dissertation was the synthesis of conformationally constrained analogs 
of the KOR antagonist arodyn that could be potentially useful in the development of drug abuse 
therapy as well as pharmacological tools to study KOR receptors. Arodyn (Figure 8.1) is a potent 
and selective KOR antagonist that was shown to shown to block stress-induced reinstatement of 
cocaine-seeking in vivo.1, 2 Conformational constraint using ring closing metathesis (RCM), which 
can potentially stabilize a bioactive conformation, increase metabolic stability, and increase 
membrane permeability,3 was explored (Figure 8.1). Conformationally constrained arodyn analogs 
could facilitate further in vivo studies.  
8.2 Conclusions and future studies 
RCM is widely used, but side reactions such as olefin isomerization due to catalyst 
degradation products can limit yields of the RCM product in addition to complicating 
purification.4-6 During the synthesis of arodyn analogs with constrained aromatic residues desallyl 
products due to olefin isomerization compromised RCM product yields (Figures 8.2 and 8.3). 
Therefore, we explored modifications of reaction parameters and the use of additives5,6 to enhance 
yields of the RCM product in RCM involving Tyr(All) residues. In chapter 4, optimized reaction 
conditions in the model dipeptide studies resulted in a 4-fold increase in the yield of the RCM 
product compared to the original conditions7 used to cyclize Dyn A analogs containing AllGly 
residues. High temperature and high catalyst concentration generally increased side product 
formation, whereas lower catalyst concentration in the presence of phenol promoted formation of 





Figure 8.1 Conformational constraints of aromatic residues in arodyn. 
                
Figure 8.3 Olefin isomerization8, 9 resulting in deallylation during acid catalyzed cleavage from the solid-
phase resin.10 
Optimized RCM reaction conditions from the model dipeptide study and microwave 
heating were then employed in the synthesis of cyclic arodyn analogs for pharmacological 
evaluation in chapter 5. Molecular modeling and docking studies suggested that arodyn analogs 
cyclized between adjacent aromatic residues would retain affinity at the KOR, as these analogs 
displayed the same general structure as arodyn (Figure 8.4). Accordingly, constrained analogs 
were synthesized to examine the pharmacological effects of constraining aromatic residues. 
                                      
 
R = Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2 
 
              Figure 8.2 Products resulting from RCM of [Tyr(All)2,3]arodyn including desallyl pruducts. 
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Figure 8.4 Overlay of arodyn and several analogs following docking in the KOR (not shown). Arodyn 
(green) and its p1p2 (magenta), m1m2 (purple), p2p3 (orange), and m2m3 (brown) analogs have the same 
general structure (in referring to arodyn analogs, e.g. p1p2, letters indicate phenyl ring substitution patterns 
while the superscript indicates residue position in arodyn). 
Varying yields of the RCM products were observed using the optimized RCM conditions 
under conventional heating, especially during RCM involving m-Tyr(All) in the 1st or 2nd position 
of arodyn. Microwave irradiation was therefore explored to facilitate cyclization of arodyn analogs 
containing m-Tyr(All). Microwave-assisted RCM conditions using Hoveyda-Grubbs 2nd 
generation catalyst (HG II) were identified that resulted in enhanced cyclization yields compared 
to conventional heating.  
Initial pharmacological analysis showed that cyclization between aromatic residues was 
generally well tolerated at the KOR, with affinities within 1- to 4-fold that of arodyn, with the 
exception of the p1m2 and m1m2 analogs (which exhibited a 5.7- and 6.8-fold decrease in KOR 
affinity, respectively). These results are consistent with the similar binding modes of the cyclic 
analogs in the docking study (Figure 8.4). The cyclic arodyn analogs examined in the GTPγS assay 
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exhibited negligible activation of KOR similar to arodyn, a potent and selective KOR antagonist. 
Further pharmacological analysis to determine receptor selectivity and antagonist potency is 
ongoing. 
In chapter 6 head to side chain cyclization motifs involving Tyr(All) and AllGly were 
explored using microwave heating. Head to side chain cyclizations involving Tyr(All) residues 
generally resulted in low (<20%) yields, whereas cyclizations involving AllGly exhibited varying 
yields dependent on reaction temperature. The temperature dependent RCM product yields were 
consistent with the temperature dependence of Grubbs catalysts.11 Elevated temperatures increased 
side products including CH2 deletions and insertions (Figure 8.5), presumably due to catalyst 
degradation products.12 Notably, microwave heating facilitated the synthesis of arodyn analogs 
that could not be obtained via conventional heating. Initial pharmacological analysis indicates that 
both the cis and trans isomers of cyclo[5hex,AllGly5]arodyn retained affinity at the KOR, 
exhibiting 5-fold lower affinity compared to arodyn.  
 
Figure 8.5 Head to side chain arodyn analogs involving AllGly residues showing a ring contraction product. 
4pent=4pentenoic acid and 5hex=5hexenoic acid. 
Lastly, chapter 7 explored the synthesis of bicyclic arodyn analogs with constraints in both 
the N- and C-terminal segments using microwave irradiation. Polycyclic peptides are particularly 
promising due to their enhanced metabolic stability which can improve bioavailability.13, 14 Given 
that there are no reports of bicyclic opioid peptide ligands,15 novel bicyclic arodyn analogs with 
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interesting topologies could potentially be useful pharmacological tools. The structure-activity 
relationships (SAR) of monocyclic arodyn analogs were used in designing bicyclic arodyn analogs 
that could interact with KOR. Notably, optimized microwave-assisted RCM conditions from 
chapters 5 and 6 were successfully used to synthesize a bicyclic arodyn analog, 
cyclo[Tyr(All)2,3,AllGly5,8]arodyn, with two side-chain to side-chain constraints. Sequential RCM 
facilitated regioselective cyclization in the synthesis of cyclo[Tyr(All)2,3,AllGly5,8]arodyn, thereby 
limiting unwanted cyclizations. Encouragingly, initial pharmacological evaluation showed that 
this bicyclic analog retained affinity at the KOR (Ki= 26.4 ± 5.9 nM), with slightly higher affinity 
(approximately 2-fold) than the related monocyclic arodyn analogs cyclo[Tyr(All)2,3,Ile8]arodyn 
and cyclo[AllGly5,8]arodyn. Further pharmacological analysis of the synthesized bicyclic arodyn 
analogs is in progress.  
Lactam chemistry was used to synthesize a second bicyclic arodyn analog using trimesic 
acid (TMA), a rigid aromatic linker. The lactam-based bicyclic arodyn analog 
cycloN,5,8[TMA,Dap5,8]arodyn contained head to side-chain and side-chain to side-chain 
constraints. In initial pharmacological evaluation however, cycloN,5,8[TMA,Dap5,8]arodyn 
displayed a substantial loss (51-fold) in KOR affinity, suggesting that the constraint resulted in 
unfavorable interactions in the KOR similar to arodyn analogs with lactam constraints involving 
residue 2 in the “message”16 sequence of arodyn.10  
This dissertation research has identified several constrained analogs of arodyn that can 
compliment non-peptide KOR selective ligands, facilitate studying ligand-receptor interactions, 
and could ultimately aid the development of new therapeutic agents. There has been an increased 
interest in peptide drug discovery17 and cyclic peptides18 in the recent past. Since arodyn can be 
rapidly metabolized, thus precluding systemic administration, cyclic arodyn analogs could be 
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useful for further in vivo studies. Future studies will also include metabolic stability studies, and 
metabolically stable arodyn analogs can be examined in blood-brain barrier permeability studies.  
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aChromatograms from RCM reaction table entries (baseline resolution was not achieved so 
yields shown are an estimate) 




Table A1.1 Analytical data of synthesized linear and cyclic peptides 




1 Fmoc-Tyr(All)-Tyr(All)-OH 23.0 [M+Na]+ 669.25 [M+Na]+ 669.25 
2 cyclo-Fmoc-Tyr(All)-Tyr(All)-OH 18.0 [M+Na]+ 641.22 [M+Na]+ 641.22 
3 Fmoc-Tyr(All)-Tyr-OH 14.7 [M+Na]+ 629.22 [M+Na]+ 629.22 
4 Fmoc-Tyr-Tyr(All)-OH 14.7 [M+Na]+ 629.22 [M+Na]+ 629.22 
5 Fmoc-Tyr-Tyr-OH 6.0 [M+Na]+ 589.19 [M+Na]+ 589.19 
6 Fmoc-Tyr(All)-Phe-Tyr(All)-OH 26.4 [M+Na]+ 816.32 [M+Na]+ 816.33 
7 cyclo-Fmoc-Tyr(All)-Phe-Tyr(All)-OH 21.6 [M+Na]+ 788.29 [M+Na]+788.29 
8 [Tyr(All)2,3]arodyn 32.2b [M+H] + 1647.01 [M+H] + 1647.86 
9 cyclo[Tyr(All)2,3]arodyn 29.3b [M+3H]3+ 540.30 [M+3H]3+ 540.50 
 a30-70% Aqueous MeCN with 0.1% TFA over 40 min 
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Figure A1.1 Reaction mixture resulting from RCM of 1 showing the RCM product 2 and desallyl 




















SM b (%) 
1 [Tyr(All)2,3]arodync 60 32 31 -c 
2 [Tyr(All)2,3]arodync 40 18 44 - 
3 Fmoc-Tyr(All)-Tyr(All)c 60 20 25 - 
4 Fmoc-Tyr(All)-Tyr(All)c 40 - 18 16 
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R = Arg(Pbf)-Leu-Arg(Pbf)-Arg(Pbf)-D-Ala-Arg(Pbf)-Pro-Lys(Boc)-NH-resin 
 
R1 = Arg-Leu-Arg-Arg-D-Ala-Arg-Pro-Lys-NH2 
 
Figure A1.3 Reaction mixture resulting from RCM of 8 showing the RCM product 9 and desallyl          
products 10, 11, and 12. 
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Table A1.2 entry 1: RCM of 8; 60 oC, DCM/DMF(4/1), 40 mol %, 3 mM G II 
 
Table A1.2 entry 2: RCM of 8; 40 oC, DCM/DMF(4/1), 40 mol %, 3 mM G II 
 
Table A1.2 entry 3: RCM of 1; 60 oC, DCM/DMF(4/1), 40 mol %, 3 mM G II. Note multiple 




Table A1.2 entry 4: RCM of 1; 40 oC, DCM/DMF(4/1), 40 mol %, 3mM G II.  
 
Table A1.3. Effect of temperature and catalyst concentration on model dipeptide RCM product 
yields.a 
Entry Temp. (°C) [Cat.] (mM) 
Yield (%)b 




1 60 3 - 82 -d 
2 60 1 - 39 - 
3 60 0.3 - 78 - 
4 40 3 63 16 - 
5 40 1 55 13 - 
6 40 0.3 24 10 60 
7 40 0.1 - 18 69 
 a G II 15 mol%, in DCE (60 oC) or DCM (40 oC) for 2d; b Determined from 












Table A1.3 entry 1: Fmoc-Tyr(All)-Tyr(All) RCM; 60 oC, DCE, 15 mol %, 3 mM G II 
    
Table A1.3 entry 2: RCM of 1; 60 oC, DCE, 15 mol %, 1 mM G II 
 




Table A1.3 entry 4: RCM of 1; 40 oC, DCM, 15 mol %, 3 mM G II 
 
Table A1.3 entry 5: RCM of 1; 40 oC, DCM, 15 mol %, 1 mM G II 
 




Table A1.3 entry 7: RCM of 1; 40 oC, DCM, 15 mol %, 0.1 mM G II 
  
Table A1.4 Effect of phenol, temperature,a,b and catalyst concentration on model dipeptide RCM 
product yields.  




RCM pdt. Total 
desallyl pdt. 
SMd 
1 3 phenol 42 20 -e 
2 1 phenol  60 - - 
3 0.3 phenol  79 - - 
4 0.1 phenol  31 15 43 
aResults shown are in DCM at 40 oC for 2 d; bat 60 oC in DCE, phenol did not effectively suppress 






Table A1.4 entry 1: RCM of 1; 40 oC, DCM, 15 mol %, 3 mM G II, phenol 
 
Table A1.4 entry 2: RCM of 1; 40 oC, DCM, 15 mol %, 1 mM G II, phenol 
 




Table A1.4 entry 4: RCM of 1; 40 oC, DCM, 15 mol %, 0.1 mM G II, phenol 
 
Table A1.5. Model dipeptide RCM product yields with Hoveyda-Grubbs 2nd generation catalyst 












1 60 0.3 -  86 - - 
2 60 0.3 phenol 25 26 14 
3 40 0.3 -  80 - - 
4 40 0.3 phenol  72 15 - 
-< 10%; a Solvent: DCE for 60, DCM for 40 °C, 2d; b S.M: Starting material 
 




Table A1.5 entry 2: RCM of 1; 60 oC, DCM, 15 mol %, 0.3 mM HG II, phenol 
 




Table A1.5 entry 4: RCM of 1; 40 oC, DCM, 15 mol %, 0.3 mM HG II, phenol 
 
Table A1.6. Tripeptide RCM product yields with optimized conditions with G II and HG II. a  
Entry Catalyst Temp.(°C) 
Additive 
(1 equiv.) 
  RCM 
Pdt. 
Total 
desallyl     
pdt. 
1 HG II 60 - 27 28 
2 HG II 40 - 84 - b 
3 HG II 40 phenol 67 - 
4 G II 40 phenol 65 - 
a 0.3 mM 15 mol% G II or HG II in DCE (60 oC) or DCM (40 oC) for 2d; b - < 10%;  
 




Table A1.6 entry 2: RCM of 6; 40 oC, DCM, 15 mol %, 0.3 mM HG II, phenol 
 
 









Table A1.7 Summary showing yieldsa of model dipeptide (1) RCM under various conditions 













SM Solvent T (0C) 
Catalyst 
(Mol %) 
1 3 - 20 25 - c DCM/DMF(4/1) 60 40 
2 3 - - 50 - DCE 80 15 












35 23 - DCE 60 15 
7 3 (1d) - 30 37 - DCE 60 15 
8 3 (1d) 
phenol 
(10) 
38 19 18 DCE 60 15 




11 25 26 DCE 60 15 








- 35 37 Toluene 60 15 
14 0.3 - - 49 24 Toluene 60 15 
15 3 - - 18 16 DCM/DMF(4/1) 40 40 




42 20 - DCM 40 15 




60 - - DCM 40 15 




















- - 69 Toluene 40 15 
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31 15 43 DCM 40 15 
28 0.1 - - 18 69 DCM 40 15 
a HPLC: 30-70% Aqueous MeCN with 0.1% TFA over 40 min; b 2 d unless otherwise indicated; 


















Appendix 2 - Modeling of arodyn analogs cyclized by RCM between Tyr(All) residues* 
*Perfomed by Dr. Michael Ferracane, Department of Chemistry, University of Redlands, 





All conformational work was performed using the 2015 Molecular Operating Environment 
(MOE) software suite.1 Briefly, the appropriate four residue fragments of arodyn (Ac-Phe-Phe-
Phe-Arg-NHCH3) and its cyclic p
1p2, m1m2, p2p3, and m2m3 analogs were constructed, subjected 
to conformational search, and docked into the prepared KOR crystal structure (PDB ID: 4DJH) 
using a pharmacophore.2 The original crystal structure was solved as a homodimer, and all work 
was done with the structure 4DJH.A, as it is better resolved than 4DJH.B. 
A2.1.1 Conformational searches 
 For arodyn and its cyclic analogs, each appropriate fragment was constructed and subjected 
to 30,000 iterations of stochastic stretching and rotation of its bonds in the Amber10:EHT 
forcefield. 3 The resulting conformers were considered plausible and unique if they (a) obtained 
calculated energies within 25 kcal/mol of the species’ global minimum, (b) contained only trans 
amide bonds (180±20o) outside the exocyclic region, and (c) possessed heavy atom (C, N, and O) 
RMSD values greater than 0.05 Å. The calculated energy and atomic coordinates of each species’ 
conformers were saved to a corresponding database that contained between 700-10,000 unique 
conformers for each of the five species. 
A2.1.2 Receptor preparation 
 The reported crystal structure of the KOR requires preparation before it can be used in 
docking experiments. First, the unresolved residues in ECL3 (Thr302-Thr306) were constructed 
and spliced – in their lowest energy conformation – into the receptor structure. Following this, the 
first resolved residue of the N terminus (Ser55) and the last resolved residue of the C terminus 
(Pro347) were “capped” by affixing an acetyl group to the truncated N terminus and an N-methyl 
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amide to the truncated C terminus. Then, any unresolved atoms of side chains (Ile85, Thr88, Lys89, 
Lys165, Leu167, Phe169, Lys200, Asp217, Arg257, Leu259, Lys265, Arg267, Arg270, Arg271, 
Val296, Ser301, Thr302, Ser303, His304, Ser305, Thr306, Glu335, Arg342) were added, also in 
their lowest energy conformation. Finally, hydrogen atoms were added to the receptor, ligand, and 
solvent so that all atoms achieved their proper valency and charge (pH = 7, T = 300K). This work 
yielded the prepared κ opioid receptor (KOR), which was used in subsequent docking studies. 
A2.1.3 Pharmacophore generation 
 A pharmacophore (Figure A2.1) was created to guide placement of the conformers into the 
receptor during docking. The pharmacophore consisted of four elements: two aromatic sites and 
two cationic sites. The first aromatic element (radius = 1.5 Å) was defined using the atomic 
coordinates of the phenolic ring of the 7-hydroxytetrahydroisoquinoline moiety of JDTic from its 
cocrystal structure with the KOR. 2 Following this, the cocrystal structures of BU72 in the μ opioid 
receptor (PDB ID: 5C1M) 4 and DIPP-NH2 in the δ opioid receptor (PDB ID: 4RWA)
5 were 
overlaid with that of JDTic in the KOR. The second aromatic element (radius = 1.5 Å) was then 
generated between the pendant phenyl group of BU72 and the phenyl ring of Phe3 in DIPP-NH2, 
groups with centroids that lie within 2.2 Å of each other when overlaid. The two cationic sites lie 
adjacent to Glu209 (radius = 2.5 Å) and Glu297 (radius = 2.5 Å), non-conserved acidic residues 





Figure A2.1 Structure of KOR model and pharmacophore for docking. Left: KOR model (gray loops) 
highlighting the acidic residues Glu209 and Glu297 (gray sticks), the crystallized ligand JDTic (gray 
sticks), and defined pharmacophore elements (colored spheres). Right: The KOR model was overlaid with 
crystal structures of the μ and δ opioid receptor (not shown). The pharmacophore consists of one aromatic 
element (orange sphere) in the same site and plane as the phenol of JDTic (gray sticks), a second aromatic 
site (orange sphere) between the phenyl rings of BU72 (yellow sticks) and DIPP-NH2 (magenta sticks), and 
two basic sites (cyan spheres) adjacent to Glu209 and Glu297. 
A2.1.4 Docking 
The pharmacophore was used to guide initial placement of each arodyn/analog conformer 
into the prepared KOR, holding both the ligand and the receptor fixed. The ligands were required 
to obtain geometries that positioned an aromatic moiety inside each aromatic site and place the 
basic guanidinium in either of the two cationic sites. Poses that satisfied these criteria were 
analyzed to calculate their binding energies using the GBVI/WSA dG scoring function;6 those that 
did not were filtered out prior to docking. 
The top 1000 ligand-receptor complexes for arodyn and each of its analogs underwent 
subsequent induced fit docking. Each ligand-receptor complex was minimized (500 iterations) in 
the Amber10:EHT forcefield. The ligand and receptor residues containing atoms within 9 Å of the 
ligand were allowed to move freely, while all other atoms were held fixed. Similar to before, any 
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resulting ligand-receptor complexes that did not fulfill the pharmacophore criteria were filtered 
out. Each remaining minimized ligand-receptor complex was then rescored using the GBVI/WSA 
dG scoring function to estimate the binding energy. 
A2.2 Results and discussion 
A2.2.1 Conformational Searches 
 The conformational search protocol was designed to generate large libraries of conformers 
that thoroughly explored the unique conformational space of arodyn and each of its analogs. For 
each species, the conformational search largely yielded conformers with extended shapes, though 
there was an oversampling of compacted conformers in which the guanidinium of Arg4 formed 
contacts with the carbonyls of the peptide backbone. Interestingly, there were also a number of 
conformers (~10%) containing higher energy cis amides or alkenes. Taken together, these findings 
demonstrated that our protocol thoroughly explored the spatial and energetic landscape of each 
species, as each search generated between 700-10,000 unique conformers for arodyn and each of 
its analogs. 
A2.2.2 Receptor Preparation  
The X-ray crystal structure of the KOR was originally determined in its anatogonist-bound 
state. JDTic binds in a unique “V” shape, deep in receptor’s orthosteric site. The arodyn analogs, 
on account of their bulky macrocyclic structure, likely bind to a slightly different conformation of 
the receptor. Rather than model prospective KOR structures – which we felt would be speculative 
and complicate interpretation of the docking results – we focused on using an induced fit docking 
methodology that would hopefully accommodate the unique shape of these ligands. In keeping 
with this thinking, most alterations made during structure preparation were conservative in nature 
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and are standard practice (side chain and hydrogen addition) and/or affect residues distant from 
the orthosteric site (termini capping). 
Still, the unresolved residues of ECL3 (Thr302-Thr306) – which flank the orthosteric site 
– had to be modeled in to properly reflect the environment of the receptor pocket. Differences in 
the sequence and number of the residues among ECL3 – as well as the arrangement of the helices 
flanking it – for the κ (GSTSHS), μ (ITIPET), and δ (VDIDRRD) opioid receptors make 
extrapolation of the unresolved region’s structure challenging. As a result, the missing residues of 
ECL3 were spliced into the receptor in their lowest energy conformation, a reasonable 
approximation of the actual structure of this inherently flexible region.  
Finally, the water molecules observed in the X-ray crystal structure of the KOR were 
removed during structure preparation. Importantly, some of these water molecules occupy the 
orthosteric site, forming a solvent network that connects the side chain of His2916.52 7 to the 
phenolic hydroxyl of JDTic. Analogous networks were observed in other opioid receptor crystal 
structures;2,4,5,8,9 they similarly connect the conserved His6.52 residue to each ligand’s phenolic 
hydroxyl group. This functionality is notably absent in arodyn and its analogs, and we anticipate 
the water network to change accordingly. We opted to leave this site vacant rather than model a 
hypothetical solvent network. Instead, we used the pharmacophore to prevent ligands from 
entering this region of the orthosteric site, ultimately approximating the steric environment of a 
solvated KOR. 
A2.2.3 Pharmacophore generation and docking  





Table A2.1a Energy scores of arodyn analogs cyclized between adjacent residues and conformational data 
of the first residue from modeling studies. 




Pose        
Energy 
  Residue 1 
ωAc φ1 ψ1 χ11 χ12 
Arodyn 63 -10.7718 -217.1639 179.76 -64.07 -57.13 177.28 -87.67 
p1p2 72 -11.0986 -205.1700 -176.65 -53.72 -49.68 168.69 -81.48 
m1m2 62 -11.0600 -206.1420 -172.62 -63.99 -52.39 171.43 -85.26 
p2p3 312 -10.9785 -206.2552 -178.13 -60.36 -29.93 -179.84 -88.18 
m2m3 27 -11.9973 -205.7217 -177.70 -70.98 -51.39 -168.21 -103.65 
 
Table A2.1b Conformational data of the second residue in arodyn analogs cyclized between adjacent 
residues. 
Compound Pose  
# 
  Residue 2 
ω1,2 φ2 ψ2 χ21 χ22 
Arodyn 63 178.14 -81.41 -61.82 -112.24 41.72 
p1p2 72 173.28 -87.15 -50.58 -79.91 -81.62 
m1m2 62 175.90 -73.04 -51.96 -75.44 -110.78 
p2p3 312 -155.83 -126.47 -49.32 -167.01 -82.98 
m2m3 27 168.06 -80.05 -42.10 -60.23 170.34 
 
Table A2.1c Conformational data of the third residue in arodyn analogs cyclized between adjacent 
residues. 
Compound Pose  
# 
  Residue 3 
ω2,3 φ3 ψ3 χ31 χ32 
Arodyn 63 -166.37 -81.54 151.27 -49.73 -95.87 
p1p2 72 -151.42 -92.90 19.07 -53.81 -79.10 
m1m2 62 -159.16 -87.19 157.90 -66.53 -85.24 
p2p3 312 -168.82 -93.21 4.09 -63.18 -90.20 









Table A2.1d Conformational data of the fourth residue in arodyn analogs cyclized between adjacent 
residues. 
Compound Pose  
# 
  Residue 4 
ω3,4 φ4 ψ4 χ41 χ42 
Arodyn 63 -179.67 -92.09 139.48 -80.92 66.26 
p1p2 72 159.58 -144.79 130.05 -156.36 75.97 
m1m2 62 -172.58 -77.85 -27.56 -86.21 62.77 
p2p3 312 -174.85 64.07 154.51 -56.99 -60.38 
m2m3 27 -161.49 -73.25 -30.86 -60.16 -71.47 
 
A2.4 Conclusions 
Among the different species, only the p1p2 analog did not form an ionic contact between 
the guanidinium of its Arg4 and the important nonconserved residue Glu297;10 it instead oriented 
this moiety toward the side chain of Glu209. This analog is probably capable of forming a contact 
with Glu297, but our protocol likely undersampled its conformational space and missed that 
particular binding pose. The side chain of the m1m2 and m2m3 analogs adopted strained 
conformations to form additional ion-dipole contacts with the carbonyl of m-Tyr2. Again, the 
docking experiments were performed using an unsolvated receptor, which biases the ligand-
receptor complex toward forming the maximum amount of possible contacts. In reality, there are 
solvent molecules that must be displaced in order for this interaction to occur, and we question 
whether this contact is truly relevant in vivo. 
The four species that formed contacts between Arg4 and Glu297 positioned their 
guanidinium groups near the 5’ carbon of naltrindole (~2.5 Å from 5’ carbon to guanidyl carbon) 
when overlaid with the crystal structure of naltrindole in the δ opioid receptor (Figure A2.2).8 
Interestingly, the analog 5'-guanidinonaltrindole (5’-GNTI) acts as a κ-selective antagonist, and its 
guanidinium was previously shown to impart selectivity for the κ opioid receptor – via interaction 
with Glu297 – over the δ opioid receptor, which has Trp284 in this position.11 Taken together, 
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these results support this orientation of the guanidinium of Arg4 and the overall binding mode of 
arodyn and its analogs. 
 
Figure A2.2 Overlay of arodyn (green) docked in the κ opioid receptor model (green) and the crystal 
structure of naltrindole (purple) in the δ opioid receptor (not shown). The guanidium of Arg4 is positioned 
within 2.5 Å of the 5’ position of naltrindole, where the guanidinium group of the κ-selective antagonist 5’-
guanidinonaltrindole (5’-GNTI) would lie. This moiety was previously found to bind Glu297 of the κ opioid 
receptor, a finding that – by extension – supports the results from the docking study. 
 
The dihedral angles of the peptide backbones all fell within acceptable Ramachandran 
values (Table A3.1a-d), including the residues constrained by the macrocycle. The dihedral 
angles from ωAc-1 to φ3 are nearly identical among the docked peptides, and the backbones of 





Figure A2.3 Overlay of arodyn (green) docked in the κ opioid receptor model (green) and the crystal 
structure of DIPP-NH2 (magenta) in the δ opioid receptor (not shown). The two peptidic ligands have 
different sequences, yet they can arrange the aromatic rings of residues 1 and 3 similarly in the 
pharmacophore (orange spheres). Interestingly, the backbones of the two peptides are strikingly similar 
from Cα2 to N4, suggesting that peptidic ligands may bind in similar conformations. Phe4 and Arg4 of both 
peptides do not overlay well, although Phe4 of DIPP-NH2 was found to occupy different conformations 
even in the crystal structure. 
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aCompound numbers are the same as those used in Chapter 5  
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Figure A3.1 1H-spectra of 2. The spectrum of olefinic protons following decoupling of adjacent 
methylene protons at 4.64 is shown at the bottom as well a COSY showing olefinic and O-
methylene protons. 
 









        Figure A3.2 1H-spectra of 3. 








      
 
 




Figure A3.3 1H-spectra of 4. 
 











Figure A3.4 1H-spectra of 5. 
 













Figure A3.5 1H-spectra of 6. The spectrum of olefinic protons following decoupling of adjacent 
methylene protons at 4.68 is shown at the bottom.  
 
            
    
 











































           
 
 

































Figure A4.1 1H-spectra of 14 cis.  
 
                                
 

















Figure A4.2 1H-spectra of 14 trans.  
 
                                         
 
 
